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Diabetes mellitus results in chronic hyperglycaemia, leading to defects in carbohydrate, fat 
and protein metabolism. Diabetes mellitus is also linked with elevated plasma cholesterol and 
triglyceride levels, which may promote the development of cardiovascular disease.  Psidium 
guajava(PG) leaf is known to have a blood-glucose lowering effect in diabetic rats. The aim 
of this study was to carry out a phytochemical study of PG leaf extract; investigate its 
protective effect on pancreas and also its effect on muscle and liver glycogen synthase and 
phosphorylase activities in streptozotocin induced diabetic male Sprague-Dawley rats; Serum 
biomarkers of liver and muscle dysfunction such as alanine amino transferase (ALT), 
aspartate amino transferase (AST) and lactate dehydrogenase (LDH) were also analyzed. The 
effect of PG on markers of lipid metabolism and on hormone sensitive lipase (HSL) enzyme 
was also investigated. A single dose of 40 mg/kg body weight of streptozotocin was 
administered to fasted male Sprague-Dawley rats intraperitoneally for diabetes induction. The 
aqueous extract of PG leaves was used to treat both normal and diabetic animals (400 mg/kg 
body weight) for 2 weeks while control animals were treated with the vehicle. After 2 weeks 
of treatment, PG was shown to enhance lowering of blood glucose in diabetic rats following a 
glucose load and protected pancreatic tissue from diabetic damage. GC-MS analysis of the 
aqueous extract of PG indicated the presence of phenolic compounds and triterpenes. In acute 
study, PG activated Protein kinase B(PKB/Akt) in skeletal muscle of streptozotocin induced 
diabetic rats. In the sub-chronic study, the treatment of rats with PG extract restored glycogen 
synthase activity depressed by diabetes and decreased glycogen phosphorylase activity in 
skeletal muscle. These changes in enzyme activity mirrored those in enzyme expression. It 
also restored glycogen synthase activity depressed by diabetes which was accompanied by 
reduced glycogen phosphorylase activity and increased glycogen levels in liver. PG 
decreased HSL activity in adipose tissue and liver and this was accompanied by reduced 
levels of serum triglycerides, total cholesterol, LDL-cholesterol, cardiac risk factor, 
atherogenesis and increased HDL-cholesterol.  We conclude that PG has significant 
antidiabetic and hypolipidemic effects, and that these effects may be associated with the 
presence of triterpenes and phenolic compounds. PG increased GS activity, glycogen storage 






1.0 DIABETES MELLITUS 
Diabetes mellitus (DM) is a metabolic disorder, characterized by inadequate or inefficient 
insulin secretory response and high blood glucose level (Prabhakar and Doble, 2008). It is 
also characterized by impaired uptake and storage of glucose as well as reduced glucose 
utilization for energy purposes (Jacobsen et al., 2009; Sangeetha et al., 2010). Glucose 
homeostasis helps to maintain blood glucose levels constant, and this is achieved by a 
balance in endogenous glucose production and utilization (Roden and Bernroider, 2003).  
Diabetes-induced hyperlipidaemia is one of the major factors responsible for cerebrovascular 
and cardiovascular disorders. Two important lipids such as cholesterol and triacylglycerols 
have been implicated in these disorders (Sriplang et al., 2007). Recent studies reported a link 
between diabetes and gall bladder disease (Liu et al., 2012; Chen et al., 2014).  
1.1 TYPES OF DIABETES MELLITUS 
1.1.1 Type I and Type II diabetes mellitus  
Type I and Type II diabetes mellitus are the two main types. A distinctive feature of type I 
diabetes is an absolute lack of insulin production, leaving the patient relying on exogenous 
insulin for survival (Varshosaz, 2007). Approximately, 10 % of patients with diabetes 
mellitus suffer from Type I diabetes (Gilespie, 2006). Type II diabetes (non-insulin-
dependent diabetes mellitus), is characterized by relative lack of insulin and/or insulin 
resistance (Kumar et al., 2005b). Type II diabetes also accounts for over 90 % of all cases of 
diabetes mellitus (World Health Organization, 2014). Type II diabetes can be properly 
managed by regulating the patient’s diet and also treating with synthetic antidiabetic drugs 
such as biguanides (e.g metformin), sulphonylureas (e.g glibenclamide), alpha glucosidase 
inhibitor (e.g acarbose), dipeptidyl peptidase 4 inhibitors (e.g vildagliptin) and 
thiazolidinediones (e.g rosiglitazone). Hyperglycaemia affects the insulin signalling pathway 
through various mechanisms such as activation of c-Jun-N terminal kinase and oxidative 
stress driven pathways (Bensellam et al., 2012). The generation of reactive oxygen species 
causes damage to cellular lipids, proteins and nucleic acids, resulting in the activation of the 
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unfolded protein response (UPR) and endoplasmic reticulum stress (Hotamisligil, 2003; 
Ozcan et al., 2004).  
1.1.2 Gestational diabetes mellitus (GDM) 
GDM can be defined as any degree of glucose intolerance which is first recognized during 
pregrancy (Metzger and Coustan 1998). GDM usually occurs in women who are at risk of 
type II diabetes (Cheung, 2009). During pregnancy, GDM is linked with several 
complications for the child. The inability of insulin to cross the placenta barrier exposes the 
foetus to the maternal hyperglycaemia, but the foetal pancreas is capable of responding 
appropriately to this hyperglycaemia (Scollan-Kolippoulos et al., 2006). Hyperinsulinaemia 
is observed in the foetus, which promotes growth and subsequent macrosomia (Perkins et al., 
2007). Foetus born to mother suffering from GDM has higher risk of developing 
hyperbilirubinaemia, clavicle fracture, macrosomia, shoulder dystonia with its attendant risk 
of brachial injury and neonatal hypoglycaemia (Hapo Study Cooperative Research Group, 
2008; Ramos et al., 2012; Alberico et al., 2014). 
1.1.3 Maturity onset diabetes of young (MODY) 
MODY is also known as monogenic diabetes which is caused by mutations in an autosomal 
dominant gene (sex independent) altering insulin production (Barry and Dirk, 2008). Eleven 
genetic forms of MODY have been identified. About 10 % of patients with diabetes cases 
suffer from MODY (Johnson, 2007). People suffering from MODY do not possess traits that 
can be found in type 2 diabetic patients such as high blood pressure and obesity (Fajans and 
Bell, 2011). MODY can be treated with oral anti-diabetic medications (America Diabetes 
Association, 2012). Next generation sequencing (NGS) technology is used to identify patients 
with MODY gene mutations (Colclough et al., 2014). 
1.1.4 Neonatal diabetes mellitus (NDM) 
This condition occurs in the first 6 months of life because infants with NDM do not produce 
enough insulin, there is increase in blood glucose level and therefore exogenous insulin is 
required for management. (Shield, 2000). There are two types of NDM, Transient Neonatal 
Diabetes Mellitus (TNDM) and Permanent Neonatal Diabetes Mellitus (PNDM) (Neve et al., 
2005). The etiology of NDM is genetically heterogeneous characterized by absence or 
abnormal development of pancreas or islets, and β-cell dysfunction that reduces insulin 
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secretion (Aguilar-Bryan and Bryan, 2008). A report by Garin et al., (2012) revealed that 
mutation (p.L30Q) in the insulin gene (INS) caused PNDM in a four-month old female who 
was showing symptoms such as hyperglycaemia with glucosuria, polyphagia, irritability and 
ketonuria without acidosis.  
1.2 COMPLICATIONS ASSOCIATED WITH DIABETES MELLITUS   
1.2.1 Diabetic nephropathy 
The factors that promote the development of diabetic nephropathy are dyslipidaemia 
(Chaturvedi et al., 2001, Appel et al., 2003), high blood pressure (Nelson et al., 1995; Ravid 
et al., 1998; Adler et al., 2000), hyperglycaemia (Gall et al., 1997; The Microalbuminuria 
Collaborative Study Group, 1999), epithelial-to-mesenchymal transition (Tang et al., 2013), 
smoking (Sawicki et al., 1994; Hovind et al., 2003), reactive oxygen species (ROS) (Singh 
and Winocour, 2011), and increased formation of advanced glycation end products (AGEs) 
(Yamagishi and Imaizumi 2005). Glomerular hyperfiltration is one of the problems that have 
been proposed to promote the development of diabetic nephropathy. Type I and II diabetic 
patients experience this problem in the early years of the disease (Vora et al., 1992; Nelson et 
al., 1996; Levine, 2008). Various hypotheses have been proposed promoting the development 
of glomerular hyperfiltration. In a study using animals, it was observed that afferent 
glomerular arterioles dilate more than efferent arterioles, thereby increasing filtration 
fraction, intraglomerular pressure and glomerular filtration rate (Hostetter et al., 1981). Such 
changes have been suggested to promote diabetic glomerulopathy in STZ-induced diabetic 
Munich-Wistar rats (Zatz et al., 1985). AGE products also initiate the development and 
progression of diabetic nephropathy; they are formed by non-enzymatic reaction of reducing 
sugars with the amino groups of proteins to form reversible Schiff bases and then Amadori 
products (Yamagishi and Imaizumi, 2005). These early glycation products undergo further 
complex reactions such as rearrangement, dehydration and condensation to form AGEs 
(Rahbar and Figarola, 2003). There is increased formation and accumulation of AGEs during 
diabetes. Various studies reported that serum and tissue AGEs levels were significantly 
increased in type I and type II diabetic patients when compared with non-diabetic control 
subjects (Galler et al., 2003). One of the several mechanisms by which accumulation of 
AGEs in the kidney may contribute to the alteration in renal architecture and loss of renal 
functions in rodents and patients is by activating downstream signalings and cross-linking (β-
sheets or cross-β structure) properties of matrix proteins (Bouma et al., 2003; Bohlender et 
4 
 
al., 2005). In addition, AGE formation on different types of matrix proteins impairs their 
degradation by matrix metalloproteinases, contributing to mesangial expansion and basement 
membrane thickening which are the hallmarks of diabetic nephropathy (Mott et al., 1997). 
Yamagishi et al., (2002) reported that AGEs stimulate monocyte chemoattractant protein-1 
(MCP-1) expression in mesangial cells. Monocyte infiltration in association with increased 
MCP-1 expression in mesangium has been observed in the early phase of diabetic 
nephropathy (Banba et al., 2000). Ye et al., (2009) reported that urinary MCP-1/creatinine 
ratios in type II diabetic patients with microalbuminuria were much higher when compared to 
those in normal controls, but with intensive insulin treatment, there was a significant 
reduction in urinary MCP-1/creatinine ratios. Therefore, diabetic nephropathy is initiated by 
AGE accumulation in glomerulus and subsequent secretion of MCP-1 in mesangial cells. 
1.2.2 Diabetic neuropathy 
Diabetic neuropathy affects motor neurons, pain fibres and the autonomic nervous system 
(Said, 2007). During hyperglycaemia, when there is a decline in insulin secretion, the polyol 
pathway becomes activated; glucose is converted to sorbitol in a process catalysed by aldose 
reductase, because of the inability of sorbitol to cross cell membrane, it accumulates in the 
nervous tissue, leading to a condition known as osmotic stress. This condition increases 
Schwann cell damage, water influx, intracellular fluid molarity (The amount of solute per 
unit volume of solution within the cell) and nerve fibre degeneration (Oates, 2002). Current 
studies suggest that osmotic stress in cells and tissues may contribute to various human 
diseases (Brocker et al., 2012). Another way in which hyperglycaemia contributes to the 
development of diabetic neuropathy is the production of advanced glycation endproducts 
(AGEs) (Sugimoto et al., 2008), via attachment of reactive carbohydrate groups to nucleic 
acids, proteins or lipids. Extracellular AGEs bind to the receptor for AGE (RAGE), which 
activates NADPH oxidases, leading to a condition known as oxidative stress (Vincent et al., 
2007). Dyslipideamia is also known to contribute to the pathogenesis of diabetic neuropathy 
(Wiggin et al., 2009). Plasma lipoproteins, especially low-density lipoproteins (LDLs), are 
modified by glycation or oxidation (oxLDL). These modified LDLs can bind to extracellular 
receptors such as Toll-like receptor 4 (Nowicki et al., 2010), oxLDL receptor LOX 1 
(Vincent et al., 2009) and RAGE (Vincent et al., 2007). These receptors trigger signalling 
cascades that activate NADPH oxidase and oxidative stress (Vincent et al., 2009). Impaired 
insulin signalling is also a factor underlying diabetic neuropathy. Insulin has been shown to 
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promote neuronal growth and survival (Toth et al., 2006). Reduction of this neurotrophic 
signalling as a result of insulin deficiency or insulin resistance contributes to the development 
of diabetic neuropathy (Kim and Feldman, 2012).  
1.2.3 Diabetic cardiomyopathy 
This is a disease which affects the myocardium in diabetic patients causing several structural 
disorders such as left ventricular hypertrophy (LVH). Hyperglycaemia leads to the production 
of excess reactive oxygen species (ROS) in the mitochondria (Singh, 2001), this affects 
transcription of a segment of DNA, which leads to contractile dysfunction (Rosen et al., 
1998). Elevated ROS levels leads to decreased nitric oxide (NO) levels, which promotes the 
development of endothelial dysfunction and myocardial inflammation via poly ADP-ribose 
polymerase (PARP). Inhibition of PARP has been reported to reverse diabetic endothelial 
dysfunction (Soriano et al., 2001). In a state of chronic hyperglycaemia, there is increased 
oxidative stress, which may lead to DNA breakage and render the DNA unstable, thereby 
activating PARP as a reparative response to the damage done to DNA (Chiu et al., 2008). 
Activation of PARP depletes NAD
+
, reducing the rate of glycolysis and mitochondrial 
function and eventually leading to apoptosis. The activity of glyceraldehyde-3-phosphate 
dehydrogenase is inhibited by PARP, which causes hyperglycaemia-induced activation of 
hexosamine pathway and protein kinase C (PKC) (Zheng and Kern, 2009). Previous studies 
reported the beneficial effects of PARP inhibition as illustrated by PARP-1 knockout mice; 
the inhibition of this enzyme protected the animals against streptozotocin-induced diabetes 
and myocardial ischemia/reperfusion injury (Yang et al., 2000). Recent studies implicate 
xanthine oxidase and NADPH oxidase in the pathogenesis of diabetic cardiomyopathy 
(Rajesh et al., 2009; Li et al., 2010; Ma et al., 2013). 
1.3 GLUCOSE HOMEOSTASIS 
1.3.1 Insulin 
Insulin is produced by beta cells in the pancreas (Aronoff et al., 2004; Wright et al., 2014). 
Insulin regulates blood glucose levels, by increasing glucose uptake, into adipose tissue, liver 
and muscle. It also inhibits glucagon secretion (Gerich, 1993). Insulin is first synthesized as 
preproinsulin in β-cells after which it is translocated to the rough endoplasmic reticulum to 
form proinsulin (Steiner and Oyer, 1967; Kahn et al., 2005). After about 5-10 min in the 
endoplasmic reticulum, proinsulin is transported to the trans-Golgi network (TGN) where it 
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develops into active insulin through the action of enzymes such as prohormone convertases 
and carboxypeptidase E (Steiner and Oyer, 1967). The insulin is packaged inside mature 
granules waiting for vagal nerve stimulation and metabolic signals such as mannose, arginine, 
leucine and glucose before it is released into circulation (Najjar, 2001). 
 
 
Figure 1.1:  Amino acid sequence of insulin (Adapted from Berg et al., 2002) 
 
                   
                  
                                                   
   
                                           
 Fig 1.2: Insulin action in tissues. Adapted from Ganong, 2005). Review of Medical 
Physiology, 22nd edition                                                                                                                                                               
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Glucagon is produced by the alpha cells of the pancreatic islets of Langerhans and  is secreted 
during periods of hypoglycaemia (Cryer, 2002) resulting in stimulation  of hepatic glucose 
production mainly through processes such as gluconeogenesis and glycogenolysis, thereby 
increasing blood glucose levels (Szablewski, 2011). Glucagon is also activated by 
epinephrine (through α1, α2 and β2 adrenergic receptors) (Skoglund et al., 1987: Layden et 
al., 2010) and acetylcholine (Honey and Weir, 1980). It is inhibited by Peroxisome 
proliferator-activated receptor gamma (PPARγ)/retinoid X receptor heterodimer (Kratzner et 
al., 2008) and insulin (Xu et al., 2006). 
1.3.3 Incretin 
The incretins are peptide hormones secreted from the gut and elicit an array of biological 
effects such as downregulating the activity of glucagon and stimulating a decrease in blood 
glucose levels by increasing the amount of insulin released from pancreatic beta cells (Baggio 
and Drucker, 2007). Various incretin hormones have been characterized, but G-I-P (Glucose 
dependent insulinotropic polypeptide) and G-L-P 1(Glucagon like peptide-1) are the two 
main types (Drucker, 2007). GIP and GLP-1 are both inactivated by dipeptidyl peptidase-4 
(DPP-4) (Drucker and Nauck, 2006; Russell-Jones and Gough, 2012).  
1.3.4 Glycogen metabolism in tissues 
1.3.4.1 Glycogen metabolism in muscle 
There is also an inverse relationship between muscle glycogen and both basal and insulin-
stimulated glucose uptake (Jensen et al., 1997). Increased glycogen synthase activity has a 
stimulating influence on glycogen synthesis in the muscle. Skeletal muscle glycogen synthase 
activity is lowered in diabetic subjects studied under euglycemic conditions (Kelley and 
Mandarino, 1990). During low muscle glycogen conditions, there is increase in AMP-
activated protein kinase activity and translocation of glucose transporter type 4 (GLUT-4), 
these mechanisms increase glucose uptake (Kawanaka et al., 2000; Wojtaszewski et al., 





Figure 1.3: Glucose metabolism in the muscle (Source: Lehninger Principles of        
Biochemistry, Nelson and Cox, 2005) 
1.3.4.2 Glycogen metabolism in liver 
Glycogen is mainly stored as glucose in the liver. The mechanism by which glycogen is 
synthesized and degraded is the same in all tissues (Smythe and Cohen, 1991; Alonso et al., 
1995; Bollen and Stalmans, 1995). Furthermore, livers from diabetic animals show a 
decreased capacity for glycogen synthesis, (Friedman et al., 1967; Hornbrook, 1970; Postle 
and Bloxham 1980; Van de Werve et al., 1984). Luo and colleagues (2011) reported that 
during fasting, the activity of protein phosphatase 1 regulatory subunit 3G (PPP1R3G) in the 
liver is upregulated and downregulated after feeding. 
1.4 PATHWAYS INVOLVED IN THE PATHOGENESIS OF DIABETES MELLITUS 
1.4.1 Insulin signalling pathway 
Insulin binds to insulin receptor (IR) which triggers the activation of intrinsic tyrosine kinase 
activity of IR. (Insulin receptor substrate-1 (IRS-1) phosphorylated by IR activates 
phosphoinositol-3-kinase (PI3K), which converts phosphatidyl inositol-4,5-bisphosphate 
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(PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) and subsequently activates protein 
kinase B (PKB/Akt). PKB phosphorylates GSK-3 on a Ser 9 residue, inactivating it. GSK-3, 
inactivated by phosphorylation, cannot phosphorylate glycogen synthase (GS), so GS remains 
active. This action of PKB, promotes increase in the rate of glycogen synthesis from glucose 
(Nelson and Cox, 2005).  
1.4.1.1 PI3-K/AKT signalling cascade 
1.4.1.1.1 Insulin receptor (IR) 
The insulin receptor plays vital regulatory roles in development, cell division, and 
metabolism (Ullrich and Schlessinger, 1990; Schlessinger and Ullrich, 1992; Fantl et al., 
1993). The insulin receptor plays an important role in glucose homeostasis; under degenerate 
conditions, a range of diseases such as diabetes and cancer may occur (Malaguarnera and 
Belfiore, 2012). The enzymes involved in the control of glucose metabolism by insulin 
appear to be regulated by phosphorylation and dephosphorylation on serine and/or threonine 
residues (Hubbard and Cohen, 1993; Lawrence, 1992). The insulin receptor has two sub 
units; the α-subunit consists of 723 amino acids with a molecular mass of 130 kDa (Lawrence 
et al., 2007; De Meyts, 2008). It shares this feature with the insulin-like growth factor 1 (IGF-
1) receptor and members of the epidermal growth factor (EGF) receptor family (Schlessinger 
and Ullrich, 1992). The β subunit contains 620 amino acids and has a molecular mass of 95 
kDa (Lawrence et al., 2007; De Meyts, 2008). Each α subunit is joined to one β subunit by so 
called class II disulphide bonds (Massague and Czech 1982). The insulin receptor is derived 
from a single gene and two isoforms are produced by alternative splicing of exon 11 (Seino 
and Bell, 1989). The insulin receptor with exon 11 (HIR-B or Exll+) has 12 more amino 
acids at the carboxy-terminus of the α-subunit after Arg-723, compared with the other 
isoform (HIR-A or Exll-). The tissue distribution established by Northern blotting suggests 
that Exll- is the predominant species in liver and is very rare in leukocytes and muscle. 
Placenta and adipocytes express both isoforms of the insulin receptor at nearly equal levels 
(Benecke et al., 1992). 
1.4.1.1.2 Insulin receptor substrates (IRSs) 
The IRS family is made up of six family members, IRS-1, 2, 3, 4, 5 and 6 (Chakraborty et al., 
2011), but the two main types present in most cells are IRS-1 and IRS-2 (Sun et al., 1991; 
Sun et al., 1995). It has been reported that mice lacking IRS-1 or IRS-2 proteins develop 
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insulin resistance (Waterfield & Greenfield 1991, Araki et al., 1994, Withers et al., 1998). In 
animal models and patients with type 2 diabetes and insulin resistance, insulin-stimulated 
tyrosine phosphorylation of IRS-1 and IRS-2 is impaired in adipose tissue, liver and skeletal 
muscle (Bjornholm et al., 1997; Kerouz et al., 1997; Cusi et al., 2000). Dearth et al., (2006) 
reported that the overexpression of IRS-1 in transgenic mice leads to the development of 
breast cancer. IRS-1 is essential for cell cycle progression and cell maturation (Fasshauer et 
al., 2001; Machado-Neto et al., 2011), while IRS-2 plays an important role in neural 
homeostasis (Martin et al., 2012; Murillo-Cuesta et al., 2012). 
1.4.1.1.3 Phosphoinositide 3-kinase (PI3-K) 
PI3Ks are divided into three classes (I–III). The class I family consists of four distinct protein 
species with a molecular weight of 110 kDa (p110a, p110b, p110d and p110g). Most 
structural features and substrate specificity of class I enzymes are similar (Rameh and 
Cantley, 1999; Fry, 2001; Katso et al., 2001). Based on their mechanisms of activation, the 
class I family members are further subdivided into two groups, Class 1A and class 1B. Active 
PI3-K triggers PKB activation (Reif et al., 1997, Astoul et al., 1999) which can accelerate the 
rate of glycogen formation. Previous studies reported that peripheral insulin resistance occurs 
at the proximal end of insulin signalling, where the activation of PI3-K is attenuated (Saltiel 
and Kahn 2001; Shulman, 2004). The EGF receptor that functions upstream of PI3-K, has 
been linked with a number of cancers, when it is overexpressed as a result of mutation 
(Walker et al., 2009; Bleeker et al., 2012; Bleeker et al., 2014). 
1.4.1.1.4 Phosphoinositide-dependent protein kinase-1 (PDK1) 
The 556-residue enzyme isolated from human tissues (hPDK1) contains a catalytic domain 
(residues 84–341) and a COOH-terminal pleckstrin homology or pleckstrin homology (PH) 
domain (residues 450–550). hPDK1 phosphorylates Akt at Thr308 and activates the enzyme 
in a PI3-kinase-dependent manner. In addition to Akt, hPDK1 phosphorylates and activates 
another PI3-kinase downstream target, p70S6K (Pullen et al., 1998). PDK1 activates and 
phosphorylates protein kinase A, B, C, G and p70 S6 kinase (Cheng et al., 1998; Chou et al., 
1998; Le Good et al., 1998; Dutil et al., 1998; Dong et al., 1999; Kobayashi and Cohen, 
1999; Park et al., 1999). Lack of PDK-1 in mice causes mild glucose intolerance, 
approximately 40 % decrease in body mass (Frodin et al., 2002; Mora et al., 2004) and it is 
also known to promote the development and growth of melanomas (Scortegagna et al., 2014). 
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The overexpression of phosphorylated PDK-1   has been implicated in human breast cancer 
(Lin et al., 2005; Maurer et al., 2009).  
1.4.1.1.5 Protein kinase B (PKB)  
Protein kinase B (also termed Akt) is involved in mediating the metabolic actions of insulin 
(Vanhaesebroeck and Alessi, 2000). It has three functional domains: an N-terminal PH 
domain, which comprises the lipid-binding region that facilitates the translocation of the 
protein to the membrane. The C-terminal hydrophobic motif, contains both the 
phosphorylation site Ser473 and a docking site for PDK-1, which phosphorylates PKB on 
Thr308 (Scheid and Woodgett, 2003). Akt1 and Akt2 play significant roles in insulin 
signalling in skeletal muscle and adipose tissue, whereas Akt3 is additionally activated by 
insulin in liver (Cho et al., 2001a; Cho et al., 2001b). Akt indirectly activates glycolytic 
enzymes through HIF transcription factors and phosphorylation of phosphofructokinase-2 
(PFK 2) which activates phosphofructokinase-1 (PFK 1) (Simons et al., 2012).  
1.4.1.1.6 Glycogen synthase kinase 3 (GSK-3) 
This enzyme plays a key role in the regulation of glycogen metabolism. Glycogen synthase 
kinase 3 (GSK-3) is also necessary for proper axis formation during embryonic development 
(Frame and Cohen, 2001). Two forms of GSK-3 are found in mammals, GSK3α and GSK3β. 
GSK3β is found in the central nervous system (Leroy and Brion, 1999). GSK-3 is 
constitutively active in cells, and its activity can be suppressed by several extracellular 
stimuli, such as insulin, fibroblast growth factor (FGF), epidermal growth factor (EGF) and 
Wnt ligands (Frame and Cohen, 2001; Grimes and Jope,  2001; Woodgett, 2001). GSK-3 is 
inhibited by phosphorylation on a serine residue (Ser9 in GSK-3β and Ser21 in GSK-3α) 
located in the N-terminal domain. In certain cell types, such as adipocytes, insulin activates 
glycogen synthase, whereas EGF does not (Robinson et al., 1993). One of the main 
characteristics of diabetic muscle is the inhibition of glycogen synthase (GS) and the loss of 
glycogen synthesis (Shulman, et al., 1995). The role of GSK-3 in diabetes was further 
demonstrated in two model systems: in fat tissue of obese diabetic mice, where GSK-3 
activity was found to be twofold higher than in control mice (Eldar-Finkelman, 1999); and in 
skeletal muscle of type II diabetics, where GSK-3 activity and expression levels were 
significantly higher than in healthy individuals (Nikoulina et al., 2000). GSK-3 inhibitors 
induce apoptosis in pancreatic and glioma cancer cells (Marchand et al., 2012). It is also used 
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in the treatment of type II diabetes (Rayasam et al., 2009). Studies have shown that 
competitive inhibitors of GSK-3 improve glucose tolerance in diabetic mice (Jope et al., 
2007). 
1.4.1.1.7 Glycogen synthase (GS) 
Glycogen synthase is a rate-limiting enzyme and is key to the regulation of the rate of 
glycogen synthesis (Villar-Palasi and Larner, 1961; Leloir and Cardini 1962).  GS requires 
glycogenin to initiate the synthesis of glycogen (Palm et al., 2013). The highest concentration 
of GS is found in the blood stream 30 – 60 minutes following vigorous exercise (Jentjens and 
Jeukendrup, 2003). GS occurs in two forms: synthase I and synthase D (Rosell-Perez et al., 
1962; Traut and Lipmann, 1963; Rosell-Perez and Larner 1964 b) and is activated mainly 
through allosteric regulation instead of covalent regulation (Bouskila et al., 2008; Bouskila et 
al., 2010). In humans with type II diabetes, hyperglycaemia has been shown to reduce both 
GS activity (Thorburn et al., 1990) and glycogen synthesis (Shulman et al., 1990; Rothman et 
al., 1992). Insulin activates GS by activating protein phosphatase-1 (PP-1) and inhibiting 
glycogen synthase kinases (Saltiel, 2001). 
1.4.1.1.8 Glycogen phosphorylase (GP) 
Glycogen phosphorylase is an enzyme that occurs in two forms, phosphorylase GPa and GPb 
(Kristiansen et al., 2004; Johnson, 2009). The isozymes of GP are found in brain, liver and 
muscle of mammals. The brain type can be found in embryonic tissues and adult brain, 
whereas, the muscle and liver types are located in skeletal muscle and adult liver respectively 
(David and Crerar, 1986). GP is present in resting skeletal muscle almost entirely in the b 
form (Krebs and Fischer 1955). The inhibition of GP activity has been proposed as one 
method for treating type II diabetes (Somsak et al., 2003; Henke, 2012). Since glucose 
production in the liver has been shown to increase in type II diabetic patients (Moller, 2001), 
downregulating GP activity will stop the release of glucose from the liver’s glycogen 
supplies. Insulin terminates the glycogenolytic process in order to prevent further breakdown 
of glycogen. Docsa and colleagues (2011) reported that glucopyranosylidene-spiro-
thiohydantoin (TH) was effective in lowering glycogen phosphorylase a levels and also in 






This process involves the removal of glucose monomers to produce glucose-1-phosphate and 
glycogen with one less glucose molecule this reaction being catalyzed by the phosphorylated 
form of glycogen phosphorylase (Krebs, 1997). Adrenaline and glucagon are known to 
stimulate glycogenolysis by binding to a G-protein coupled receptor (Ring et al., 2013, Siu et 
al., 2013) which activates adenyl cyclase (Williamson et al., 1981, Krebs, 1997). Adenyl 
cyclase in turn converts ATP to cyclic AMP which activates protein kinase A (PKA), PKA 
then activates glycogen phosphorylase (Newgard et al., 1989). Lodish and colleagues (2007) 
also reported that glycogen degradation in myocytes may be stimulated by neural signals. 
1.4.3 Gluconeogenesis 
Gluconeogenesis describes the production of glucose from non-carbohydrate sources such as 
glucogenic amino acids, glycerol, lactate, glutamine and alanine. It takes place in the liver, 
intestine and kidney (Mithieux et al., 2004, Widmaier, 2006). When blood sugar levels are 
low, glucagon activates the gluconeogenic process and inhibits glycolysis (Mutel et al., 
2011). 
 




1.5 LIPID HOMEOSTASIS 
1.5.1 Lipoproteins 
There are four types of lipoproteins 
1.5.1.1 Chylomicrons (CMs) 
Chylomicrons (CMs) are composed of triglyceride (85-92 %), phospholipids (6-12 %), 
cholesterol (1-3 %) and proteins (1-2 %) (Mahmood, 2000). They are produced in the small 
intestines and promote the delivery of dietary fats to muscles or fat cells. Chylomicrons also 
enhance the delivery of dietary cholesterol from the intestines to the liver (Chung and Wasan, 
2004). They have been implicated in the progression of atherosclerosis (Gower et al., 2011). 
1.5.1.2 Very low density lipoproteins (VLDLs) 
The liver is responsible for the production of very low density lipoproteins (VLDLs) 
(Gibbons et al., 2004). It facilitates the transportation of triglycerides, cholesterol and 
phospholipids from the liver to fat cells. VLDL transports about 10-15 % of the total 
cholesterol present in the blood (Antonopoulos, 2002). The main structural and regulatory 
proteins that can be found in VLDLs are apolipoprotein B100, apolipoprotein E and 
microsomal triglyceride transfer protein (Bobe et al., 2004). Accumulation of lipid in the 
liver occurs when triglyceride synthesis exceeds the rate of triglyceride clearance either 
through hydrolysis or secretion of VLDLs (van Dorland et al., 2011). 
1.5.1.3 Low density lipoproteins (LDLs) 
The main particle responsible for the movement of cholesterol from the liver to other cells of 
the body is low density lipoproteins (LDLs). LDLs carry about 60-70 % of serum cholesterol 
(Antonopoulos, 2002). They are strongly linked with atherosclerosis but ingestion of 
antioxidants may reduce LDL’s contribution to atherosclerosis (Esterbauer et al., 1991; 
Stocker and Keaney 2004). Green tea has been reported to protect human LDL against 
oxidative damage (Ohmori et al., 2005), as a result of radical scavenging ability of catechins 
(Zhu et al., 1999). Oral ingestion of catechins by healthy Japanese men protected them 
against the deleterious effect of LDL oxidation and improved their total antioxidant capacity 
(Suzuki-Sugihara et al., 2016). 
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1.5.1.4 High density lipoproteins (HDLs)  
HDL particles are small in size, about 5-17 nm (Assmann and Gotto, 2004). HDL subclasses 
differ in their composition of lipids, apolipoprotein (apo A-I and apo A-II) and lipids transfer 
proteins such as cholesteryl ester transfer protein (CETP), lecithin cholesterol acetyl 
transferase (LCAT), PAF-AH, PON1, and phospholipid transfer protein (Link et al., 2007). 
The removal of excess cholesterol from the arterial wall is done by HDL. The anti-
inflammatory effect of HDL has been reported in vivo. Patel et al., (2010) reported that 
infusion of apo-A1 inhibits acute vascular inflammation in normo-cholesteromic New 
Zealand white rabbits.  
1.5.2 Lipoprotein lipase (LPL) 
Lipoprotein lipase is a hydrophilic enzyme that plays an important role in lipid metabolism. 
LPL includes hepatic lipase, pancreatic lipase and endothelial lipase. LPL is synthesized 
mainly in muscle and adipose tissues (Goldberg, 1996; Fielding and Frayn, 1998). Insulin 
regulates the synthesis and activity of LPL in adipose tissue. In the fed state, the activity of 
LPL is upregulated in adipose tissue, while it is downregulated in muscle (Goldberg, 1996; 
Fielding and Frayn, 1998). During fasting, insulin levels are low; this leads to HSL activation 
and adipose tissue lipolysis stimulated by catecholamine begins. Fasting also increases LPL 
activity in muscle, while in adipose tissue, LPL activity is downregulated. LPL deficiency 
causes hypertriglyceridemia (Okubo et al., 2007), while overexpression of LPL in mice has 
been reported to promote obesity (Delezie et al., 2012) and affect insulin response (Ferreira et 
al., 2001; Kim et al., 2001). 
1.5.3 Hormone sensitive lipase (HSL) 
Hormone-sensitive lipase (HSL) is an intracellular lipase capable of hydrolyzing stored fat in 
the form of triacylglycerol (TAG), diacylglycerol (DAG), monoacyglycerol (MAG) and 
cholesteryl esters, to release free fatty acids (FFA) (Kraemer and Shen, 2002). HSL can be 
sub-divided into four regions, amino terminal domain, lipid binding domain, carboxyl 
terminal domain and the regulatory domain of the enzyme, which contains the 
phosphorylation sites of HSL (Antonis et al., 2011). Furthermore, previous studies reported 
that HSL may play a role in the polygenic background of obesity and type II diabetes 
(Klannemark et al., 1998; Magre et al., 1998). The activity of HSL is enhanced by 
adrenocorticotrophic hormone, (ACTH) and catecholamines, whereas insulin suppresses its 
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activity (Holm et al., 2000). Evidence also suggests that hydrogen peroxide (H2O2) generated 
by insulin inhibited lipolysis (Zentella de Pina et al., 2008).  
1.5.4 Insulin 
Insulin activates lipogenic enzymes like acetyl CoA carboxylase and fatty acid synthase and 
also enhances the activity of lipoprotein lipase (Kersten, 2001). It also inhibits the activity of 
hormone sensitive lipase in adipose tissue (Anthonsen et al., 1998). During lipodystrophy, 
plasma fatty acid levels are high; this leads to accumulation of triglycerides in islet cells, 
muscle, plasma and liver, resulting in hypertriglyceridemia and insulin resistance (Garg and 
Misra, 2004). 
1.6 Cholesterol 
Cholesterol is the main component of cellular membranes and serves two functions. Firstly, it 
modulates the fluidity of membranes, enabling them to maintain their function over a wide 
range of temperatures. Secondly, it acts as a cellular insulator by preventing leakage of ions 
(Haines, 2001).   About 20-25 % of the daily cholesterol synthesis occurs in the liver, other 
sites of synthesis include the reproductive organs, intestines and adrenal glands. The 
synthesis of cholesterol is regulated by SREBP (sterol regulatory element-binding protein) 
(Espenshade and Hughes, 2007). Cholesterol is susceptible to oxidation leading to the 
formation of oxysterols that participate in various aspects of lipid metabolism such as 
regulation of gene transcription and biosynthesis of bile acid (Russell, 2000). 
Hypercholesterolemia is associated with an increased risk of developing atherosclerosis and 
coronary heart disease (Lewis, 2011). 
1.7 Triglycerides 
Triglycerides are the major components of human skin oils, vegetable oil and animal fats 
(Lampe et al., 1983; Nelson and Cox, 2000). Triglycerides are the main constituents of 
chylomicrons and very low density lipoprotein (VLDL) and play a vital role in metabolism as 
energy sources and also facilitate the movement of dietary fats. They contain more calories 
per gram than carbohydrates (Drummond et al., 2014).  Yki-Jarvinen (2010) reported that 




1.8 TREATMENT OF DIABETES MELLITUS 
1.8.1 Synthetic hypoglycaemic agents 
Management of diabetes mellitus involves the use of insulin and synthetic hypoglycaemic 
agents such as biguanides (metformin), sulphonylureas (glibenclamide), alpha glucosidase 
inhibitor (acarbose), dipeptidyl peptidase 4 inhibitors (DPP-4) (vildagliptin) and 
thiazolidinediones (TZDs) (rosiglitazone). Several side effects are associated with these 
synthetic anti-diabetic drugs (Moller, 2001). Compared with synthetic compounds, natural 
products have significant antidiabetic potential with little side effects (Verspohl, 2002; 
Neelesh et al., 2010).  
1.8.1.1 Insulin 
Insulin is produced by the beta cells of the pancreas. It facilitates the uptake of glucose from 
the blood into adipose tissue and skeletal muscle. It also suppresses the production of glucose 
by the liver (Sonksen and Sonksen, 2000). Type I diabetic patients depend solely on insulin 
for survival (Varshosaz, 2007).  Side effects associated with insulin include blurry vision, 
water retention, hypoglycaemia, sweating, hunger and weakness. Examples of biosynthetic 
insulin include rapid acting insulin analogues (aspart and lyspro) and long acting insulin 












   
 
        





Figure 1.5: Hypoglycaemic action of different drugs (Adapted from Oiknine and Mooradian, 
2003).  
 
1.8.1.2 Sulphonylureas  
Sulphonylureas are antidiabetic drugs used in the management of type II diabetes mellitus 
and   trigger the release of insulin from the beta cells of the islets of Langerhans (Amod et al., 
2012, South African Medicines Formulary, 2012). Evidence suggests that when 
sulphonylureas are used with another anti-diabetic drug, diabetic patients experience a better 
blood sugar lowering effect (Hanefeld, 2007). Some side effects associated with 
sulphonylureas include weight gain and hypoglycaemia (Fowler, 2010, Amod et al., 2012, 
South African Medicines Formulary, 2012). Examples of sulphonylureas include gliclazide, 
glipizide, glimepiride, glibenclamide and chlorpropamide. 
1.8.1.3 Biguanides 
Biguanides (e.g metformin) are oral hypoglycaemic drugs used for treating type II diabetes 
mellitus (Rang et al., 2003). They enhance insulin sensitivity, resulting in decreased plasma 
glucose levels, decreased gluconeogenesis and increased glucose uptake. Previous studies 
reported that biguanides reduce triglyceride and LDL cholesterol levels (El Messaoudi et al., 
2011; Joint Formulatory Commitee, 2013). One of the proposed mechanisms of action of 
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metformin is that it activates AMP-activated protein kinase (AMPK), which in turn increases 
small heterodimer partner (SHP) expression, thereby inhibiting the expression of 
gluconeogenic genes in the liver such as glucose-6-phosphatase and phosphoenol pyruvate 
carboxykinase (Kim et al., 2008), This series of enzyme activities suppresses the production 
of glucose by the liver (Kirpichnikov et al., 2002). Side effects include diarrhoea, nausea and 
vomiting (Sumari, 2012). 
1.8.1.4 Thiazolidinediones  
Thiazolidinediones are synthethic oral hypoglycaemic agents used for the treatment of type II 
diabetes mellitus. Examples of thiazolidinediones include rosiglitazone, pioglitazone, 
lobeglitazone and troglitazone. The mechanism of action of thiazolidinediones entails the 
activation of peroxisome proliferator activated receptors (PPARs), specifically PPAR 
gamma. PPAR alpha is found in the liver (Lee et al., 2003), PPAR delta is found in the 
spleen, colon, heart, small intestine, brain, skeletal muscle, keratinocytes, thymus and lung 
(Girroir et al., 2008) while PPAR gamma is located in the heart, colon, liver, macrophages, 
adipocytes and skeletal muscle. Thiazolidinedione is a ligand which activates PPARγ. PPARγ 
complexes with retinoid X receptor (RXR) to form a heterodimer, which binds to DNA and 
then upregulates the transcriptional and translational activities of a number of proteins 
involved in lipid and glucose metabolism as well as cellular differentiation. 
Thiazolidinediones act by increasing insulin sensitivity, thereby enhancing glucose uptake 
into liver, muscle and adipose tissue, with concomitant decrease in glucose production (Nolan 
et al., 1994; Iwamoto et al., 1996; Yki-Jarvinen, 2004). Increased risk of fractures and 
oedema is associated with the use of thiazolidinediones, especially in women (Sumari, 2012).  
1.8.1.5 Alpha glucosidase inhibitors 
Alpha glucosidases are membrane bound intestinal enzymes that hydrolyze disaccharides, 
trisaccharides and oligosaccharides into glucose and some other monosaccharides for 
absorption by the body. They are hypoglycaemic drugs used for treating type II diabetes 
mellitus, and act by preventing carbohydrate absorption such as sugar from the gut (Campbell 
et al., 1996). Side effects include diarrhoea and flatulence (Sumari, 2012). Examples of alpha 





1.8.1.6 Dipeptidyl peptidase 4 (DPP-4) inhibitors 
These inhibitors are oral hypoglycaemic agents used for treating type II diabetes mellitus. 
Examples include sitagliptin, alogliptin, saxagliptin, anagliptin, vildagliptin and gemigliptin. 
They inhibit dipeptidyl peptidase 4. The mechanism of action of DPP-4 inhibitors is to 
enhance levels of  incretin (GLP-1 and GIP) (Dupre et al., 1995; Behme et al., 2003; 
McIntosh et al., 2005), which in turn inhibit the release of glucagon, this leads to increased 
insulin secretion and decreased blood sugar levels. Side effects include nasopharyngitis, 
upper respiratory tract infection and headache (John, 2008). Oxidative stress leads to the 
production of reactive oxygen species such as superoxide radical and hydroxyl radical. 
Various DPP-4 inhibitors have been reported to reduce oxidative stress (Kroller-Schon et al., 
2012; Maeda et al., 2012). Recently, a novel DPP-4 inhibitor (teneligliptin) was reported to 
possess hydroxyl radical (.OH) scavenging activity (Shinichiro et al., 2016). 
1.9 REVIEW ON MEDICINAL PLANTS WITH ANTIDIABETIC POTENTIAL 
1.9.1 Introduction 
The ethnobotanical survey route has been identified as a major route in the search for plants 
that can provide new drugs for the treatment of diabetes. Several plants have been shown to 
have antidiabetic properties and some are discussed below.  
1.9.2 Achyranthes aspera 
This plant can be found growing in Australia, Asia, America, Baluchistan and Ceylon. It is a 
medicinal herb and can grow up to 2 m, the plant is crushed and boiled, and then taken for the 
treatment of pneumonia. It can also be used for treating night blindness and cutaneous 
diseases (Nadkarni, 2009). Previous studies reported the hypoglycaemic activity of aqueous 
and methanolic extracts of the whole plant (Akhtar and Iqbal, 1991). Treatment of normal 
and alloxan induced diabetic animals with this plant reduced blood glucose levels (Akhtar 
and Iqbal, 1991). A dose of 100 mg/kg of this plant reduced serum triglycerides, cholesterol, 
total lipids and phospholipids in hyperlipidemic rats (Khanna et al., 1992).  
1.9.3 Artemisia afra 
Artemisia afra (AN) grows in Ethiopia, Kenya, Tanzania, Uganda, Zimbabwe, Namibia, 
Lesotho, Swaziland and South Africa (Hilliard, 1977; van Wyk et al., 1997). It is also called 
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Umhlonyane. Leaves are dark green, producing butter-coloured yellow flowers (Hilliard, 
1977). The leaves and roots are boiled and then taken for the treatment of diabetes. This plant 
has also demonstrated antioxidant, antimalarial and antimicrobial effects (Burits et al., 2001; 
Gathirwa et al., 2007; Vagionas et al., 2007). 
1.9.4 Brachylaena discolor 
Brachylaena discolor (BD) is also known as Umphahla. Leaves from this plant have been 
reported to possess antihyperglycaemic activity (Erasto et al., 2005). It is an evergreen tree 
and can grow up to 10 metres (van Wyk and van Wyk, 2007). It can be found growing in 
South Africa and Mozambique. Mellem et al. (2013) reported that the methanolic extract of 
this plant reduced blood sugar levels in STZ-induced diabetic rats.  
1.9.5 Catharanthus roseus 
Catharanthus roseus (CR) is also known as Isisushlungu. This plant originated from 
Madagascar, but can also be found growing in South Africa (van Wyk et al., 1997). It grows 
as high as 1m (van Wyk et al., 2002). Studies carried out on the ethanolic extracts of the 
leaves and flowers of C. roseus showed that the plant extracts possess anti-hyperglycaemic 
activity (Ghosh and Gupta, 1980; Chattopadhyay et al., 1991a; 1991b). It has also been 
reported to possess antibacterial activity (Chinnavenkataraman and Rajendran, 2012). 
1.9.6 Helichrysum nudifolium 
Helichrysum nudifolium (HN) is a highly nutritious plant. It is also known as Ichocholo, and 
its boiled leaves and roots have been reported to elicit an anti-hyperglycaemic effect (Erasto 
et al., 2005). It is found in tropical Africa and Lesotho. 
1.9.7 Helichrysum odoratissimum   
Helichrysum odoratissimum (HO) is also known as Imphepho in Zulu and is considered 
native to Southern Africa. It can also be found growing in Angola, Uganda, Botswana, 
Congo, Ethiopia and Sudan. The main stalk grows as high as 1 m with lots of side branches. 
The flowers produce a repulsive and pungent fragrance (Metafro, 2009). HO is used for the 
treatment of ailments like coughs and colds. The flower of HO is made into a paste for the 
treatment of acne and pimples. The plant is burnt and used to repel mosquitoes and other 
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biting insects (Hyde and Wursten 2007). The antidiabetic potential of this plant has also been 
reported (Erasto et al., 2005; Njagi et al., 2015). 
 
Figure 1.6: Picture of Helichrysum odoratissimum (source: www.plantzafrica.com) 
 
 1.9.8 Helichrysum petiolare  
Helichrysum petiolare (HP) is a plant which can be found in South Africa, Portugal and the 
United States of America. Leaves are hairy and dark green in colour (Hilliard, 1983). It is 
also called Imphepho in Zulu. The whole plant is crushed and boiled and taken as infusion. 
Its blood glucose lowering effect has been reported (Erasto et al., 2005).  
1.9.9 Hypoxidaceae hypoxis hemerocallidea 
Hypoxidaceae hypoxis hemerocallidea (HHH) is also called Inongwe. Pulverized fresh corms 
are soaked in hot water and taken to treat diabetes (Erasto et al., 2005). It is a medicinal plant 
which can be found growing in Lesotho, Mozambique, Zimbabwe, Limpopo, Guateng, 
Eastern Cape and KwaZulu-Natal provinces (van Wyk et al., 1997). This medicinal plant is 
edible and is taken for the treatment of various ailments such as asthma, tuberculosis, cancer, 
arthritis and hypertension (Watt and Breyer-Brandwijk, 1962; Hutchings, 1989; Pujol, 1990; 
23 
 
Albrecht, 1995; Hutchings 1996; van Wyk et al., 2002). Mahomed and Ojewole (2003) 
reported that the aqueous extract of this plant caused reductions in blood sugar levels in 
fasted normal and STZ-treated diabetic rats. The leaf and corm of this plant demonstrate an 
anti-inflammatory effect through the inhibition of COX-1 and COX-2 enzymes (Ncube et al., 
2012). 
1.9.10 Moringa oleifera  
Moringa oleifera (MO) grows in Paraguay, Brazil, North-Eastern Pakistan, West Asia, the 
Arabian Peninsula, North-Eastern Bangladesh, Sri Lanka, East and West Africa and the West 
Indies, Central and South America from Mexico to Peru and Southern Florida, (Roloff et al., 
2009). This plant is also called drumstick tree. MO is a deciduous, fast-growing tree which is 
9 m high. It is highly nutritious and has been used for human medication. Leaves are about 
30-45 cm long (Roloff et al., 2009). MO plant is highly nutritious and the health benefits 
derived from the consumption of MO are numerous.  MO leaves, roots, flowers, seeds and 
gums are used for treating various ailments such as inflammation, liver and cardiovascular 
diseases (Faizi et al., 1994; Limaye et al., 1995; Rao and Misra, 1998). It has been reported 
that the methanolic extract of MO dried fruit powder can trigger insulin release from the 
rodent pancreatic beta cells (Francis et al., 2004). A recent report showed that the aqueous 




Figure 1.7: Picture of Moringa oleifera (Source: www.scholarsresearchlibrary.com) 
 
1.9.11 Trigonella foenum graecum 
Trigonella foenum graecum (TFG) can be found growing in Afghanistan, France, Iran, 
Argentina, Nepal, Pakistan, Morocco, Bangladesh, Spain, India and Turkey. It is known to 
have a sweet smell and the seed is known to possess hypoglycaemic and hypocholesterolemic 
effects in type I and type II diabetics and diabetic animals (Khosla et al., 1995; Puri et al., 
1995; Puri et al., 2002; Kumar et al., 2005a; Hamza et al., 2012). It is also used for treating 
allergic and inflammatory diseases (Min-Jung et al., 2012). 
1.9.12 Vernonia amygdalina 
Vernonia amygdalina (VA), is a plant known for its bitter taste, can be found growing in most 
countries of tropical Africa, and it can also be found growing in Limpopo, Mpumalanga, 
Eastern Cape and KwaZulu-Natal provinces of South Africa (Bonsi et al., 1995; Awe et al., 
1999). This plant has been reported to elicit antioxidant and hepatoprotective effects 
(Nwanjo, 2005; Adaramoye et al., 2008; Owolabi et al., 2008; Adesanoye and Farombi, 
2010). Previous studies reported the hypoglycaemic potential of aqueous and ethanolic 
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extract of the leaves of this plant (Erasto et al., 2005; Ekpo et al., 2007; Khang et al., 2011). 
The aqueous, ethanolic and methanolic extracts of the leaves of this plant have been reported 
to modulate serum lipid levels (Nwanjo, 2005; Ekpo et al., 2007 Adaramoye et al., 2008). 
1.9.13 Vernonia oligocephala 
Vernonia oligocephala (VO) is also called Umhlunguhlungu. It is widely distributed in 
Zimbabwe, Zambia and South Africa (South African National Biodiversity Institute, 2009). 
Twigs, leaves and roots of this plant are used for the treatment of ailments like diabetes, 
fever, abdominal pain, dysentery, constipation and rheumatism (Watt and Breyer Brandwijk, 
1962; Pujol, 1990; Hutchings, 1996; Erasto et al., 2005; South African National Biodiversity 
Institute, 2009). The in vitro anti-plasmodial activity of this plant has been reported (Clarkson 
et al., 2004). 
1.9.14 Psidium guajava 
Psidium guajava (PG) originated from Mexico (Rios et al., 1977). It is also found growing in 
South America, Europe, Africa and Asia (Stone, 1970). PG is a small tree that grows up to 10 
m high. The beneficial effects of PG on human health are numerous. The reported 
pharmacological activities include hepatoprotection, antispasmodic, anti-allergy, 
antiplasmodial, cardioactive, anticough, antimicrobial, antigenotoxic and anti-cancer effects 
(Gutierrez et al., 2008). Its antidiabetic potential in the regulation of blood glucose levels in 
STZ induced diabetic rats has also been reported (Chin Siu et al., 2011).  
The roots, immature fruits, leaves and bark of PG can be used in the treatment of 
gastroenteritis, dysentery and diarrhoea. Leaves can also be used for the treatment of ulcers 
and rheumatic pain, while the consumption of PG relieves toothache (Heinrich et al., 1998). 
Treatment of diabetic patients with PG protected them against cytotoxicity induced by 
glucose, glyoxal, and methylglyoxal, showing the antiapoptotic potential of PG (Hsieh et al., 
2007). Besides the medicinal uses, PG is employed as food: juice, pastes, concentrates, and 
jelly nectar etc. (Jimenez-Escrig et al., 2001). PG is also used to make hair combs (Morton, 
1987).  Previous studies have reported that the bark (Mukhtar et al., 2006), fruit (Chin Shiu et 
al., 2011) and leaves (Oh et al., 2005; Banu  et al., 2013) of the common guava, P. guajava, 
exhibit an anti-diabetic effect. Previous authors have suggested that the antidiabetic effects of 
PG can be linked to polyphenolic compounds and triterpenes present in the plant, which 
ameliorates the deleterious effects of free radicals (Gutierrez et al., 2008).  
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Insulin responsive tissues such as liver, muscle, adipose tissue, kidney, brain and pancreatic β 
cells play important roles in the removal of excess glucose from the circulatory system 
(Thirone et al., 2006). There is little information on how oral PG supplementation might 
change the function of liver, muscle and adipose tissue in glucose homeostasis and 
pathogenesis of diabetes. It is with these considerations that this study was designed to 
investigate the anti-diabetic mechanism of action of PG, and also effects of PG on enzymes 
such as protein kinase B (PKB/Akt), glycogen synthase (GS) and glycogen phosphorylase 
(GP). The deposition of glycogen in liver and muscle following treatment was also 
investigated. The effect of PG on serum lipids; hormone sensitive lipase (HSL) enzyme and 
markers of liver and muscle dysfunction was also investigated. Compared with synthetic 
compounds, natural products are, less expensive, with minimal side effects and have 
antidiabetic potential (Verspohl, 2002; Neelesh et al., 2010). Therefore studies on edible 
plants with anti-diabetic properties will be valuable in the management of diabetes. In this 
study aqueous extracts of the medicinal plants listed below were investigated for their anti-
diabetic potential in streptozotocin induced diabetic rats. 
1. Moringa oleifera 
2. Psidium guajava  








The pancreas is made up of 1 million islets of Langerhans (Hellman et al., 2007). Most islets 
contain five types of cell: alpha cells (secretes glucagon), beta-cells (secrete insulin), delta 
cells (secrete somatostatin), epsilon cells (secrete ghrelin), and PP cells (secrete pancreatic 
polypeptide). Streptozotocin (STZ) is a glucosamine nitrosourea compound which is used to 
induce diabetes when administered to rats (Balamurugan et al., 2003) by targeting beta cells. 
STZ enters the beta cell via the glucose transporter GLUT2 and causes damage to the DNA 
by adding an alkyl group to DNA molecule (Melmed et al., 1973; Bennett and Pegg, 1981). 
DNA damage promotes activation of poly ADP-ribosylation, formation of superoxide 
radicals, leading to the destruction of beta cells (Szkudelski, 2001).  
 
Figure 1.9: Structure of streptozotocin (STZ) (Source: commons.wikimedia.org)  
1.11 AIM 
To investigate the antidiabetic effects and mechanism of action of Psidium guajava in 
streptozotocin-induced diabetic rats. 
1.12 OBJECTIVES 
1. To determine the in vivo antidiabetic effects of aqueous extracts of Moringa oleifera, 
Helichrysum odoratissimum and Psidium guajava in streptozotocin induced diabetic rats. 
2. To assess changes in the expression of p-Akt, GP, GS and HSL after treatment with PG 
using SDS-PAGE Western Blot analysis. 
3. To measure the activities of glycogen phosphorylase and glycogen synthase enzymes in 
liver and skeletal muscle. This objective will also include an assessment of changes in levels 
of glycogen in liver and muscle following treatment of rats with PG. 
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4. To determine the effect of PG aqueous extract on the activity of hormone sensitive lipase 
enzyme in liver and adipose tissue and on serum triglycerides, total cholesterol, LDL-
cholesterol, HDL-cholesterol, cardiac risk factor and atherogenesis. 
5. Phytochemical characterization of the extract via Gas Chromatography Mass Spectroscopy 
(GCMS) to identify the bioactive compounds. 
6. To investigate the effect of PG on ameliorating diabetic damage done to the pancreatic 
islets through histopathological analysis of the pancreas. 
7. To determine the activities of serum lactate dehydrogenase, aspartate aminotransferase and 
alanine transaminase levels after treating rats with PG. These enzymes are used as biomarkers 



















MATERIALS AND METHODS 
2.1 MATERIALS 
The following antibodies and chemicals used for this study were bought from South Africa 
and Germany. The antibodies for anti-phospho-Akt (Akt 1/PKB α), anti-glyceraldehyde-3-
phosphate dehydrogenase (anti-GAPDH) and anti-GS were purchased from Cell Signalling 
Technology, South Africa. The rabbit anti-GP and rabbit anti-HSL antibodies were purchased 
from ABCAM, Centurion, South Africa while the secondary goat anti rabbit antibody IgG 
alkaline phosphatase conjugate was purchased from BIORAD, Johannesburg, South Africa.  







C-UDPG) were purchased from BIOTREND, Cologne, Germany. 
Sodium hydroxide (NaOH), hydrochloric acid (HCl), disodium hydrogen phosphate 
(Na2HPO4), potassium sodium tartarate (KNaC4H4O4.H2O), sodium citrate, potassium iodide 
(KI), sodium sulphate (NaSO4), copper sulphate (CuSO4.H2O), potassium hydroxide (KOH), 
citric acid and sulphuric acid were purchased from MERCK, South Africa. Ammonium 
persulphate, 10X Tris/Glycine/SDS buffer, N, N, N, N -tetramethylethylenediamine 
(TEMED), sodium dodecyl sulphate (SDS) and Tris base were purchased from either 
SIGMA-ALDRICH or BIORAD, South Africa. Bovine serum albumin (BSA), streptozotocin 
(STZ), leupeptin hemisulphate, β-mercabromophenol blue, sodium pyrophosphate (Na4P2O7), 
Nonidet P-40, sodium orthovanadate (Na3VO4), sodium fluoride (NaF), 3-(N-morpholino) 
propanesulfonic acid (MOPS), di-potassium hydrogen orthophosphate (K2HPO4), glycogen, 
2-(N-morpholino) ethanesulfonic acid (MES), benzamidine hydrochloride hydrate, Triton-X 
100, dithiothreitol (DTT), glucose-6-phosphate disodium salt, uridinediphosphoglucose 
(UDPG), α-D-glucose 1-phosphate disodium salt hydrate, N’N’- bis- methylene-acrylamide, 
phenol solution, acrylamide, adenosine monophosphate, methanol, 
phenylmethanesulfonylfluoride (PMSF), potassium chloride (KCl), potassium dihydrogen 
phosphate (KH2PO4), ethylene diaminetetraacetic acid (EDTA), dimethyl sulfoxide (DMSO), 
Tween-20, glycerol, sodium chloride (NaCl) and glycine were purchased from SIGMA-




2.2 ETHICAL CLEARANCE 
Ethical clearance for animal studies was obtained from the Animal Ethics Committee of the 
University of KwaZulu-Natal (reference 105/12/Animal). 
2.3 ANIMALS AND DIET  
Male Sprague-Dawley rats 230-250g body weight were procured from the Biomedical 
Resource Unit (BRU) at University of KwaZulu-Natal (Westville Campus). The animals had 
free access to water and food (Meadows, Pietermaritzburg) throughout the experimental 
period.  The experiments were performed and animals maintained according to guidelines 
stipulated in the University of KwaZulu-Natal (UKZN) Animal Ethics Committee Standard 
Protocol Booklet.      
2.4 METHODS 
2.4.1 Preparation of plant materials 
Fresh leaves of Psidium guajava Linn (PG), Moringa oleifera (MO), Helichrysum 
odoratissimum (HO) were collected in Durban, KwaZulu-Natal province, South Africa. They 
were identified and authenticated by Prof Ashley Nicholas, Taxonomist, University of 
KwaZulu-Natal, South Africa, in the month of July 2012. A voucher specimen number TO 1-
4/2012 has been submitted at the ward herbarium, University of KwaZulu-Natal, Westville 
Campus, Durban, South Africa. The leaves were washed with distilled water, air dried, 
crushed using a blender and extracted with distilled water for 48 hours at room temperature. 
The extract was filtered and the filtrate lyophilized using a freeze drier (Wirsam Scientific 
and Precision Equipment, (PTY) Ltd, Germany). The powder product was stored at room 
temperature for further analysis. 
2.4.2 Induction of diabetes 
After overnight fasting, a single dose of 40 mg/kg body weight of streptozotocin dissolved in 
0.1 M citrate buffer pH 4.5 was administered to male Sprague-Dawley rats intraperitoneally 
for diabetes induction. Animals having blood glucose levels of 7-14 mmol/l
 
after a week 




 2.4.3 Preliminary studies 
The leaves of MO, HO and PG were dried under shade and ground into powder. The powder 
was extracted in water only at room temperature for 48h. Each of the three extracts was 
filtered and filtrates subsequently lyophilized using a freeze drier (Wirsam Scientific and 
Precision Equipment, (PTY) Ltd, Germany). The samples were stored at room temperature. 
The filtrate was used for subchronic studies. 
After induction of diabetes, the route of administration for both the test substance and vehicle 
was via oral gavage. Animals were separated into eight groups of 6 rats each, NC (normal 
control), NPG (normal treated with Psidium guajava (PG)), NMO (normal treated with 
Moringa oleifera (MO)), NHO (normal treated with Helichrysum odoratissimum (HO)) and 
DC (diabetic control), DPG (diabetic animals treated with PG), DMO (diabetic animals 
treated with MO), DHO (diabetic animals treated with HO). The untreated normal and 
diabetic rats were given distilled water, while the treated normal and diabetic rats were given 
400 mg/kg body weight of PG, MO and HO for 14 days after which animals were sacrificed.  
Blood samples were collected into non-heparinized tubes and centrifuged at 3000 g for 10 
min to obtain serum which was stored at -20 
0
C pending analysis. A portion of adipose tissue 
(visceral side), liver and muscle was removed and stored at -20 
0
C for subsequent analysis. 
The pancreas was also removed and fixed in 10 % formalin. Animals having blood glucose 
levels of 7-14 mmol/l
 
after a week were considered having a stable type II diabetic state 
before starting the experiment. 
 2.5 SUB-CHRONIC STUDIES 
Male Sprague-Dawley rats were separated into 8 groups of 6 rats each: non-diabetic control 
(NC), non-diabetic PG (NPG), diabetic control (DC), diabetic PG (DPG). The NC and DC 
groups were given the vehicle (distilled water). The NPG and DPG groups were treated with 
aqueous extract of Psidium guajava (400 mg/kg body weight) daily for 14 days. Rats were 
euthanized after treatment. The adipose tissue, liver and skeletal muscle was collected, and 
stored at -20 
0
C for subsequent analysis.  
2.6 ORAL GLUCOSE TOLERANCE TEST (OGTT) 
OGTT was conducted on both normal and diabetic rats. The animals were fasted for 12 hours 
after which glucose (1g/kg b.w.) was administered orally via oral gavage. Blood glucose 
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levels were measured at 0 (just before glucose ingestion), 15, 30, 60, 90 and 120 min after the 
ingestion of glucose using a glucometer (ACCU CHEK, Basel, Switzerland). 
2.7 ACUTE STUDIES ON EFFECT OF PSIDIUM GUAJAVA AQUEOUS EXTRACT 
ON THE INSULIN SIGNALLING CASCADE 
Male Sprague-Dawley rats of 230-250 g body weight were separated into 4 groups and in 
each group 2 rats were used at each time interval. The groups were as follows: non-diabetic 
control (NC), non-diabetic PG (NPG), diabetic control (DC), diabetic PG (DPG). The NC 
and the DC groups were given the vehicle (distilled water). The NPG and DPG were treated 
with Psidium guajava aqueous extract (400 mg/kg body weight). Rats were euthanized after 
treatment at the following time intervals: (n = 2) for 15 and 30 minutes and (n = 6) for 60 
minutes. The adipose tissue, liver and muscle were collected and stored at -20 
0
C. 
2.8 TISSUE PROCESSING FOR WESTERN BLOTS 
2.8.1 Skeletal muscle 
Skeletal muscle samples were prepared for Western blotting by the method of Sakamoto et 
al. (2003). Samples were homogenized in a buffer comprising 20 mM Tris, pH 7.5, 10 mM 
Na4P2O7, 100 mM NaF, 5 mM EDTA, 3 mM benzamidine, 1 % Nonidet P-40, 7 µM 
leupeptin, 2 mM Na3VO4 and 1 mM PMSF. Homogenates were transferred into centrifuge 
tubes, maintained on ice, and then centrifuged at 14,000 g for 10 mins at 4 
0
C. Supernatants 
were removed and kept for subsequent analysis. Thereafter, the protein concentrations in each 
sample were measured using the Biuret method.   
2.8.2 Liver 
The liver samples were processed according to the method of Feres et al., (2010). Samples 
were homogenized in a solution containing 1 % Triton X-100, 2.0 mmol/L of PMSF, 100 
mmol/L of Tris-HCl pH7.4, 100 mmol/L of Na4P2O7, 10 mmol/L of EDTA, 10 mmol/L of 
Na3VO4, 100 mmol/L of NaF and 3 µg/ml aprotinin. The homogenates were decanted into 
centrifuge tubes maintained on ice and then centrifuged at 12,000 g for 20 min at 4 °C.  
Supernatants were removed and stored for further analysis. The protein concentrations in 




2.8.3 Adipose tissue 
Adipose tissue samples were prepared using a method described by Alonso et al. (2005). 
Samples were homogenized in 3 ml of 3mM benzamidine, 50 mM Tris–HCl (pH 7.5), 0.05 % 
sodium deoxycholate (C24H39NaO4), 1 % Nonidet P-40, 1 mM Na3VO4 and 150 mM NaCl. 
The homogenates were centrifuged at 12000 g at 4 
0
C for 10 min. Three different layers 
developed after centrifugation; the upper and bottom layers were discarded; only the middle 
layer (infranatant) was stored at - 20 
0
C for subsequent analysis. The protein concentrations 
in each sample were measured using the Folin-Lowry method.  
2.9 SDS-PAGE AND WESTERN BLOT ANALYSIS 
Proteins in homogenates of samples from liver, skeletal muscle and adipose tissue were 
mixed with loading buffer with equal amounts of protein being loaded on each gel and 
separated by SDS-PAGE (10 % gel) in Tris/Glycine/SDS buffer, pH 8.3 at 110 V using a 
Bio-Rad Mini – PROTEAN 3 Electrophoresis cell, BIORAD (South Africa). The proteins on 
gels were transferred to nitrocellulose membranes containing Tris/glycine/methanol buffer, 
pH 8.3 at 100 V for 2 hours using a Bio-Rad Electrophoretic Transfer Cell, BIORAD (South 
Africa). After transfer, the membranes were blocked in buffer containing 3 % non fat dried 
milk, Tris buffered saline containing 0.1 % Tween 20 and 20 mM Tris, and NaCl overnight at 
4 ⁰C for the three primary antibodies listed below except phospho-Akt. p-Akt was blocked in 
(Tris Buffer Saline-Tween 20 (TBS-T) only. The membranes were probed with primary 
antibodies (anti-glycogen synthase, anti-glycogen phosphorylase, anti-phospho Akt and anti-
hormone sensitive lipase) diluted 1:1000 in TBS 0.1 % Tween 20 with shaking for an hour at 
room temperature. Thereafter the membranes were washed (3×10 min) with TBS 0.1 % 
Tween 20. After washing, membranes were probed with Goat anti-Rabbit IgG alkaline 
phosphatase conjugate (1:1500 in TBS 0.1 % Tween 20 for 1 hour at room temperature after 
which the membranes were washed (4×5 min) with TBS 0.1 % Tween 20. Proteins were 
viewed after exposure to 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium/nitro 
blue tetrazolium chloride (BCIP/NBT), thereafter, images were captured and the intensity of 
the bands was quantified using Gene Tools Analysis Software. Western blot analysis of 






2.10 ANALYSIS OF ENZYME ACTIVITY 
2.10.1 Glycogen synthase activity assay 
Liver and skeletal muscle samples were prepared and processed for glycogen synthase 
activity assay using a radiochemical procedure as described by Mandarino et al. (1987). 
Samples were homogenized in a buffer containing 50 mM potassium phosphate buffer, pH 
7.4, 20 mM EDTA, 2 mM DTT and 20 mM NaF. The homogenates were centrifuged, after 
which supernatants were collected and diluted in a buffer containing 50 mM Tris-HCl, pH 
7.8, 25 mM NaF and 20 mM EDTA. The reaction was started by mixing 50 µl of the sample 
and 50 µl of reaction mixture containing 25 mM NaF, 10 mM glucose-6-phosphate (G6P), 20 
mM EDTA, 50 mM Tris-HCl (pH 7.8), 1 µCi [U-
14
C]uridinediphosphate glucose (UDPG), 1 
% glycogen and 5 mM UDPG. The reaction mixture was placed in a water bath for 
incubation at 30 
0
C for 20 minutes and the reaction was stopped by adding 50 µl of the 
incubated mixture on a filter paper, which was dropped in a vial containing cold 70 % (v/v) 
ethanol for glycogen precipitation. Filter papers were washed (2×30 minutes) in 70 % 
ethanol, allowed to dry and placed in scintillation vials containing scintillation fluid for 
14
C 
determination. A blank was prepared containing buffer only.  
2.10.2 Glycogen phosphorylase activity (GP) assay 
Glycogen phosphorylase activity was assayed using a radiochemical procedure adapted from 
Taylor et al. (2006). Liver and muscle samples were homogenized in a solution containing 50 
mM NaF, 10 mM MOPS, 5 mM EDTA, and 1 mM DTT, pH 7.0.  Homogenates were 
transferred into centrifuge tubes and maintained on ice. The homogenates were centrifuged at 
4 
0
C for 10 minutes at 9000 g, after which supernatants were removed and stored for 
subsequent analysis. The reaction was started by mixing 50 μL of sample and 50 μL of assay 
buffer consisting 22.3 mM G-1-P, 33 mM MES, 0.34 % glycogen, and 1 μCi/ml D-[U
14
C]-
glucose-1-phosphate and the mixture was incubated inside a water bath at 30 
0
C for 20 mins. 
Thereafter the reaction was stopped by adding 50 µl of the incubated mixture on a filter paper 
which was dropped in a vial containing cold 70 % (v/v) ethanol for glycogen precipitation. 
The filter papers were washed (2×30 minutes) in 70 % ethanol, allowed to dry and placed in 
scintillation vials containing scintillation fluid for 
14
C determination. A blank was prepared 




2.10.3 HORMONE SENSITIVE LIPASE ACTIVITY (HSL) ASSAY 
2.10.3.1 Adipose and liver tissue homogenization  
Adipose tissue samples were prepared by the method described by Alonso et al. (2005). 
Samples were homogenized in a buffer containing 50 mM Tris–HCl (pH 7.5), 1 mM 
dithiothreitol, 0.25 mM sucrose, 1 mM EDTA, 5 μg/ml leupeptin, 1mM PMSF and 3 mM 
benzamidine. The homogenates were transferred into centrifuge tubes and centrifuged at 
12,000 g at 4 
0
C for 10 mins using a Beckman Coulter centrifuge (Avanti J-26 XPI). Three 
layers developed after centrifugation, only the middle layer (infranatant) was collected and 
stored for subsequent analysis. 
The liver was processed according to a method by Feres et.al. (2010).  Liver samples were 
homogenized in a buffer containing 1 % Triton X-100, 2 mM of PMSF, 100 mM of Tris-HCl 
(pH 7.4), 100 mM of Na4P2O7, 100 mM of NaF, 10 mM of EDTA, 3 µg/ml aprotinin and 10 
mM of Na3VO4). Homogenates were then centrifuged at 12,000 X g for 20 min at 4 
0
C using 
Beckman Coulter J26-XPI centrifuge (USA) and the supernatant collected. 
2.10.3.2 Preparation of the substrate solution  
Two and a half (2.5 ml) substrate solutionwas prepared by emulsifying 1.8 mM cholesteryl 
(
3
H) oleate (S.A: 2.3 x 10
-3
 Ci/mmol) with 5.6 mg of 
phosphatidylcholine/phosphatidylinositol (3/1 by weight) in chloroform. (2 ml, 0.1 M) 
potassium phosphate (pH 7) was then added to the solution. The substrate solution was then 
subjected to a mild heat at 37 
0
C to allow for chloroform removal. The substrate solution was 
sonicated (2 x 2 minutes) with 1 minute intervals. The sonication process was repeated, and 
thereafter, 0.5 ml of 0.5 g/ml BSA in 0.1 M potassium phosphate (pH 7) was added.  
2.10.3.3 Activity assay  
Hormone sensitive lipase activity was assayed by the procedure of Ylitalo et al. (2000) with 
some modifications. A mixture of 0.03 ml aliquot of substrate solution, 5 µl of 50 mM 
EDTA, 5 µl of 5 mM DTT and 100 µl of sample was incubated for 120 mins at 20 
0
C with 
shaking at 100 cycles/min. The reaction was stopped by adding 800 µl of 
methanol/chloroform/heptane (1.41/1.25/1 by volume) and 250 µl of 0.1 M potassium 
carbonate/0.1 M boric buffer (pH 10.5). The released radioactively labeled oleate was 
retrieved by a one-step liquid-liquid partition system. The mixture was shaken for 20 sec and 
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centrifuged at 800 g for 20 min. A 0.25 ml aliquot taken from the upper phase was mixed 
with 1.8 ml scintillation fluid and placed in scintillation vials for counting. 
2.11 SERUM ENZYMES 
Blood samples were collected into non-heparinized tubes and placed in a container containing 
ice. Thereafter, serum was obtained by centrifuging the samples at 3000 rpm for 10 minutes. 
The serum was collected and stored at -20 
0
C for subsequent analysis. The activities of 
alanine aminotransferase (ALT), aspartate amino transferase (AST) and lactate 
dehydrogenase (LDH) were carried out using a Labmax Plano Chemistry analyzer from 
Brazil. The principles of the methods are described below. 
2.11.1 Alanine Amino Transferase (ALT) 
ALT activity was determined using the method described by Reitman and Frankel (1957). 
Principle 
ALT catalyzes the reaction between L-alanine and α-oxoglutarate, to yield L-glutamate and 
pyruvate. The pyruvate formed is reduced to lactate in a reaction catalysed by lactate 
dehydrogenase to form L-lactate and NAD
+
. The rate of the NADH oxidation is determined 
by measuring the absorbance of NADH at 340 nm. 
 α-oxoglutarate + L-alanine         ALT                Pyruvate + L-glutamate 
Pyruvate + NADH + H
+ 
LDH              L-lactate + NAD
+
 
2.11.2 Aspartate Amino Transferase (AST) 
AST activity was measured using the method described by Reitman and Frankel (1957). 
Principle 
The transfer of an amino group from L-aspartate to α-oxoglutarate is catalyzed by the enzyme 
aspartate amino transferase. The products of the reaction are L-glutamate and oxaloacetate. 
Oxaloacetate reacts with NADH in a reaction catalysed by malate dehydrogenase (MDH) to 
form NAD
+
. The catalytic AST activity is determined by measuring the absorbance of NADH 
at 340 nm.  
α-oxoglutarate + L-aspartate            AST             oxaloacetate + L-glutamate 
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Oxaloacetate + NADH + H
+
            MDH            L-malate + NAD
+
 
2.11.3 Lactate Dehydrogenase (LDH) 
LDH assay was carried out using the method described by Wroblewski and La Due (1955). 
Principle 
The conversion of lactate to pyruvate, is catalyzed by the enzyme lactate dehydrogenase 
(LDH). The increase in absorbance of NADH at 340 nm is directly proportional to lactate 
dehydrogenase activity in the sample. 
Lactate dehydrogenase (LDH) catalyzes the following reaction: 
Lactate + NAD
+
                                      Pyruvate + NADH 
2.12 ESTIMATION OF LIVER AND SKELETAL MUSCLE GLYCOGEN CONTENT 
Liver and skeletal muscle glycogen content was determined using a procedure adapted from 
Nader and Esser (2001). The tissues (0.25 g) were weighed and thereafter 1 ml of 30 % KOH 
saturated with NaSO4 was added to each sample. The samples were boiled for 30 minutes for 
complete digestion, removed from water bath and placed on ice. While on ice; 4 ml of 95 % 
cold ethanol was added to the samples. Samples were vortexed immediately and incubated on 
ice for 30 minutes. After incubation, samples were centrifuged at 550 rpm using Beckman 
centrifuge 5810R for 30 minutes. The supernatants were discarded and this was followed by 
addition of 1 ml of H2O and 5 % phenol. Samples were vortexed and 5 ml of 36N sulphuric 
acid was added followed by incubation on ice for 30 minutes. Thereafter; the absorbances 
were measured using a UV-VIS spectrophotometer (Shimadzu, Corporation, Kyoto, Japan) at 
490nm. A glycogen standard curve was constructed in the range of 0-100 µg/ml (see 
Appendix). 
 2.13 ESTIMATION OF SERUM LIPIDS 
The blood samples were collected into non-heparinized tubes and placed in a container 
containing ice. Thereafter, serum was obtained by centrifuging the samples at 3000 rpm for 
10 minutes using a centrifuge (Labofuge 200-Heraeussepatech). The serum was collected and 
stored at -20 
0
C for subsequent analysis. Serum lipid profiles (total cholesterol, triglycerides, 
LDL-c, cardiac risk factor, atherogenic index and HDL-c), were measured using a Labmax 
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Plano Chemistry analyzer, Brazil. The levels of low-density lipoprotein (LDL-c) were 
calculated using the Friedewald et al, (1972) formula, while atherogenic index (AI) and 
cardiac risk factor (CRF) were calculated using the formulae of Hostmark et al. (1991) and 
Kim and Sho (2007) respectively. The principles of the methods are described below. 
2.13.1 Estimation of total serum cholesterol  
This was carried out using the method described by Roschlau et al. (1974) 
Principle 
Cholesterol esters undergo enzymatic hydrolysis by an enzyme esterase to yield cholesterol 
and fatty acids, one of the products of hydrolysis. Cholesterol is further oxidized to give 
hydrogen peroxide and cholestene-3-one. The final process is the reaction of phenol with 
hydrogen peroxide and 4-aminoantipyrine to yield quinoneimine; this process is catalysed by 
peroxidase. The change in absorbance is measured at 520 nm. The color intensity is directly 
proportional to the concentration of cholesterol in the sample. 
Cholesterol ester + H2O   
Cholesterol esterase            
Cholesterol + Fatty acids 
Cholesterol + O2               
Cholesterol oxidase              
Cholestene-3-one + H2O2 
2H2O2 + 4- aminoantipyrine + phenol       
Peroxidase 
              quinoneimine + 4H2O 
2.13.2 Estimation of serum HDL-Cholesterol 
Serum HDL cholesterol analysis was performed using the method described by Loppes-
Virella (1977). 
Principle 
In this assay, the first process is the addition of a precipitating reagent (20 % w/v 
polyethylene glycol in glycine buffer at pH 10 and 25 
0
C) to serum samples. Thereafter, the 
samples are vortexed, centrifuged and all beta lipoproteins (LDL and VLDL fractions) are 
precipitated. The resulting supernatant (which contains the HDL fraction) is used for the 
determination of HDL-cholesterol. The concentration of HDL-cholesterol is measured by 
hydrolyzing HDL-cholesteryl esters to yield free HDL-unesterified cholesterol and fatty acid. 




peroxide. After oxidation, the indicator of HDL-cholesterol is quinoneimine. Absorbance is 
measured at 600 nm and is directly proportional to HDL-cholesterol concentration. 
 
HDL-cholesteryl esters + H2O                                           HDL-unesterified cholesterol + fatty 
acid  
Unesterified cholesterol + O2                                                 cholestene-3-one + H2O2  
H2O2 + 4-aminoantipyrine + phenol                             quinoneimine dye + H2O  
2.13.3 Estimation of serum triglyceride concentration 
The concentration of triglyceride in serum samples was determined using the method  
described by Fossati and Lorenzo (1982)  
Principle 
A lipase hydrolyses triglycerides into fatty acids and glycerol. Glycerol is converted to 
glycerol-1-phosphate and ADP in the presence of ATP and glycerol kinase. Thereafter, 
glycerol-1-phosphate is broken down by the enzyme glycerol phosphate oxidase to yield 
dihydroxyacetone, phosphate and hydrogen peroxide. Finally, the indicator of triglycerides 
(red colored quinoneimine dye) is formed when 4-chlorophenol reacts with 4-
aminophenazone and hydrogen peroxide. The absorbance of the colored complex, which is 
measured spectrophotometrically at 546 nm, is directly proportional to the triglycerides 
concentration in the sample. 
Triglycerides + 3H2O       
lipases
            fatty acids + glycerol 
Glycerol + ATP              
glycerol kinase
            glycerol-1-phosphate + ADP 
Glycerol-1-phosphate + O2     
glycerol phosphate oxidase
      dihydroxyacetone + H2O2 + phosphate 
2H2O2 + 4-chlorophenol + 4-aminophenazone          
peroxidase









2.14 PROTEIN DETERMINATION 
2.14.1 Biuret assay for protein determination 
The protein concentration in the liver was determined using the procedure described by 
Gornall et al., (1949) with modifications. The standard was prepared using bovine serum 
albumin (10 mg/ml BSA). To prepare the biuret reagent, 3 g of copper sulphate (CuSO4. 
5H2O) and 9 g of sodium potassium tartarate (NaKC4H4O6.4H2O) were dissolved in 500 ml 
of 0.2 M sodium hydroxide (NaOH), thereafter, 5 g of potassium iodide, (KI) was added and 
the solution made up to 1000 ml with 0.2 M NaOH. To 2 ml of protein sample, 3 ml of the 
biuret reagent was added. The solutions were vortexed and incubated for 10 minutes at 37 
0
C. 
Thereafter, solutions were read in a spectrophotometer at 540 nm. A standard curve of the 
absorbances against protein concentrations in the range of 0-10 mg/ml was plotted. The 
protein content of the samples was extrapolated from the standard curve. 
2.14.2 Folin-Lowry assay for protein determination 
Protein concentrations for muscle and adipose tissue were determined using a procedure 
described by Lowry et al. (1951). The samples were diluted using 0.1N NaOH, thereafter 5 
ml of alkaline reagent (2 % Na2CO3 in 0.1 N NaOH) and copper sulphate-sodium in 
potassium tartrate solution (0.5 % CuSO4.5H2O in 1 % Na-K tartarate) were mixed together 
in the ratio of 50:1 (v/v). The resulting mixture was vortexed and incubated at 40 
0
C for 15 
minutes. The tubes were cooled and 0.5 ml of Folin Ciocalteau reagent was added. The tubes 
were incubated at 25 
0
C for 30 minutes again and thereafter the absorbances of the resulting 
solutions were read in a spectrophotometer at 600 nm. The standard used was BSA and the 
standard curve of the absorbances against protein concentrations in the range of (20 – 100 µg) 
was plotted. 
2.15 HISTOPATHOLOGY OF THE PANCREAS 
Histopathological analysis of  pancreatic tissues was carried out using a standard laboratory 
protocol by immersing the tissue in 10 % formalin  after which it was dehydrated with (70 %, 
80 %, 95 %, 100 %, 100 % 100 % alcohol) each for 1 hour. Thereafter, clearing was done 
with xylene (2×1 hour), and the sample was infiltrated with paraffin wax for (1.5 hour × 2) 
and placed in an oven overnight. 
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Specimens were then orientated for optimal sectioning and embedded in moulds. Moulds 
were placed on cold plate to settle wax and then the block was popped out. Specimens were 
sectioned at 4 μm on the HM 315 microtome and picked up on frosted slides. Sectioned 
tissue was then stained with haematoxylin and eosin as follows: xylene–3 min, 2 min, alcohol 
(100 %, 90 %, 70 % and 50 %) for 2 min each, after which it was immersed in distilled water, 
then haematoxylin for 5 min, the blue sections were put in water and then eosin for 3 min, 
after which the slides were dipped in 90 % alcohol and then 100 % alcohol. Excess alcohol 
was drained off and slides were placed in xylene before the coverslip was mounted 
permanently with DPX mountant. Coverslips were left overnight to dry thoroughly. The 
slides were then mounted in distyrene plasticizer xylene (DPX), cover-slipped and viewed 
with Leica slide scanner (SCN 4000, Leica Biosystems Germany). 
2.16 GAS CHROMATOGRAPHY-MASS SPECTROMETRIC (GC-MS) ANALYSIS  
Aqueous extract of Psidium guajava (PG) leaf was subjected to GC-MS analysis for 
identification of bioactive compounds present in PG. A standard laboratory protocol was used 
in the analysis of Psidium guajava. The analysis was done using Agilent Technologies 6890 
Series GC coupled with an Agilent 5973 mass selective detector driven by Agilent 
chemstation software. A HP-5MS capillary column was used (30 m × 0.25 mm internal 
diameter, 0.25 μm film thickness).  Helium was used as carrier gas at a flow rate of 1.0 
mL/min and a linear velocity of 37cm/sec. The injector temperature was set at 250 
0
C. The 
initial oven temperature was 60 
0
C and was programmed to increase to 280 
0
C at the rate of 
10 
0
C/min with a hold time of 4 min at each increment. The injection volume of 2 μL was 
made in the splitless mode with a split ratio of 20:1. The mass spectrometer was operated in 
the electron ionization mode at 70 eV and electron multiplier voltage at 1859 V. Other MS 





C, solvent delay 4 min and scan range 50-700 amu. The retention times, 
fragmentation pattern and mass spectral data were used in the identification of the unknown 
compounds by comparing them with those stored in the National Institute of Standards and 
Technology (NIST) library. This was done to confirm the name, molecular weight and 





2.17 DATA ANALYSIS 
All data analysis was done using GraphPadInStat Software (version 5.00, GraphPad 
Software, San Diego, California, USA). Statistical comparison between groups was done 
using one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 

































3.1 Preliminary studies on the effect of plant extracts on blood glucose levels 
 
Table 3.1 Effect of plant extracts on blood glucose levels  
 




























 Fasting blood glucose levels of normoglycaemic and hyperglycaemic male Sprague –Dawley rats n=6. 
The data is represented as mean ± SEM. Blood glucose levels were expressed in mmol/L. NC (normal 
control), NPG (normal treated with PG), NMO (normal treated with MO), NHO (normal treated with 
HO) and DC (diabetic control), DPG (diabetic animals treated with PG), DMO (diabetic animals treated 
with MO), DHO (diabetic animals treated with HO). MO – Moringa oleifera; HO – Helichrysum 
odoratissimum and PG – Psidium guajava 
The results in Table 3.1 show the fasting blood glucose levels of normal and diabetic animals 
after 14 days of treatment. Three different plants were used in this study (MO, HO and PG). 
There was an increase in blood glucose levels in both MO and HO diabetic treated animals 
after 14 days whilePG treatment caused a slight  in blood glucose levels in diabetic 









3.1 Effect of Psidium guajava on blood glucose levels 
 
 
Figure 3.1: Effects of PG on blood glucose levels after 14 days of treatment n = 5. * p < 0.05 values differ 
significantly from normal control (NC), normal treated (NPG) and diabetic treated (DPG) groups. 
 
Figure 3.1 above shows the fasting blood glucose levels of normal and diabetic male 
Sprague-Dawley rats after 14 days of treatment with PG. PG reduced blood glucose levels in 
the diabetic treated group (DPG). In Figure 3.1, a significant p < 0.05 reduction in blood 
glucose levels was observed in normal control (NC), normal treated (NPG) and diabetic 










































Figure 3.2: Oral glucose tolerance tests (OGTT) were conducted on normal and diabetic 12-hr fasted rats 
treated with PG. Values are expressed as % of the initial glucose concentration which was taken to be 
100%. The data is represented as mean ± SEM.  (n = 4). NC = 4.76 ± 0.1208 NPG= 5.5 ± 0.1183 DC= 13.92 
± 0.3470 DPG= 9.280 ± 0.8434 
 
Following a glucose load, fasting blood glucose levels of normal and diabetic male Sprague-
Dawley rats were measured over a 2 hour period. The blood glucose levels are expressed as 
% variation in blood glucose levels from time zero. In Figure 3.2, there was a rapid decline in 
blood glucose levels in normal control (NC), normal treated (NPG) and diabetic treated 
(DPG) animals as compared to untreated diabetic animals at 120 minutes. This showed that 






3.3 SDS-PAGE gels for liver, muscle and adipose tissue homogenates 
 
  
                   
 
Figure 3.3 Coomassie stained 10% SDS-PAGE gels of: liver and skeletal muscle supernatants with 20 μg 
of protein loaded in each lane, A. Lanes: 1 (molecular weight marker); 2 and 6 (NC) = normal control; 3 
and 7 (NPG) = normal treated group; 4 and 8 (DC) = diabetic control; 5 and 9 (DPG) = diabetic treated 
group; and adipose tissue infranatant with 10 μg of protein loaded in each lane.  
B. Lanes: 1 (molecular weight marker); 2 (NC) = normal control; 3 (NPG) = normal treated group; 4 
(DC) = diabetic control; 5 (DPG) = diabetic treated group. 
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 The SDS-PAGE gels for liver, muscle and adipose tissue homogenates are shown in Fig 3.3 
and differences in intensity of bands. The bands in the adipose tissue gel were faint due to 
low protein content in adipose tissue. 
 
3.4 Acute studies on effects of PG on expression of enzymes of the insulin signalling 
pathway 
 
An effect of PG on the activation of PKB/Akt was studied. The enzyme was phospho-Akt 
(Ser 473) with GAPDH being used as a loading control. Phospho-Akt was detected at one 
time point (30 minutes). 
 







Figure 3.4: Expression of (A) phospho-Akt and (B) GAPDH in muscle of diabetic and non-diabetic rats at 
30 minutes following treatment. 40 μg of protein was loaded for A and 20 μg for B. (C) are the normalized 
values showing the ratio of phospho-Akt/GAPDH (loading control). NC (normal control), NPG (normal 
animals treated with PG), DC (diabetic control), DPG (diabetic animals treated with PG). 
 
The result of AKT phosphorylation in muscle is shown in Figure 3.4. After thirty minutes of 
PG treatment, the expression of phosphorylated Akt was highest in diabetic treated animals, 
followed by the normal control group and then the untreated diabetic animals. Non-diabetic 
treated animals had the lowest expression of phospho-Akt. The bands at 15 and 60 minute 
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Figure 3.5 A: Assessment of PG treatment on liver glycogen synthase activity. The results are presented 
as mean ± SEM for five rats. * p<0.05significant when compared to normal control (NC) and diabetic 
control group (DC). NC (normal control), NPG (normal animals treated with PG), DC (diabetic control), 









Figure 3.5 B: Assessment of PG treatment on liver glycogen phosphorylase activity. The results are 
presented as mean ± SEM for five rats. NC (normal control), NPG (normal animals treated with PG), DC 








































































The results in Figure 3.5 A show liver glycogen synthase activity on day 14 post treatment 
with PG. In normal animals, PG caused an elevation of GS. Of note was the significant 
elevation of GS activity in treated diabetic animals compared to normal untreated animals. 
PG treatment enhanced GS activity in diabetic rats.  
 
The result in Figure 3.5 B shows the liver GP activity on day 14 post treatment with PG. GP 
activity was slightly higher in untreated diabetic animals compared to diabetic treated 
animals. PG lowered GP activity in both NPG and DPG groups. 
 
3.6 Effect of PG on expression of GP in liver 
GP expression on day 14 of the subchronic study was lowest in untreated diabetic animals 
followed by diabetic treated animals. Non-diabetic control had the highest expression of GP 
amongst all groups. 
             








Figure 3.6: Expression of (A) GP and (B) GAPDH in liver of diabetic and non-diabetic rats. Forty micro 
gram (40µg) of protein was loaded for A and (20µg) for B. (C) are the normalized values showing the 
ratio of GP/GAPDH (loading control). NC (normal control), NPG (normal animals treated with PG), DC 















































Figure 3.7 A: Assessment of PG treatment on muscle glycogen synthase activity. The values are presented 
as mean ± SEM for five rats. * p < 0.05 significant compared to normal control group (NC) and normal 
treated group (NPG). NC (normal control), NPG (normal animals treated with PG), DC (diabetic 




































Figure 3.7 B: Assessment of PG treatment on muscle glycogen phosphorylase activity. The results are 
presented as mean ± SEM for five rats. NC (normal control), NPG (normal animals treated with PG), DC 
(diabetic control), DPG (diabetic animals treated with PG). nmol (nano moles of the reaction mixture). 
51 
 
The results in Figure 3.7 A show muscle glycogen synthase activity on day 14 post treatment 
with PG. In normal animals PG caused an elevation of GS. Of note was the significant 
depression of GS activity in untreated diabetic animals compared to both normal control and 
normal treated animals. PG treatment enhanced GS activity in diabetic animals.                                 
 
The results in Figure 3.7 B show that the muscle GP activity on day 14 post treatment with 
PG. GP activity was higher in untreated diabetic animals compared to diabetic treated 
animals. PG depressed GP activity in diabetic rats. 
 
3.8 Effect of PG treatment on Glycogen synthase and Glycogen phosphorylase 
expression in muscle 
The expressions of glycogen synthase and phosphorylase enzymes were investigated in liver 
and skeletal muscle on day 14 post treatment with PG. GAPDH was used as a loading control 
(Figures 3.8 A and 3.8 B). 
 
    
Figure 3.8 A: Expression  of (A) GS and (B) GAPDH in muscle of diabetic and non-diabetic rats. 40 μg of 
protein was loaded for A and 20 μg for B. (C) are the normalized values showing the ratio of  GS/GAPDH 
(loading control). NC (normal control), NPG (normal animals treated with PG), DC (diabetic control), 








Figure 3.8 B: Expression of (A) GP and (B) GAPDH in muscle of diabetic and non-diabetic rats. 20 μg of 
protein was loaded for A and 20 μg for B. (C) are the normalized values showing the ratio of GP/GAPDH 
(loading control). NC (normal control), NPG (normal animals treated with PG), DC (diabetic control), 
DPG (diabetic animals treated with PG). 
 
GS expression was depressed in untreated diabetic animals. Treatment of diabetic animals 
caused a dramatic rise in GS expression to levels beyond the control groups (Figure 3.8 A). 
GP expression on day 14 of the subchronic study was highest in untreated diabetic animals 
followed by diabetic treated animals. Untreated normal animals had the lowest expression of 
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Figure 3.9: Estimation of liver glycogen content. The results are presented as mean ± SEM for five rats. * 
p<0.05 significant when compared to diabetic control group (DC), # p < 0.05 significant when compared 
to normal control group (NC).  
 
The results in Figure 3.9 show that untreated diabetic animals had the lowest amount of 
glycogen which was 60 % of that in normal animals. The amount of liver glycogen was 















































Figure 3.10: Estimation of muscle glycogen content. The results are presented as mean ± SEM for five 
rats. * p < 0.05 significant when compared to diabetic control group (DC). NC (normal control), NPG 
(normal animals treated with PG), DC (diabetic control), DPG (diabetic animals treated with PG). 
 
The results in Figure 3.10 show that the amount of muscle glycogen was significantly higher 
in treated diabetic animals compared to untreated diabetic animals. Diabetic treated animals 
















































Figure 3.11: Assessment of PG treatment on liver hormone sensitive lipase activity. The results are 
presented as mean ± SEM for five rats. * p < 0.05 significant when compared to normal control group 
(NC), normal treated group (NPG) and diabetic treated group (DPG). NC (normal control), NPG (normal 
animals treated with PG), DC (diabetic control), DPG (diabetic animals treated with PG). nmol (nano 
moles of the reaction mixture). 
The result in Figure 3.11 shows the liver HSL activity on day 14 of the subchronic study. 
HSL activity in diabetic control animals was the highest being over 1000 % that in normal 
untreated animals. Treatment with PG depressed HSL activities for both diabetic and non-









3.12 Hormone sensitive lipase activity in adipose tissue 
The results in Figure 3.12 below show adipose tissue HSL activity on day 14 post treatment 
with PG. In normal animals PG treatment depressed HSL activity. Of note was the elevation 





Figure 3.12: Assessment of PG treatment on adipose tissue hormone sensitive lipase activity. The results 
are presented as mean ± SEM for five rats. * p < 0.05 significant when compared to diabetic treated 
group (DPG). NC (normal control), NPG (normal animals treated with PG), DC (diabetic control), DPG 








3.13 Effect of PG on expression of HSL in liver  
An effect of PG on the expression of hormone sensitive lipase enzyme was investigated in the 
liver after 14 days of treatment. Three isoforms of HSL were detected: 149, 90, 37 kDa (Fig 
3.13 A). In Fig 3.13 A, the 149 kDa isoform was highly expressed in untreated normal 
animals, compared to untreated diabetic animals. PG treatment of diabetic animals reduced 
the expression of this isoform of HSL. The normal treated animals had the highest expression 
of this isoform.  
The lowest expression for 90 kDa isoform was in diabetic treated animals. Treatment of 
normal animals with PG increased the expression of this isoform. The 37 kDa isoform was 
expressed more in non-diabetic animals when compared to untreated diabetic animals. The 
lowest expression was seen in untreated diabetic animals.  
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Figure 3.13: Expression of (A) HSL and (B) GAPDH in liver of PG-treated rats after 14 days. 60 μg of 
protein was loaded for A and 40 μg for B. (C) are the normalized values showing the ratio of 
HSL/GAPDH protein (loading control). NC (normal control), NPG (normal animals treated with PG), 
DC (diabetic control), DPG (diabetic animals treated with PG). 
 
3.14 Serum lipid profile 
Table 3.2 
Effect of PG treatment at 400mg/kg body weight for 14 days on serum triglycerides (TG), 
total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c), cardiac risk factor (CRF), 
atherogenic index (AI) and high density lipoprotein-cholesterol (HDL-c). 
   LIPID PROFILE       NC                                      NPG                           DC                                 DPG                                       
TG (mmol/l)         5.9±0.48                          5.6±0.34                     6.5±0.12                        4.85±0.87 
TC (mmol/l)         3.49±0.36                        3.4±0.09                     4.2±0.12                        3.7±0.16 
LDL-c (mmol/l)   0.5±0.15                          0.6±0.07                     1.5±0.07
a
                       0.4±0.2 
HDL-c (mmol/l)  1.8±0.13                          1.6±0.08                     1.3±0.17
b
                        2.4±0.19 
CRF (mmol/l)      1.9±0.13                          2.1±0.05                     3.2±0.39                         1.5±0.06
c
 
AI (mmol/l)          0.9±0.13                          1.10±0.05                   2.2±0.39                         0.5±0.06
d
        
 
 
Values are means ± SEM, n=5. Values of p<0.05 will be taken to imply statistical significance. NC 
(Normal Control); NPG (Normal treated group); DC (Diabetic Control); DPG (Diabetic treated group). 
a
 
p < 0.05 compared to NC, NPG and DPG; 
b
 p < 0.05 compared to NC, NPG and DC 
c
 p < 0.05 compared 
to NC, NPG and DC; 
d
 p < 0.05 compared to NC, NPG and DC  
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The results in Table 3.2 show serum levels of triglycerides, total cholesterol, low density 
lipoprotein cholesterol, high density lipoprotein cholesterol cardiac risk factor and 
atherogenic index on day 14 post treatment with PG. 
In treated diabetic animals, PG reduced the level of triglycerides but this was not statistically 
significant when compared to untreated diabetic animals. The level of total cholesterol was 
slightly higher in untreated diabetic animals compared to treated diabetic animals. Treatment 
with PG slightly reduced total cholesterol levels for both diabetic and treated non-diabetic 
animals. 
LDL-c cholesterol levels were significantly higher in untreated diabetic animals compared to 
untreated normal animals. Treatment with PG reduced LDL-c in both treated diabetic and 
non-diabetic animals. In treated diabetic animals, PG caused an elevation of HDL-c. Of note 
was the significant elevation of HDL-c levels in treated diabetic animals compared to 
untreated diabetic animals. 
Cardiac risk factor was significantly higher in untreated diabetic animals when compared to 
both non-diabetic and treated diabetic animals. In treated diabetic animals, PG depressed 














3.15 HISTOPATHOLOGY OF THE PANCREAS 
     
     
Figure 3.15: H&E staining for pancreatic tissues in normal and STZ induced diabetic rats. Rats were 
treated with P. guajava (PG) at 400 mg/kg body weight for 14 days.  
IL = islets of Langerhans, NC = Normal control group, NPG = Normal treated group, DC = Diabetic 
control group, DPG = Diabetic treated group.  
 
Histological examination was done on the pancreatic islets to assess the damage done by STZ 
and the protective effect of PG. The photomicrographs show the effect of PG on the pancreas 
of normal and diabetic rats. Photomicrographs of the NC and NPG animals showed that the 
morphology of the islet cells remained intact, whereas in the DC group extensive damage was 
done to the morphology of the islets of Langerhans which show a high degree of 
disintegration. In the DPG group, the deleterious effects of STZ on the morphology of the 









3.16 Serum biomarkers of tissue damage 
Table 3.3 
Effect of PG treatment on serum ALT, AST and LDH 
                                 NC                         NPG                                 DC                                   DPG 
ALT (U/l)     80.40±6.80             68.00±3.93                     123.6±8.50
β
                      80.60±10.88 
AST (U/l)     247.4±15.35            260.0±17.66                   208.2±14.34                      283.8±33.61        
LDH (U/l)    283.4±18.34            279.6±29.06                   230.6±16.33                      344.2±52.57 
 
 
Values are means ± SEM, n = 5. Values of p < 0.05 will be taken to imply statistical significance. NC 
(Normal Control); NPG (Normal treated group); DC (Diabetic Control); DPG (Diabetic treated group). 
β
 p < 0.05 compared to NC, NPG and DPG 
 
The results in Table 3.3 above show the levels of ALT, AST and LDH on day 14 of the sub-
chronic study. The serum level of ALT was highest in diabetic control animals. PG treatment 
decreased ALT levels in treated diabetic animals. The level of AST was high in both normal 
control and normal treated animals compared to untreated diabetic animals. The highest level 
of AST was seen in treated diabetic animals. Untreated normal animals showed slightly 
higher LDH levels compared to normal treated animals. The treated diabetic animals had the 















3.17 Phytochemical characterization of aqueous extract of PG using GC-MS  
 
Table 3.4: Identified bioactive compounds in the leaf of aqueous extract of Psidium 
guajava using GC-MS 




Protocatechuic acid 17.629 154 
Guavanoic acid 13.634 529 
Oleanolic acid 14.029 456 
2α-Hydroxyursolic acid 13.634 473 
Benzene-1,2-diol 5.799 110 






Aqueous extract of Psidium guajava leaves was subjected to GC-MS analysis in order to 
identify the bioactive compounds in the aqueous extract of the leaf. Seven compounds were 
identified in the extract by comparing their MS spectra to those of standard spectra from the 
NIST library. Guavanoic acid, oleanolic acid, protocatechuic acid, 2α-hydroxyursolic acid, 
benzene-1,2-diol, 2’-O-methyl guanosine and 5-bromo-8-(5-nitrosalicylideneamino)quinoline 
































































Figure 3.24 : GC-MS structure and spectrum of 5-Bromo-8-(5-nitrosalicylideneamino) quinoline 
hydrochloride 




  DISCUSSION 
a. Introduction 
Diabetes mellitus is characterized by impaired uptake and storage of glucose as well as 
reduced glucose utilization for energy purposes (Jacobsen et al., 2009; Sangeeta et al., 2010). 
Ethnomedical literature contains a large number of plants that have a potential in the 
treatment of diabetes, a disease in which reactive oxygen species and free radicals play a 
major pathophysiological role (Gutierrez et al., 2008).  
 
The liver plays a major role in regulating blood sugar levels; it absorbs glucose and stores it 
in the form of glycogen. The absorption and release of glucose by the liver helps to maintain 
blood glucose homeostasis. Glucose homeostasis helps to keep blood glucose levels constant, 
and this is achieved by a balance in endogenous glucose production and utilization (Roden 
and Bernroider, 2003). Previous studies reported that skeletal muscle accounts for about 75% 
of glucose disposal (Jensen et al., 2011). The primary site for lipid storage is adipose tissue 
which also contains little amounts of glycogen. Glucose entering the fat cell can also be 
stored as glycogen (Leonards and Landau, 1960; Moody and Gliemann, 1968). High levels of 
plasma free fatty acids (FFA) impair insulin signaling processes and have been linked with 
type 2 diabetes mellitus and insulin resistance (Arner, 2002).  
Various studies have shown that the bark (Leonti et al., 2001; Mukhtar et al., 2006), fruit 
(Chin-Shiu et al., 2011) and leaves (Mukhtar et al., 2004; Oh et al., 2005; Ojewole, 2005) of 
the common guava, P. guajava, exhibit anti-hyperglycaemic effect. In this study, we 
investigate the anti-diabetic mechanism of action of PG, and also effects of PG on the 
enzymes PKB/Akt, GS and GP. The deposition of glycogen in liver and muscle after 
treatment was also investigated. PG effect on markers of liver and muscle dysfunction, such 
as the activities of alanine amino transferases, aspartate amino transaminases and lactate 
dehydrogenase were measured in the serum. We also investigated the possibility that PG may 
exert its anti-hyperlipidemic effects by down-regulating the activity of hormone sensitive 
lipase enzyme, and also improve lipid profile reducing total cholesterol, triglycerides, cardiac 




b. Oral glucose tolerance test (OGTT) 
In the present study, there was a significant decrease in blood glucose levels of diabetic 
animals treated with PG compared to untreated diabetic animals (Figure 3.1), indicating its 
anti-diabetic potential. Furthermore, in the oral glucose tolerance test (OGTT) analysis, 
untreated diabetic animals showed high glucose intolerance while better glucose tolerance 
abilities were observed in diabetic animals treated with PG (Figure 3.2).  
c. Histopathological analysis 
Bioactive compounds in plants which possess antioxidant activity reduced the complications 
of diabetes mellitus (DM) by quenching the effects of free radicals (Yokozawa et al., 2002; 
Fenercioglu et al., 2010). In our present study, phytochemical characterization of Psidium 
guajava aqueous extract revealed that the identified compounds might possess antioxidative 
activity which might be responsible for the observed antidiabetic effect. The above 
hypothesis was supported by histopathological examinations of the pancreatic islets as shown 
in Figure 3.16 above. Previous authors reported that markers of oxidative stress can be seen 
in diabetic rats, such as necrosis and degranulation in islets of Langerhans (Coskun et al., 
2004; Amaral et al., 2008; Chin Siu et al., 2011). Our finding is similar to the work of the 
above mentioned authors. The improvement in the morphology of the pancreatic islets of 
diabetic animals treated with PG might be as a result of the bioactive compounds present in 
the plant; the treatment ameliorated the diabetic damage done to the pancreatic islets.  
d. Glucose transport 
Various studies have reported that the pathogenesis of diabetes can be linked to various 
signalling pathways, such as insulin signalling pathway (Huang and Chen, 2009). Regulation 
of enzymes in insulin, glycogenolytic or gluconeogenic pathways has presented promising 
sites therapeutic of interventions. For proper understanding of the mechanisms underlying the 
action of PG extract, the expression of an enzyme called Akt in skeletal muscle of normal and 
diabetic rats was determined. This protein was selected because it plays an important role in 
stimulating the movement of glucose transporter type 4 (GLUT 4) from internal membrane to 
the plasma membrane, thereby increasing glucose uptake. It also facilitates the synthesis of 
glycogen from glucose. Excessive production of reactive oxygen species (ROS) and impaired 
ROS clearance by antioxidant enzymes triggers oxidative stress, which promotes the 
activation of serine/threonine kinases such as Protein kinase C (PKC), Jun N-terminal kinase 
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(JNK), leading to the phosphorylation of insulin receptor or insulin receptor substrate (IRS) 
proteins (Hirosumi  et al., 2002; Kim  et al., 2004; Ragheb  et al., 2009).  This leads to a 
decline in their tyrosine phosphorylation and subsequent decrease in the activation of PI3-K 
and Akt, thereby promoting the development of type II diabetes. The function of many 
proteins may be affected by phosphorylation and dephosphorylation on specific tyrosine, 
serine and/or threonine residues, for example, if amino acid Serine -473 in the protein Akt is 
phosphorylated, Akt is active as a kinase, if not, it is an inactive kinase (Bononi et al., 2011).  
In the present study, PG stimulated Akt phosphorylation was higher in diabetic treated 
animals compared with   non-diabetic animals. The work of Guo and colleagues (2013) 
showed that guava leaf extract showed higher Akt Ser 473 and Thr 308 phosphorylation in 
skeletal muscle of SHRSP/ZF normal rats as compared with untreated SHRSP/ZF normal 
rats, thereby promoting glycogen synthesis. Our findings are somewhat similar to those 
reported in the work of the above mentioned authors. In the present study, PG treatment 
enhanced Akt phosphorylation in skeletal muscle of diabetic treated rats (Figure 3.4), thereby 
promoting glucose uptake and storage as glycogen. 
e. Glycogen metabolism 
Glycogen phosphorylase and glycogen synthase are the two important regulatory enzymes 
that catalyze the rate-limiting steps of glycogen breakdown and synthesis, respectively 
(Ferrer et al., 2003; Bouskila et al., 2010). Increased glycogen synthase activity has a 
stimulating influence on glycogen synthesis in the muscle. Previous studies have shown that 
skeletal muscle glycogen synthase activity is lowered in diabetic subjects studied under 
euglycaemic conditions (Kelley and Mandarino, 1990). In humans with type II diabetes, 
hyperglycaemia has been shown to reduce both GS activity (Thorburn et al., 1990) and 
glycogen synthesis (Shulman et al., 1990; Rothman et al., 1992). Evidence also suggests that 
GS activity is lowered in diabetic rats (Banu   et al., 2013). Our findings mirrored those of the 
above mentioned authors. In the present study, the low activity of glycogen synthase enzyme 
in diabetic rats resulted in poor utilization of glucose as shown by the depressed synthesis of 
glycogen from glucose in the muscle (Figure 3.7 A and 3.10). PG significantly increased the 
activity of glycogen synthase enzyme in diabetic treated animals (Figure 3.7 A).  
In the liver, GS activity was enhanced and the hepatic glycogen levels also increased after 
treatment (Figure 3.5 A and 3.9), this suggests that glycogen synthesis is impaired in 
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diabetes. Based on our present findings, it would seem appropriate to consider glycogen 
synthase activation and increased glycogen formation as one of the possible mechanisms by 
which PG exerts its hypoglycaemic effect. GP is an enzyme that occurs in two forms, 
phosphorylase a and b. It is responsible for the degradation of glycogen in a process called 
glycogenolysis. GP inhibition is one of the strategies that have been pursued for the 
development of new antidiabetic agents. The activity of glycogen phosphorylase a, which is 
expressed in human skeletal muscle correlated inversely with glycogen synthesis, (Munro et 
al., 2002). In the muscle, the activity of GP enhanced by diabetes was reduced after treating 
rats with PG (Figure 3.7 B). The same effects of PG on GP activity was observed in the liver 
(Figure 3.5 B).  
Previous studies reported increased expression of the GP gene in the muscle of Type I 
diabetic humans and STZ-induced diabetic rats before treatment with insulin (Wallis et al., 
1998). In the present study, PG reduced expression of GP in the muscle of treated diabetic 
animals (Figure 3.8 B) suggesting its hypoglycaemic potential through regulating glucose 
uptake into the muscle. 
In the liver, the expression levels of GP were lower in untreated diabetic animals compared to 
non-diabetic and diabetic treated animals (Figure 3.6). It has been reported that the 
expression of phosphorylase mRNA was down-regulated in diabetic liver (Rao et al., 1995). 
It was also reported that the rate of degradation of phosphorylase mRNA was faster in 
diabetic hepatocytes as compared with normal hepatocytes (Rao et al., 1995). The authors 
show that diabetes causes a decrease in the half-life of glycogen phosphorylase mRNA from 
14 h in normal hepatocytes to 6.5 h in diabetic hepatocytes (Rao et al., 1995). In the present 
study, treatment of diabetic animals with PG for 14 days showed a slight increase in GP 
expression. This may suggest that the effect of PG on the expression of hepatic glycogen 
phosphorylase is mediated through the stabilization of its mRNA levels. 
Sub-chronic studies on GS expression in the muscle showed that the expression of GS was 
depressed in diabetic animals and treatment of diabetic animals with PG caused a dramatic 
rise in GS expression to levels beyond control levels. Some studies have provided evidence 
for the impairment in the activation of glycogen synthase in diabetes (Hers 1976; Nuttal, 




Storage of glucose as glycogen represents a major muscle of energy storage and also protects 
against hypoglycaemia (Newgard et al., 2000) and its rate of synthesis appears to be 
regulated by the enzyme glycogen synthase (Bogardus et al., 1984). Previous studies reported 
that for optimal glycogen deposition to occur, the active phosphorylated form of GP must 
decrease (Brau et al., 1997). Our findings revealed that PG was able to restore the depleted 
liver and muscle glycogen reserves in treated diabetic animals (Figures 3.9 and 3.10).  
f. Lipid homeostasis 
This study also investigated the anti-hyperlipidemic potential of PG in-vivo and its effect on 
hormone sensitive lipase enzyme followed by assessment of changes in levels of serum lipid 
profile. The adipocyte takes up dietary lipid which is assembled into triglyceride for long 
term storage. One of the disorders of lipid metabolism (Savage et al., 2007) is caused by 
inability of the adipose tissue to store lipid resulting in accumulation in other tissues (Bluher, 
2009). Lipolysis in adipose tissue is controlled by HSL (Schweiger et al., 2006). Insulin plays 
a crucial role in lipid metabolism, increasing lipid synthesis in liver and fat cells, and 
attenuating fatty acid release from triglycerides in fat (Shulman, 2000). Insulin inhibits 
lipolysis in adipocytes, primarily through inhibition of the enzyme HSL (Anthonsen et al., 
1998). The activity of the lipase can be inhibited through reductions in cAMP levels, which 
triggers a cAMP-specific phosphodiesterase in fat cells (Kitamura et al., 1999).  Insulin 
reduced the phosphorylation of HSL. 
Klannemark and colleaugues (1998) suggest that HSL is involved in the polygenic 
background of obesity and type II diabetes. It also plays a critical role in regulating cellular 
lipid homeostasis. Increased mobilization of fatty acids from adipose tissue stores in diabetic 
patients leads to high levels of free fatty acid; this condition promotes the development of 
ketoacidosis, one of the complications of type I diabetes (Foster and McGarry, 1983).  
Previous studies revealed that fat cells isolated from STZ-induced diabetic rats show 
increased maximal lipolytic response to agents acting to elevate HSL mRNA and protein 
levels (Sztalryd and Kraemer, 1995). Treatments of rat adipocytes with lipolytic agents (like 
noradrenaline) increased phosphorylation of HSL (Belfrage et al., 1980) but when treated 
with Insulin (anti-lipolytic agent), HSL showed a decline in phosphorylation (Nilsson et al., 
1980).    
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Previous studies have shown that lack of HSL in liver causes cholesterol ester accumulation 
which leads to reduced cholesterol ester hydrolase activity (Sekiya et al., 2008). This 
suggests that by reducing HSL activity, enzymatic hydrolysis of cholesterol esters and their 
products such as cholesterol and fatty acids is reduced in the liver. On day 14, post treatment 
with PG, assessment of PG treatment on HSL activity in both liver and adipose tissue was 
carried out. In the liver, HSL activity in untreated diabetic animals was the highest (Figure 
3.11). Treatment with PG depressed HSL activities for both diabetic and non-diabetic treated 
animals as shown in Figure 3.11. In adipose tissue, the result obtained mirrored that of the 
liver as shown in Figure 3.12. 
Increases in cholesterol and triglyceride levels were reported in STZ-induced diabetic rats 
(Khan et al., 1995; Mitra et al., 1995; Sachdewa and Khemani, 2003; Steinberg, 2004), which 
may lead to the development of cardiovascular and cerebrovascular diseases. The results in 
Table 3.2 show the level of total cholesterol in the serum after the 14 day sub-chronic study. 
The level of total cholesterol was slightly higher in untreated diabetic animals compared to 
untreated normal animals. PG treatment slightly reduced total cholesterol levels for both 
diabetic and non-diabetic treated animals. 
Carr and colleagues (2000) reported that elevated TG, LDL-c and TC with reduced HDL-c 
will promote the development of atherosclerosis and cerebrovascular disorders. The results in 
Table 3.2 show serum triglycerides levels following 14 days of treatment with PG. In diabetic 
treated animals PG reduced the level of triglycerides but the difference was not significant 
when compared to that of untreated diabetic animals.  
Subjects with diabetes have a high risk for developing atherosclerosis and glycated LDL 
plays a vital role in promoting cardiovascular disease prevalence in this population (Calvo, 
1997). LDL carries about 60-70 % of serum cholesterol and transports it from the hepatocytes 
to other cells of the body (Antonopoulos, 2002).  
Elevated levels of blood sugar increase the rate at which glycation reactions occur (Singh et 
al., 2014). Glycated LDL impairs endothelial function (Nivoit, 2003), enhances oxidative 
stress and inflammation in muscle cells (Toma, 2009) and also contributes to the atherogenic 
process (Calvo, 1997). Studies have reported that green tea leaves which contain oleanolic 
acid and 2α-hydroxyursolic acid reduce LDL (Tinahones et al., 2008). In the present study 
we also observed that PG treatment reduced LDL levels in diabetic rats. 
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The results in Table 3.2 show serum atherogenic index after the 14 day sub-chronic study. 
Atherogenesis is a process of developing atheromatous plaques in the walls of arteries. 
Increased levels of LDL and VLDL causes atherogenesis (National Institutes of Health; 
National Heart, Lung and Blood Institute, 2008). In diabetic treated animals, PG caused a 
reduction in atherogenesis. AI was significantly higher in untreated diabetic animals 
compared to non diabetic animals. 
Studies have shown that oxidised LDL in particular plays an important role in the 
development of cardiovascular disease (Reaven and Witztim 1996; Steinberg, 2008). The 
results in Table 3.2 shows that the serum cardiac risk factor following 14 days of treatment 
with PG was significantly higher in untreated diabetic animals compared to non-diabetic, 
non-diabetic treated and diabetic treated animals. 
HDLs are small, dense lipoprotein particles, and they reduce invasion and accumulation of 
white blood cells (WBC) within the walls of arteries that may lead to atherosclerosis (Ross 
and Ross, 1999). Previous studies reported that consumption of pomegranate polyphenols 
significantly reduced LDL-cholesterol levels while maintaining HDL levels in subjects with 
elevated cholesterol levels (Esmaillzadeh, 2006).  Our study identified triterpenoids and 
phenolic compounds in guava extract which reduced LDL-cholesterol levels and increased 
HDL levels. Thus phenolic compounds could be implicated in these effects. 
Previous studies have also reported that chemicals in guava increased serum high density 
lipoprotein cholesterol level (Singh et al., 1992). In the present study, treatment of diabetic 
rats with PG decreased serum triglyceride, total cholesterol, cardiac risk factor, atherogenic 
index, and LDL-cholesterol with simultaneous increase in serum HDL-cholesterol results 
which suggest that PG can reduce risk of cardiovascular and cerebrovascular diseases. 
g. Biomarkers of tissue damage 
In a diabetic state, there is elevation in the activities of ALT, AST and LDH enzymes. The 
serum levels of ALT were significantly increased in the untreated diabetic animals, PG 
treatment of diabetic animals reduced serum levels of this enzyme. Ogueri et al. (2014) also 
reported the same effect of PG on serum ALT levels in alloxan induced diabetic rats. In our 
present study there was an increase in AST levels in the treated diabetic group compared to 
diabetic control group. An increase in AST levels has also been reported in diabetic  animals 
treated with an acetone fraction of Senna singueana stem bark (Ibrahim and Islam, 2014) or 
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an aqueous extract of Bridelia ferruginea leaves ( Aja et al., 2013). It was suggested that the 
increase may be due to cholastasis in which conjugated bilirubin is retained (Crook, 2006). A 
similar trend was observed for LDH levels in treated diabetic animals. In our present study, 
the beneficial effect of PG on ameliorating diabetic damage done to the pancreatic islets is 
evident from the improved morphology of pancreatic islets in PG treated diabetic animals. 
These results are similar to those observed with guava fruit extracts (Chin Siu et al. 2011). 
h. Phytochemical characterization 
Excessive production of free radicals within the living system can generate reactive oxygen 
and nitrogen species, leading to a condition called oxidative stress (Valko, 2006). Many 
diseases such as atherosclerosis, hypertension, and cancers have been shown to be mediated 
by oxidative stress (Tiwari, 2001). Previous studies reported that antioxidants protect the cells 
against the deleterious effects of free radicals (Lien et al., 2008). There are several ways by 
which the body protects itself against the toxic effects of free radicals. Firstly, through 
endogenous antioxidants (Halliwell, 2007) and secondly, through exogenous antioxidants 
provided through foods or supplements (Willcox et al., 2004). 
Our findings showed that Psidium guajava aqueous extract contain free radical scavenging 
phytochemicals that might have the potential to inhibit free radical accumulation which 
usually build up due to chronic hyperglycaemia.  
GC-MS analysis of the aqueous extract of the leaves of Psidium guajava was carried out in 
order to know the bioactive-compounds responsible for the observed antidiabetic effect. In 
the present study, guavanoic acid, oleanolic acid, protocatechuic acid, benzene-1,2-diol, 2'-O-
methyl guanosine, 5-Bromo-8-(5-nitrosalicylideneamino)quinoline hydrochloride and 2α-
Hydroxyursolic acid were identified. 
Previous authors reported the presence of guavanoic acid, oleanolic acid, protocatechuic acid, 
2α-Hydroxyursolic acid in PG leaf and fruit (Okuda et al., 1984; Begum et al., 2002a; Begum 
et al., 2002b; Begum et al., 2004).  
Protocatechuic acid was reported by Thaipong et al. (2005) to exert antioxidative activity. 
Oleanolic acid also possesses anti-hyperglycaemic activity (Wang et al., 2011). Previous 
studies reported the presence of benzene-1,2-diol in the rhizomes of Bergenia purpurascens 
(Bajracharya et al., 2011), stem of Ficus religiosa (Manorenjitha et al., 2013) and stem bark 
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of Annona senegalensis (Awa et al., 2012). It has been reported to exert potent activities 
against food borne bacteria (Kim and Lee, 2014) and also known to possess antioxidant 
activity (Cervellati et al., 2001). To our knowledge this is the first report to show the 
presence of benzene-1,2-diol, 2'-O-methyl guanosine and 5-Bromo-8-(5-
nitrosalicylideneamino) quinoline hydrochloride in the aqueous extract of PG leaves. 
Therefore, from our findings we can speculate that the observed antidiabetic effect might be 





















1. PG increased expression of muscle GS and restored its activity which was depressed 
by diabetes in both liver and muscle thereby increasing glycogen storage. PG 
decreased expression of muscle GP and reduced its activity which had been elevated 
by diabetes in both liver and muscle. Thus glycogen breakdown would be expected to 
be slowed down. The effects of PG on these two enzymes could be one mechanism 
responsible for the observed anti-hyperglycaemic effect of PG.  
2. PG treatment decreased HSL activity in liver and adipose tissue, which was 
accompanied by reduced serum triglycerides, total cholesterol, LDL-cholesterol, 
cardiac risk factor, atherogenic index and increased HDL-cholesterol. 
3. PG protected pancreatic islets in STZ-induced diabetic rats and caused the restoration 
of serum ALT activity elevated by diabetes. These findings suggest that PG also 
protects the liver from diabetic damage. 
4. The observed antidiabetic and hypolipidemic activities of PG may be due to the 
synergistic effects of the identified phenolic and triterpenoid bioactive compounds, 
highlighting the potential advantage of using whole extract. 
5. PG may be a promising antidiabetic agent.  
FUTURE STUDIES 
The western blot analysis for p-Akt at 15 and 60 minutes did not come out well, so this 
will be repeated. Future studies will also involve looking at the role of glycogen synthase 
kinases (GSK-3) in glucose homeostasis and also other pathways that have been 












Adaramoye, O.A., Akintayo, O., Achem, J., and Fafunso, M.A. (2008). Lipid lowering 
effects of methanolic extracts of Vernonia amygdalina leaves in rats fed on high cholesterol 
diet. Vascular Health and Risk Management 4, 236-241. 
Adesanoye, O.A., and Farombi, E.O. (2010). Hepatoprotective effects of Vernonia 
amygdalina (astereaceae) in rats treated with carbon tetrachloride. Experimental and 
Toxicologic Pathology 62, 197–206 
Adler, A.I., Stratton, I.M., Neil, H.A., Yudkin, J.S., Matthews, D.R., Cull, C.A., Wright, 
A.D., Turner, R.C., and Holman, R.R. (2000). Association of systolic blood pressure with 
macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective 
observational study. BMJ (Clinical research ed.)  321, 412–419. 
Aguilar-Bryan, L., and Bryan, J. (2008). Neonatal diabetes mellitus. Endocrine Reviews 3, 
265-291. 
Aja, P.M., Nwafor, E.J., Ibiam, A.U., Orji, O.U., Ezeani, N., and Nwali, B.U. 
(2013). Evaluation of Anti-diabetic and Liver Enzymes Activity of Aqueous Extracts of 
Moringa oleifera and Bridelia ferruginea Leaves in Alloxan Induced Diabetic Albino 
Rats. International Journal of Biochemistry Research and Review 3, 248-258. 
Akhtar, M.S., and Iqbal, J. (1991). Evaluation of the hypoglycaemic effect of Achyranthes 
aspera in normal and alloxan-diabetic rabbits. Journal of Ethnopharmacology 1, 49-57. 
Alberico, S., Montico, M., and Barresi, V., Monasta, L., Businelli, C., Soini, V., Erenbourg, 
A., Ronfani, L. and Maso, G. (2014). The role of gestational diabetes, pre-pregnancy body 
mass index and gestational weight gain on the risk of newborn macrosomia: results from a 
prospective multicentre study. BMC Pregnancy and Childbirth 14:23. 
Albrecht, C.F. (1995). Hypoxoside: a putative prodrug for the treatment of malignancies, 
HIV infections, and inflammatory conditions. South African Medical Journal 85, 302–307. 
Alonso, A., Fernandez, Y., Fernandez, R., Ordonez, P., Moreno, M., Patterson, A.M., and 
Gonzalez, C. (2005). Effect of food restriction on the insulin signalling pathway in rat 
skeletal muscle and adipose tissue. Journal of Nutritional Biochemistry 16, 602– 609. 
81 
 
Alonso, M.D., Lomako, J., Lomako, W.M., and Whelan, W.J. (1995). A new look at the 
biogenesis of glycogen.  The Journal of the Federation of American Societies for 
Experimental Biology 9, 1126–1137. 
Amaral, S., Oliveira, P.J., and Ramalho-Santos, J. (2008). Diabetes and the impairment of 
reproductive function: possible role of mitochondria and reactive oxygen species. Current 
Diabetes Review 4, 46-54. 
American Diabetes Association (ADA). (2012). Standards of medical care in diabetes. 
Diabetes Care, 35. 
Amod, A., Ascott-Evans, B.H., Berg, G.I.,Blom, D.J., Brown, S.L., Carrihill, M.M., Dave, 
J.A., Distiller, L.A., Ganie, Y.N., Grobler, N., Heilbrunn, A.G., Huddle, K.R.L., Janse van 
Rensburg G., Jivan, D., Jashi, P., Khutsoane, D.T., Levitt, N.S., May, W.M., Mollentze, 
W.F., Mottala, A.A., Paruk, I.M., Pirie, F.J., Raal, F.J., Rauff, S., Raubenheimer, P.J., 
Randeree, H.A.R., Rheeder, P., Tudhope, L., Van Zyl, D.J. and Young, M.. (2012). The 2012 
SEMDSA guideline for the management of type 2 diabetes (revised). The 2012 SEMDSA 
treatment algorithm for type 2 diabetes. Journal of Endocrinology, Metabolism and Diabetes 
of South Africa 17, S36-S40. 
Anthonsen, M.W., Ronnstrand, L., Wernstedt, C., Degerman, E., and Holm, C. (1998). 
Identification of novel phosphorylation sites in hormone-sensitive lipase that are 
phosphorylated in response to isoproterenol and govern activation properties in vitro. Journal 
of Biological Chemistry 273, 215–221. 
Antonis, D. L., Emmanuel, R., Gerassimos, E. V., and Dimitrios, J. S. (2011). The resurgence 
of Hormone-Sensitive Lipase (HSL) in mammalian lipolysis. Gene 477, 1–11. 
Antonopoulos, S. (2002). Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) Final Report. Circulation 106, 3145-3408. 
Appel, G.B., Radhakrishnan, J., Avram, M.M., DeFronzo, R.A., Escobar-Jimenez, F., 
Campos, M.M., Burgess, E., Hille, D.A., Dickson, T.Z., Shahinfar, S., and Brenner, B.M. 
(2003). Analysis of metabolic parameters as predictors of risk in the RENAL study. Diabetes 
Care 26, 1402–1407. 
82 
 
Araki, E., Lipes, M.A., Patti, M.E., Bruning, J.C., and Haag. B., 3rd, Johnson, R.S., and 
Kahn, C.R. (1994). Alternative pathway of insulin signalling in mice with targeted disruption 
of the IRS-1 gene. Nature 372, 186–190. 
Arner, P. (2002). Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes/ 
Metabolism Research and Reviews 18, S5–S9. 
Aronoff, S.L., Berkowitz, K., Shreiner, B., and Want, L. (2004). Glucose Metabolism and 
Regulation: Beyond Insulin and Glucagon. Diabetes Spectrum 17, 183-190. 
Assmann, G., and Gotto, A.M Jr. (2004). HDL cholesterol and protective factors in 
atherosclerosis. Circulation. 109, III8–III14. 
Astoul, E., Watton, S., and Cantrell, D.A. (1999). The dynamics of protein kinase B 
regulation during B cell antigen receptor engagement. Journal of Cell Biology 145, 1511-
1520. 
Awa, E.P., Ibrahim, S., and Ameh, D.A. (2012). GC-MS Analysis and Antimicrobial activity 
of Diethyl Ether fraction of Methanolic extract from the stem bark of Annona senegalensis 
Pers. International Journal of Pharmaceutical Sciences and Research 3, 4213-4218. 
Awe, S.O., Makinde, J.M., and Olaide, O.A. (1999). Cathartic effect of the leaf extract of 
Vernonia amygdalina. Fitoterapia 70, 161-165. 
Baggio, L.L., and Drucker, D.J. (2007). Biology of incretins: GLP-1 and GIP 
Gastroenterology, 132, 2131–2157. 
Bajracharya, Gan B., Maharjan, R., and Maharjan, B.L. (2011). Potential Antibacterial 
Activity of Bergenia purpurascens. Nepal Journal of Science and technology 12, 157-162. 
Balamurugan, A.N., Miyamoto, M., Wang, W., Inoue, K., and Tabata, Y. (2003). 
Streptozotocin (STZ) used to induce diabetes in animal models. Journal of 
Ethnopharmacology 26, 102-103. 
Banba, N., Nakamura, T., Matsumura, M., Kuroda, H., Hattori, Y., and Kasai, K. (2000). 
Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. 
Kidney International 58, 684-690. 
83 
 
Banu Hedayathullah, K., Shanmugavalli, R., Deepa, R., Ramya, B., and Subramanian S. 
(2013). Protective Effect of Psidium guajava leaf Extract on Altered Carbohydrate 
Metabolism in streptozotocin –Induced Diabetic Rats. Journal of Dietary supplements 10, 
335-344. 
Barry, J.G., and Dirk, Muller-Wieland (2008). Type 2 diabetes: principles and practice 2
nd 
edition. Informa Healthcare, USA. pp 529.  
Begum, S., Hassan, S.I., and Siddiqui, B.S. (2002a). Two new triterpenoids from the fresh 
leaves of Psidium guajava. Planta Medica 68, 1149–1152. 
Begum, S., Hassan, S.I., and Siddiqui, B.S. (2004). Chemical constituents from the leaves of 
Psidium guajava. Natural Product Research 18, 135–140. 
Begum, S., Hassan, S.I., Siddiqui, B.S., Shaheen, F., Ghayur, M.N., and Gilani, A.H. 
(2002b). Triterpenoids from the leaves of Psidium guajava. Phytochemistry 61, 399–403. 
Behme, M T, Dupré, J, McDonald, T J. (2003). "Glucagon-like peptide 1 improved glycemic 
control in type 1 diabetes". BMC Endocrine Disorders 3:3. 
Belfrage, P., Fredrikson, G., Nilsson, N.O., and Strålfors, P. (1980).  Regulation of adipose 
tissue lipolysis: phosphorylation of hormones sensitive lipase in intact rat adipocytes. FEBS 
Letters 111, 120-124. 
Benecke, H., Flier, J.S., and Moller, D.E. (1992). Alternatively spliced variants of the insulin 
receptor protein. Expression in normal and diabetic human tissues. Journal of Clinical 
Investigation 89, 2066-2070. 
Bennett, R.A., and Pegg, A.E. (1981). Alkylation of DNA in rat tissues following 
administration of streptozotocin. Cancer Research 41, 2786-2790. 
Bensellam, M., Laybutt, D.R., and Jonas, J.C. (2012). The molecular mechanisms of 
pancreatic β-cell glucotoxicity: recent findings and future research directions. Molecular and 
Cellular Endocrinology 364, 1–27. 
Berg, J.M., Tymoczko, J.L., and Stryer, L. (2002). Biochemistry, Fifth edition. W.H. 
Freeman, New York. 
84 
 
Bjornholm, M., Kawano, Y., Lehtihet, M., and Zierath, J.R. (1997). Insulin receptor 
substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle 
from NIDDM subjects after in vivo insulin stimulation. Diabetes 46, 524–527. 
Bleeker, F.E., Lamba, S., Zanon, C., Molenaar, R.J., Hulsebos, T.J., Troost, D, van Tilborg, 
A.A., Vandertop, W.P., Leenstra, S, van Noorden, C.J., and Bardelli, A. (2014). "Mutational 
profiling of kinases in glioblastoma." BMC Cancer 14: 718. 
Bleeker, F.E., Molenaar, R.J., and Leenstra, S. (2012). "Recent advances in the molecular 
understanding of glioblastoma." Journal of neuro-oncology 108, 11–27. 
Bluher, M. (2009). Adipose tissue dysfunction in obesity. Experimental and Clinical 
Endocrinology and Diabetes 117, 241–250. 
Bobe, G., Young, J., and Beitz, D. (2004). Invited review: pathology, etiology, prevention, 
and treatment of fatty liver in dairy cow. Journal of Dairy Science 87, 3105–3124. 
Bogardus, C.S., Lillioja, K., Stone, and Mott, D. (1984). Correlation between muscle 
glycogen synthase activity and in vivo insulin action in man. Journal of Clinical Investigation 
73, 1185-1190. 
Bohlender, J.M., Franke, S., Stein, G., and Wolf, G. (2005). Advanced glycation end products 
and the kidney. American Journal of Physiology Renal Physiology 289, 645-659. 
Bollen, M., and Stalmans, W. (1995). In Molecular Biology and Biotechnology: A 
Comprehensive Desk Reference (Meyers, R. A., ed.), pp. 385-388. VCH Publishers Inc., 
New York. 
Bononi, A., Agnoletto, C., De Marchi, E., Marchi, S., Patergnani, S., Bonora, M., Giorgi, C., 
Missiroli, S., Poletti, F., Rimessi, A. and Pinton, P. (2011). Protein Kinases and Phosphatases 
in the Control of Cell Fate. Enzyme Research. 2011, 329098, 26 pages. 
Bonsi, M.L.K., Osuji, P.O., Tuah, A.K., and Umunna, N.N. (1995). Vernonia amygdalina as 
a supplement to teff straw (Eragrosis tef.) fed to Ethiopian Menz sheep. Agroforestry 
Systems 31, 229-241. 
85 
 
Bouma, B., Kroon-Batenburg, L.M., Wu, Y.P., Brunjes, B., Posthuma, G., Kranenburg, O. de 
Groot, P.G., Voest, E.E. and Gebbink, M.F. (2003). Glycation induces formation of amyloid 
cross-beta structure in albumin. Journal of Biological Chemistry 278, 41810-41819. 
Bouskila, M., Hirshman, M.F., Jensen, J., Goodyear, L.J., and Sakamoto, K. (2008). Insulin 
promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. 
American Journal of Physiology Endocrinology and Metabolism 294, E28–E35. 
Bouskila, M., Hunter, R.W., Ibrahim, A.F.M., Delattre, L., Peggie, M., van Diepen, J.A., 
Voshol, P.J., Jensen, J., and Sakamoto, K. (2010). Allosteric regulation of glycogen synthase 
controls glycogen synthesis in muscle. Cell Metabolism 12, 456–466. 
Brau, L., Ferreira, L.D.M.C.B., Nikolovski, S., Raja, G., Palmer, N.T., and Fournier, P.A., 
(1997). Regulation of glycogen synthase and phosphorylase during recovery from high-
intensity exercise in the rat. Biochemistry Journal 322, 303-308. 
Brocker, C., Thompson, D.C., and Vasiliou, V. (2012). The role of hyperosmotic stress in 
inflammation and disease. Biomolecular Concepts 3, 345–364. 
Burits, M., Asres, K., and Bucar, F., (2001). The antioxidant activity of the essential oils of 
Artemisia afra, Artemisia abyssinica and Juniperus procera. Phytotherapy Research 15, 103–
108. 
Calvo, C. (1997). Non-enzymatic glycosylation of lipoproteins in the pathogenesis of 
atherosclerosis in diabetics. Revista Medica de Chile 125, 460-465. 
Campbell, L.K., White, J.R., and Campbell, R.K. (1996). Acarbose: its role in the treatment 
of diabetes mellitus. The Annals of Pharmacotheraphy 30, 1255–1262. 
Carr, A.C., Zhu, B., and Frei, B. (2000). Potential antiatherogenic mechanisms of ascorbate 
(Vitamin C) and α-tocopherol (Vitamin E). Circulation Research 87, 349–354.  
Cervellati, R., Honer, K., Furrow, S.D., Neddens, C., and Costa, S. (2001). The Briggs-
Rauscher Reaction as a Test to Measure the Activity of Antioxidants. HELVETICA 
CHIMICA ACTA 84, 3533-3547. 
86 
 
Chakraborty, C., Agoramoorthy, G., and Hsu, M.J. (2011) Exploring the Evolutionary 
Relationship of Insulin Receptor Substrate Family Using Computational Biology. PLoS ONE 
6(2): e16580. doi:10.1371/journal.pone.0016580. 
Chattopadhyay, R.R., Banerjee, R.N., Sarkar, S.K., Ganguly, S., and Basu, T.K. (1991 a). 
Antiinflammatory and acute toxicity studies with leaves of Vinca rosea Linn in experimental 
animals. Indian Journal of Physiology and Pharmacology 36, 291-292. 
Chattopadhyay, R.R., Sarkar, S.K., Ganguly, S., Banerjee, R.N., and Basu, T.K. (1991 b). 
Hypoglycemic and antihyperglycemic effect of leaves of Vinca rosea Linn. Indian Journal of 
Physiology and Pharmacology 35, 145-151. 
Chaturvedi, N., Fuller, J.H., and Taskinen, M.R. (2001). Differing associations of lipid and 
lipoprotein disturbances with the macrovascular and microvascular complications of type 1 
diabetes. Diabetes Care 24, 2071–2077. 
Chen, J.Y., Hsu, C.T., Liu, J.H., and Tung, T.H. (2014). Clinical predictors of incident 
gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterology 14:83. 
Cheng, X., Ma, Y., Moore, M., Hemmings, B. A., and Taylor, S. S. (1998). Phosphorylation 
and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein 
kinase. Proceedings of the National Academy of Sciences 95, 9849–9854. 
Cheung, N.W. (2009). The management of gestational diabetes. Vascular Health and Risk 
Management 5, 153-164. 
Chin Shiu, H., Mei-Chin, Y., and Lan-Chi, C. (2011). Antihyperglycaemic and antioxidative 
potential of Psidium guajava fruit in streptozotocin-induced diabetic rats. Food and Chemical 
Toxicology 49, 2189-2195. 
Chinnavenkataraman, G. and Rajendran, S. (2012). In vitro antibacterial activity and 
phytochemical analysis of Catharanthus roseus (Linn.) G. Don. Asian Pacific Journal of 
Tropical Biomedicine. 2, S155-S158. 
Chiu, J., Farhangkhoee, H., Xu, B.Y., Chen, S., George, B., and Chakrabarti, S. (2008). 
PARP mediates structural alterations in diabetic cardiomyopathy, Journal of Molecular and 
Cellular Cardiology 45, 385–393. 
87 
 
Cho, H., Mu, J., Kim, J.K., Thorvaldsen, J.L., Chu, Q., Crenshaw, E.B., 3
rd
, Kaestner, K.H., 
Bartolomei, M.S., Shulman, G.I. and Birnbaum, M.J. (2001 a). Insulin resistance and a 
diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 
292, 1728-1731. 
Cho, H., Thorvaldsen, J.L., Chu, Q., Feng, F., and Birnbaum, M.J. (2001 b). Akt1/PKB alpha 
is required for normal growth but dispensable for maintenance of glucose homeostasis in 
mice. Journal of Biological Chemistry 276, 38349-38352. 
Chou, M.M., Hou, W., Johnson, J., Graham, L.K., Lee, M.H., Chen, C.S., Newton, A.C., 
Schaffhausen, B.S., and Toker, A. (1998). Regulation of protein kinase C zeta by PI3-kinase 
and PDK-1. Current Biology 8, 1069–1077. 
Chung, N.S. and Wasan, K.M. (2004). Potential role of the low-density lipoprotein receptor 
family as mediators of cellular drug uptake. Advanced Drug Delivery Reviews 7, 1315-1334.  
Clarkson, C., Maharaj, V.J., Crouch, N.R., Grace, O.M., Pillay, P., Matsabisa, M.G., 
Bhagwandin, N., Smith, P.J. and Folb, P.I. (2004). In vitro antiplasmodial activity of 
medicinal plants native to or naturalised in South Africa. Journal of Ethnopharmacology, 92, 
177–191. 
Colclough, K., Saint-Martin, C., Timsit, J., Ellard, S., and Bellanné-Chantelot, C. (2014). 
Clinical utility gene card for: Maturity-onset diabetes of the young. European Journal of 
Human Genetics 22, e1-e6 
Coskun, O., Ocakci, A., Bayraktaroglu, T., and Kanter, M. (2004). Exercise training prevents 
and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. The 
Tohoku Journal of Experimental Medicine 203, 145–154. 
Crook, M.A. (2006). Clinical Chemistry and Metabolic Medicine, 7th edition, Edward 
Arnold Publishers, London. pp 250-268. 
Cryer, P.E. (2002). Hypoglycaemia: the limiting factor of Type I and Type II diabetes. 
Diabetologia 7, 937-948. 
Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M.E., Pratipanawatr, T., 
DeFronzo, R.A., Kahn, C.R., and Mandarino, L.J. (2000). Insulin resistance differentially 
88 
 
affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. The Journal of 
Clinical Investigation 105, 311–320. 
David, E.S., and Crerar, M.M. (1986). "Quantitation of muscle glycogen phosphorylase 
mRNA and enzyme amounts in adult rat tissues". Biochimica et Biophysica Acta 880, 78–90. 
De Meyts, P. (2008). The insulin receptor: a prototype for dimeric, allosteric membrane 
receptors? Trends in Biochemical Science 33, 376–384. 
de Piña, M.Z., Vazquez-Meza, H., Pardo, J.P., Rendon, J.L., Villalobos-Molina, R., Riveros-
Rosas, H. and Pina, E. (2008). Signaling the signal: Cyclic AMP-dependent protein Kinase  
inhibition by insulin-formed H2O2 and reactivation by thioredoxin. Journal of Biological 
Chemistry 283, 12373–12386. 
Dearth, R.K., Cui, X., Kim, H.J., Kuiatse, I., Lawrence, N.A., Zhang, X., Divisova, J., 
Britton, O.L., Mohsin, S., Allred, D.C., Hadsell, D.L., Lee, A.V. (2006). "Mammary 
tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-
1) or IRS-2". Molecular and Cellular Biology 26, 9302–9314. 
Delezie, J., Dumont, S., Dardente, H., Oudart, H., Gréchez-Cassiau, A., and Klosen, P., 
Teboul, M., Delaunay, F., Pevet, P. and Challet, E.  (2012). "The nuclear receptor REV-
ERBα is required for the daily balance of carbohydrate and lipid metabolism."Federation of 
American Societies for Experimental Biology Journal 26, 3321–3335.  
Docsa, T., Czifrák, K., Hüse, C., Somsák, L., and Gergely, P. (2011). Effect of 
glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of 
streptozotocin-induced and obese diabetic rats Molecular Medicine Reports 4, 477–481. 
Dong, L.Q., Zhang, L.B., Langlais, P., He, H., Clark, M., Zhu, L. and Liu, F. (1999). Primary 
structure, tissue distribution, and expression of mouse phosphoinositide-dependent protein 
kinase-1, a protein kinase that phosphorylates and activates protein kinase Czeta.  Journal of 
Biological Chemistry 274, 8117–8122. 
Drucker, D.J. (2007). The role of gut hormones in glucose homeostasis. The Journal of 
Clinical Investigation 1, 24-30. 
89 
 
Drucker, D.J., and Nauck, M.A. (2006). "The incretin system: glucagon-like peptide-1 
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes". Lancet 368, 1696–
1705.  
Drummond, K..E., and Brefere, L.M.  (2014). Nutrition for Foodservice and Culinary 
Professionals 8
th 
Ed., John Wiley & Sons, River street, United States of America. 
Dupre, J., Behme, M.T., Hramiak, I.M., McFarlane, P., Williamson, M.P., Zabel, P., and 
McDonald, T.J. (1995). "Glucagon-like peptide I reduces postprandial glycemic excursions in 
IDDM". Diabetes 44, 626–630.  
Dutil, E.M., Toker, A., and Newton, A. C. (1998). Regulation of conventional protein kinase 
C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Current Biology 8, 1366–
1375. 
Ekpo, A., Eseyin, O.A., Ikpeme, A. O., and Edoho, E.J. (2007). Studies on some biochemical 
effects of Vernonia amygdalina in rats. Asian Journal of Biochemistry 2, 193-197. 
El Messaoudi, S., Rongen, G.A., de Boer, R.A., and Riksen, N.P. (2011). "The 
cardioprotective effects of metformin." Current Opinion in Lipidology 22, 445–453. 
Eldar-Finkelman, H., Schreyer, S.A., Shinohara, M.M., LeBoeuf, R.C., and Krebs, E.G. 
(1999). Increased glycogen synthase kinase-3 activity in diabetes and obesity prone 
C57BL/6J mice. Diabetes 48, 1662–1666. 
Erasto, P., Adebola, P.O., Grierson, D.S., and Afolayan, A.J. (2005). An ethnobotanical study 
of plants used for the treatment of diabetes in the Eastern Cape Province, South Africa. 
African Journal of Biotechnology 4, 1458–1460.  
Esmaillzadeh, A. (2006). Cholesterol-lowering effect of concentrated pomegranate juice 
consumption in type II diabetic patients with hyperlipidemia. International Journal for 
Vitamin and Nutrition Research 76, 147-151. 
Espenshade, P.J., and Hughes, A.L. (2007). "Regulation of sterol synthesis in eukaryotes". 
Annual Review of Genetics 41, 401–427. 
90 
 
Esterbauer, H., Puhl, H., Dieber-Rotheneder, M., Waeg, G., and Rabl, H. (1991). "Effect of 
antioxidants on oxidative modification of LDL". Annals of Medicine 23, 573–581. 
Faizi, S., Siddiqui, B., Saleem, R., Saddiqui, S., and Aftab, K. (1994). Isolation and structure 
elucidation of new nitrile and mustard oil glycosides from Moringa oleifera and their effect 
on blood pressure. Journal of Natural Products 57, 1256–1261. 
Fajans, S., and Bell, G. (2011). MODY — history, genetics, pathophysiology, and clinical 
decision making. Diabetes Care 34, 1878–1883. 
Fantl, W.J., Johnson, D.E., and Williams L.T. (1993). Signalling by receptor tyrosine kinases. 
Annual Review of Biochemistry 62, 453-481. 
Fasshauer, M., Klein, J., Kriauciunas, K.M., Ueki, K., Benito, M., and Kahn, C.R., (2001). 
Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Molecular 
and Cellular Biology 21, 319-329. 
Fenercioglu, A.K., Saler, T., Genc, E., Sabuncu, H., and Altuntas, Y. (2010). The effects of 
polyphenol-containing antioxidants on oxidative stress and lipid peroxidation in Type 2 
diabetes mellitus without complications. Journal of Endocrinological Investigation 33, 118–
124. 
Feres, N.H., de Lima Reis, S.R., Veloso, R.V., Arantes, V.C., Souza, L.M.I., Carneiro, E.M., 
Boschero, A.C., Reis, M.A.B., and Latorraca, M.Q. (2010). Soybean diet alters the insulin-
signaling pathway in the liver of rats recovering from early-life malnutrition. Nutrition 26, 
441- 448. 
Ferreira, L.D., Pulawa, L.K., Jensen, D.R., and Eckel, R.H. (2001). "Overexpressing human 
lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance." 
Diabetes 50, 1064–1068.  
Ferrer, J.C., Favre, C., Gomis, R.R., Fernandez-Novell, J.M., Garcia-Rocha, M., La Iglesia, 
N., Cid, E. and Guinovart, J.J. (2003). Control of glycogen deposition. FEBS letters. 546, 
127-132. 
Fielding, B.A., and Frayn, K.N. (1998). Lipoprotein lipase and the disposition of dietary fatty 
acids. The British Journal of Nutrition 80, 495–502. 
91 
 
Fossati, P., and Lorenzo, P. (1982). Serum triglycerides determined colorimetrically with an 
enzyme that produces hydrogen peroxide. Clinical Chemistry. 28, 2077-2080. 
Foster, D.W. and McGarry, J.D. (1983). The metabolic derangements and treatment of 
diabetic ketoacidosis. The New England Journal of Medicine 309, 159–169. 
Fowler, M.J., (2010). Diabetes treatment: oral agents. Clinical Diabetes. 28, 132–136. 
Frame, S. and Cohen, P. (2001). GSK-3 takes centre stage more than 20 years after its 
discovery. The Biochemical Journal 359, 1–16. 
Francis, J.A., Jayaprakasam, B., Olson, L.K. and Nair, M. (2004). Insulin secretagogues from 
Moringa oleifera with cyclooxygenase enzyme and lipid peroxidation inhibiting activities. 
Helvitica Chimica Acta 87, 317–326. 
Friedewald, W.T., Levy, R.I., and Fredrickson, D.S. (1972). Estimation of the concentration 
of low-density lipoprotein cholesterol in plasma without use of the preparative 
ultracentrifuge. Clinical Chemistry 18, 499-502. 
Friedman, B., Goodman, E.H., and Weinhouse, S. (1967). Effects of glucose feeding, cortisol 
and insulin on liver glycogen synthesis in the rat. Endocrinology 81, 486-496. 
Friedrichsen, M., Mortensen, B., Pehmoller, C. Birk, J.B., Wojtaszewski, J.F. (2013). 
Exercise-induced AMPK activity in skeletal muscle: role in glucose uptake and insulin 
sensitivity. Molecular and Cellular Endocrinology 366, 204–214. 
Frödin, M., Antal, T.L., Dümmler, B.A., Jensen, C.J., Deak, M., Gammeltoft, S., and Biondi, 
R.M. (2002). "A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 
mediates activation by hydrophobic motif phosphorylation". The EMBO Journal 21, 5396–
5407. 
Fry, M. J. (2001). Phosphoinositide 3-kinase signalling in breast cancer: how big a role might 
it play? Breast Cancer Research 3, 304-312. 
Gall, M.A., Hougaard, P., Borch-Johnsen, K., and Parving, H.H. (1997). Risk factors for 
development of incipient and overt diabetic nephropathy in patients with non-insulin 
dependent diabetes mellitus: prospective, observational study. BMJ 314, 783–788. 
92 
 
Galler, A., Muller, G., Schinzel, R., Kratzsch, J., Kiess, W., and Munch, G. (2003). Impact of 
metabolic control and serum lipids on the concentration of advanced glycation end products 
in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence 
spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 26, 2609-2615. 
Ganong, W.F., (2005). Review of Medical Physiology. 22
nd
 edition. The McGraw-Hill 
Companies United States of America. 
Garg, A., and Misra, A. (2004). Lipodystrophies: rare disorders causing metabolic syndrome. 
Endocrinology and Metabolism Clinics of North America 33, 305-331. 
Garin, I., Perez de Nanclares, G., Gastaldo, E., Harries, L.W., Rubio-Cabezas, O., and 
Castaὴo, L. (2012). Permanent neonatal diabetes caused by creation of an ectopic splice site 
within the INS gene. PLoS One 7(1):e29205. 
Gathirwa, J.W., Rukunga, G.M., Njagi, E.N.M., Omar, S.A., Guantai, A.N., Muthaura, C.N., 
Mwitari, P.G., and Ndiege, I.O. (2007). In vitro anti-plasmodial and in vivo antimalarial 
activity of some plants traditionally used for the treatment of malaria by the Meru community 
in Kenya. Journal of Natural Medicines 61, 261–268. 
Gerich, J.E. (1993). Control of glycemia. Bailler’s Best Practice and Research in Clinical 
Endocrinology and Metabolism 3, 551-586. 
Ghosh, R.K. and Gupta, I. (1980). Effect of Vinca rosea and Ficus racemososus on 
hyperglycemia in rats. Indian Journal of Animal Health 19, 145–148. 
Gibbons, G.F., Wiggins, D., Brown, A.M., and Hebbachi, A.M. (2004). Synthesis and 
function of hepatic very-low-density lipoprotein. Biochemical Society Transactions 32, 59–
64. 
Gilespie, K.M. (2006). Type I diabetes: pathogenesis and prevention (Review). Canadian 
Medical Association Journal 2, 165-170. 
Girroir, E.E., Hollingshead, H.E., He, P., Zhu, B., Perdew, G.H., and Peters, J.M. (2008). 
"Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ 




Goldberg, I.J. (1996). Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism 
and atherosclerosis. Journal of Lipid Research 37, 693–707. 
Gornall, A.G., Bardawill, C.S., and David, M.M. (1949). Determination of serum proteins by 
means of the biuret reaction. Journal of Biological Chemistry 177, 751-766.  
Gower, R.M., Wu, H., Foster, G.A., Devaraj, S., Jialal, I., and Ballantyne, C.M. Knowlton, 
A.A. and Simon, S.I.  (2011). CD11c/CD18 expression is upregulated on blood monocytes 
during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1 
Arteriosclerosis, Thrombosis and Vascular Biology 31, 160–166. 
Grimes, C.A., and Jope, R.S. (2001). The multifaceted roles of glycogen synthase kinase 3β 
in cellular signaling. Progress in Neurobiology 65, 391–426. 
Guo, X., Yoshitomi, H., Gao, M., Qin, L., Duan, Y., Sun, W., Xu, T., Xie, P., Zhou, J., 
Huang, L., and Liu, T. (2013). Guava leaf extracts promote glucose metabolism in SHRSP.Z-
Leprfa/lzm rats by improving insulin resistance in skeletal muscle. BMC Complementary and 
Alternative Medicine 13:52. 
Gutierrez, R. M. P., Mitchell, S., and Solis, R. V. (2008). Psidium guajava: A review of its 
traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology 117, 1–
27. 
Haines, T.H. (2001). "Do sterols reduce proton and sodium leaks through lipid bilayers?" 
Progress in Lipid Research 40, 299–324. 
Halliwell, B. (2007). Biochemistry of oxidative stress. Biochemical Society Transactions 35, 
1147-1150. 
Hamza, N., Berke, B., Cheze, C., Raphaële Le Garrec, Umar, A., Agli, Abdel-Nacer, 
Lassalle, R., Jové, J., Gin, H., and Moore, N.. (2012). Preventive and curative effect of 
Trigonella foenum-graecum L. seeds in C57BL/6J models of type 2 diabetes induced by 
high-fat diet. Journal of Ethnopharmacology 142, 516–522. 
Hanan, D. Y., and Adel, F. T. (2014). Extract of Moringa oleifera leaves ameliorates 
streptozotocin-induced Diabetes mellitus in adult rats. Acta Histochemica 116, 844-854. 
94 
 
Hanefeld, M. (2007). Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. 
International Journal of Clinical Practice 61, 20-27. 
Hapo Study Cooperative Research Group. (2008). Hyperglycaemia and adverse pregnancy 
outcomes. The New England Journal of Medicine 358, 1991-2002. 
Hartman, I. (2008). Insulin Analogs: Impact onTreatment Success, Satisfaction, Quality of 
Life, and Adherence. Clinical Medicine & Research 6, 54-67.  
Heinrich, M., Ankli, A., Frei, B., Weimann, C., and Sticher, O. (1998). Medicinal plants in 
Mexico: healers consensus and cultural importance. Social Science and Medicine 47, 1859–
1871. 
Hellman, B., Gylfe, E., Grapengiesser, E., Dansk, H., Salehi, A., Gylfe., Grapengiesser., 
Dansk., and Salehi. (2007). "[Insulin oscillations--clinically important rhythm. Anti-diabetics 
should increase the pulsative component of the insulin release]". Lakartidningen (in Swedish) 
104, 2236–2239. 
Henke, B. R. (2012). Inhibition of glycogen phosphorylase as a strategy for the treatment of 
type 2 diabetes mellitus. In New Therapeutic Strategies for Type 2 Diabetes: Small Molecule 
Approaches, Jones, R. M., Ed. RSC Drug Discovery, Dorset Press: Dorchester, UK, pp 324–
365. 
Hers, G. (1976). The control of glycogen metabolism in the liver. Annual Review of 
Biochemistry 45, 167-189. 
Hilliard, O. (1983). Helichrysum. Flora of Southern Africa 33(7) 2:61. 
Hilliard, O.M., (1977). Compositae in Natal. University of Natal Press, Pietermaritzburg, 
360–361. 
Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M. and 
Hotamisligil, G.S.  (2002). A central role for JNK in obesity and insulin resistance. Nature 
420, 333-336. 
Holm, C., Osterlund, T., Laurell, H., and Contreras, J.A. (2000). Molecular mechanisms 
regulating hormone sensitive lipase and lipolysis. Annual Review on Nutrition 20, 365-393. 
95 
 
Honey, R.N., and Weir, G.C. (1980). Acetylcholine stimulates insulin, glucagon, and 
somatostatin release in the perfused chicken pancreas. Endocrinology 107, 1065–1068. 
Hornbrook, K. R. (1970). Synthesis of liver glycogen in starved alloxan diabetic rats. 
Diabetes 19, 916-923. 
Hostetter, T. H., Olson, J. L., Rennke, H. G., Venkatachalam, M. A., and Brenner, B. M. 
(1981). Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. 
The American Journal of Physiology 241, F85–F93. 
Hotamisligil, G. (2003). Inflammatory pathways and insulin action. International Journal of 
Obesity 27, 53–55. 
Hovind, P., Rossing, P., Tarnow, L., and Parving, H.H. (2003). Smoking and progression of 
diabetic nephropathy in type 1 diabetes. Diabetes Care 26, 911–916. 
Hsieh, C.L., Yang, M.H., Chyau, C.C., Chiu, C.H., Wang, H.E., Lin, Y.C., Chiu, W.T. and 
Peng, R.Y. (2007). Kinetic analysis on the sensitivity of glucose- or glyoxal-induced LDL 
glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system. 
Biosystems 88, 92–100. 
Huang, X.F., and Chen, J.Z. (2009). Obesity, the PI3K/Akt signal pathway and colon cancer, 
Obesity Reviews 10, 610–616. 
Hubbard, M. J., and Cohen, P. (1993). On target with a new mechanism for the regulation of 
protein phosphorylation. Trends in Biochemical Sciences 18, 172-177. 
Hutchings, A. (1989). Survey and analysis of traditional medicinal plants as used by the Zulu, 
Xhosa and Sotho. Bothalia, 19, 111–123. 
Hutchings, A., Scott, A.H., Lewis, G., and Cunningham, A.B. (1996). Zulu medicinal 
plants—An inventory, University of Natal Press, Pietermaritzburg, South Africa. 




Ibrahim, M.A., Islam, Md. S., (2014). Anti-diabetic effects of the acetone fraction of Senna 
singueana stem bark in a type 2 diabetes rat model. Journal of Ethnopharmacology 153, 392-
399. 
Iwamoto, Y., Kosaka, K., Kuzuya, T., Akanuma, Y., Shigeta, Y., Kaneko, T. (1996). Effects 
of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet 
therapy. Diabetes Care 19, 151-156. 
Jacobsen, I.B., Henriksen, J.E., Hother-Nielsen, O., Vach, W., Beck-Nielsen, H., (2009). 
Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Research and Clinical 
Practice 86, 1-10. 
Jensen, J., Aslesen, R., Ivy, J.L., and Brors, O. (1997). Role of glycogen concentration and 
epinephrine on glucose uptake in rat epitrochlearis muscle. American Journal of Physiology 
272, E649-E655. 
Jensen, J., Rustad, P., Kolnes, A.J., and Lai, Y.C. (2011). The role of skeletal glycogen 
breakdown for regulation of insulin sensetivity by exercise. Frontiers in Physiology 2, 1-11. 
Jentjens, R., and Jeukendrup, A. (2003). "Determinants of post-exercise glycogen synthesis 
during short-term recovery". Sports Medicine 33, 117–144. 
Jimenez-Escrig, .A., Rincon, M., Pulido, R. and Saura, C.F. (2001). Guava fruit (Psidium 
guajava) as a new source of antioxidant dietary fiber. Journal of Agricultural and Food 
Chemistry 49, 5489–5493. 
John, R.W. (2008). Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical 
Use. Clinical Diabetes 26, 53-57. 
Johnson, J.D. (2007). Pancreatic beta-cell apoptosis in maturity onset diabetes of the young. 
Canadian Journal of Diabetes 31, 67-74. 
Johnson, L.N. (2009). The regulation of protein phosphorylation. Biochemical Society 
Transaction 37, 627–641 
Joint Formulary Committee (JFC) (2013). "Chapter 6: Endocrine system". British National 
Formulary (BNF) 65th edition. 447–448. 
97 
 
Jope, R.S., Yuskaitis, C.J., and Beurel, E. (2007). "Glycogen synthase kinase-3 (GSK3): 
inflammation, diseases, and therapeutics." Neurochemical Research 32, 577–595. 
Kahn, R., Weir, G., King, G., Jacobson, A., Smith, R., and Moses, A.  (2005). Joslin's 
Diabetes Mellitus (14th ed.). Lippincott Williams & Wilkins. 
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J. and Waterfield, M. D. (2001). 
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis 
and cancer. Annual Review of Cell and Developmental Biology 17, 615-675. 
Kawanaka, K., Nolte, L.A., Han, D-H, Hansen, P.A., and Holloszy, J.O. (2000). Mechanisms 
underlying impaired GLUT-4 translocation in glycogen-supercompensated muscles of 
exercised rats. American Journal of Physiology 279, E1311–E1318. 
Kelley, D.E., and Mandarino, L.J. (1990). Hyperglycemia normalizes insulin-stimulated 
skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. The 
Journal of Clinical Investigation 86, 1999-2007. 
Kerouz, N.J., Horsch, D., Pons, S., and Kahn, C.R. (1997). Differential regulation of insulin 
receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in 
liver and muscle of the obese diabetic (ob/ob) mouse. The Journal of Clinical Investigation 
100, 3164–3172. 
Kersten, S. (2001).Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO 
Reports 2, 282–286. 
Khan, B.A., Abraham, A., and Leelamma, S. (1995). Hypoglycemic action of Murray 
Koenigii (curry leaf), Brassica juncea (mustard); mechanism of action. Indian Journal of 
Biochemistry and Biophysics 32, 106–108. 
Khang Wei, O., Annie, H., LiXia, S., DeJian H., and Benny Kwong Huat T. (2011). 
Polyphenols-rich Vernonia amygdalina shows anti-diabetic effects in streptozotocin-induced 
diabetic rats. Journal of Ethnopharmacology 133, 598–607 
Khanna, A.K, Chander, R., Singh, C., Srivastava, A.K, and Kapoor, N.K. (1992). 
Hypolipidemic activity of Achyranthus aspera Linn in normal and triton induced 
hyperlipemic rats. Indian Journal of Experimental Biology 30, 128-130. 
98 
 
Khosla, P., Gupta, D.D., and Nagpal, R.K. (1995). Effect of Trigonella foenum graecum 
(Fenugreek) on blood glucose in normal and diabetic rats. Indian Journal of Physiology and 
Pharmacology 2, 173-174. 
Kim, B., and Feldman, E.L. (2012). Insulin resistance in the nervous system. Trends in 
Endocrinology and Metabolism 23, 133-141.  
Kim, J.K., Fillmore, J.J., Chen, Y., Yu, C., Moore, I.K., and Pypaert, M, Lutz, E.P., Kako, Y., 
Velez-Carrasco, W., Goldberg, I.J., Breslow, J.L. and Shulman, G.I. (2001). "Tissue-specific 
overexpression of lipoprotein lipase causes tissue-specific insulin resistance." Proceedings of 
the National Academy of Sciences 98, 7522–7527. 
Kim, J.K., Fillmore, J.J., Sunshine, M.J., Albrecht, B., Higashimori, T., Kim, D.W., Liu, 
Z.X., Soos, T.J., Cline, G.W., O’Brien, W.R., Littman, D.R. and Shulman, G.I.  (2004). PKC-
theta knockout mice are protected from fat-induced insulin resistance. Journal of Clinical 
Investigation 114, 823-827. 
Kim, M-G., and Lee, H-S. (2014). 1,2 Benzenediol Isolated from Persimmon Roots and Its 
Structural Analogues Show Antimicrobial Activities against Food-borne Bacteria. Journal of 
the Korean Society for Applied Biological Chemistry 57, 429-433. 
Kim, Y.D., Park, K.G., Lee, Y.S., Park, Y.Y., Kim, D.K., Nedumaran, B., Jang, W.G., Cho, 
W.J., Ha, J., Lee, I.K., Lee, C.H. and Choi, H.S. (2008). Metformin inhibits hepatic 
gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan 
nuclear receptor SHP. Diabetes 57, 306–314. 
Kirpichnikov, D., McFarlane, S.I., and Sowers, J.R. (2002). Metformin: an update. Annals of 
Internal Medicine 137, 25–33. 
Kitamura, T, Kitamura, Y., Kuroda, S., Hino, Y., Ando, M., Kotani, K., Konishi, H., 
Matsuzaki, H., Kikkawa, U., Ogawa, W., and Kasuga, M. (1999). Insulin-induced 
phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-
threonine kinase Akt. Molecular and Cellular Biology 19, 6286-6296. 
Klannemark, M., Orho, M., Langin, D., Laurell, H., Holm, C., Reynisdottir, S., Arner, P. and 
Groop, L. (1998). The putative role of the hormone-sensitive lipase gene in the pathogenesis 
of type II diabetes mellitus and abdominal obesity. Diabetologia 41, 1516–1522. 
99 
 
Kobayashi, T. and Cohen, P. (1999). Activation of serum- and glucocorticoid-regulated 
protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-
phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. The Biochemical Journal 
339, 319–328. 
Kraemer, F., and Shen, W.J. (2002). Hormone-sensitive lipase: control of intracellular tri-
(di)acylglycerol and cholesteryl ester hydrolysis, Journal of Lipid Research 43, 1585–1594. 
Krätzner, R., Fröhlich, F., Lepler, K., Schröder, M., Röher, K., Dickel, C., Tzvetkov, M.V., 
Quentin, T., Oetjen, E., and Knepel, W. (2008). "A peroxisome proliferator-activated 
receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional 
activator PAX6 to inhibit glucagon gene transcription". Molecular Pharmacology 73, 509–
517. 
Krebs, E.G., (1997). Protein phosphorylation and cellular regulation, I. Nobel lecture 
December 1992. In: Nobel Lectures Physiology or Medicine 1991-1995, Editor Nils 
Ringertz, World Scientific Publishing Co., Singapore. pp 72-89.  
Krebs, E.G., and Fischer, E.H. (1955). Phosphorylase Activity of Skeletal Muscle Extracts. 
Journal of Biological Chemistry 216, 113-120. 
Kristiansen, M., Andersen, B., Iversen, L.F. and Westergaard, N. (2004). Identification, 
synthesis and characterization of new glycogen phosphorylase inhibitors binding to the 
allosteric AMP site. Journal of Medicinal Chemistry 1, 3537-3545. 
Kroller-Schon, S., Knorr, M., Hausding, M., Oelze, M., Schuff, A., and Schell R, Sudowe, S., 
Scholz, A., Daub, S., Karbach, S., Kossmann, S., Gori, T., Wenzel, P., Schulz, E., Grabbe, S., 
Klein, T., Munzel, T. and Daiber, A. (2012). Glucose-independent improvement of vascular 
dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovascular 
Research 96, 140–149. 
Kumar, G.S., Shetty, A.K., Sambaiah, K., and Salimath, P.V. (2005 a). Antidiabetic property 
of fenugreek seed mucilage and spent turmeric in streptozotocin-induced diabetic rats. 
Nutrition Research 25, 1021-1028. 
Kumar, V., Fausto, N., Abbas, A.K., Cotran, R.S., and Robbins, S.L., (2005 b). Robbins and 
Cotran Pathologic Basis of Disease (7
th
 ed.). Philadelphia 1194-1195. 
100 
 
Lampe, M.A., Burlingame, A.L., Whitney, J., Williams, M.L., Brown, B.E., Roitman, E., and 
Elias, M. (1983). "Human stratum corneum lipids: characterization and regional variations". 
Journal of Lipid Research 24, 120–130.  
Lawrence, J.C., Jr. (1992). Signal transduction and phosphorylation in the regulation of 
cellular metabolism by insulin. Annual Review of Physiology 54, 177-193. 
Lawrence, M.C., McKern, N.M., and Ward, C.W. (2007). Insulin receptor structure and its 
implications for the IGF-1 receptor. Current Opinion in Structural Biology 17, 699–705. 
Layden, B.T., Durai, V., and Lowe, W.L. (2010). "G-Protein-Coupled Receptors, Pancreatic 
Islets, and Diabetes". Nature Education 3 (9): 13. 
Le Good, J.A., Ziegler, W.H., Parekh, D.B., Alessi, D.R., Cohen, P., and Parker, P. J. (1998). 
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase 
PDK1. Science 281, 2042–2045. 
Lee, C.H., Olson, P., Evans and R.M. (2003). Minireview: lipid metabolism, metabolic 
diseases, and peroxisome proliferator-activated receptors. Endocrinology 144, 2201-2207. 
Leloir, L.F., and Cardini, C.E., in P. D. Boyer, H. Lardy, and K. Myrbbck. (1962). UDPG-
glycogen transglucosylase. The Enzymes  6, 317-326. 
Leonards, J.R., and Landau, B.R. (1960). A study of the equivalence of metabolic patterns in 
rat adipose tissue: insulin versus glucose concentration. Archives of Biochemistry and 
Biophysics 91, 194–200. 
Leonti, M., Vibrans, H., Sticher, O., and Heinrich, M. (2001). Ethnopharmacology of the 
Popoluca, Mexico: an evaluation. Journal of Pharmacy and Pharmacology 53, 1653–1669. 
Leroy, K., and Brion J.P. (1999). Developmental expression and localization of glycogen 
synthase-3β in rat brain. Journal of Chemical Neuroanatomy 16, 279-293 
Levine, D. Z. (2008). Can rodent models of diabetic kidney disease clarify the significance of 




Lewis, S.J. (2011). Lipid-lowering therapy: who can benefit? Vascular Health and Risk 
Management 7, 525–534 
Li, J., Zhu, H., Shen, E., Wan, L., Arnold, J.M., and Peng, T. (2010). Deficiency of rac1 
blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces 
myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59, 2033–2042. 
Lien Ai Pham-Huy, Hua He and Chuong Pham-Huy. (2008.) Free Radicals, Antioxidants in 
Disease and Health. International Journal of Biomedical Science 4, 89-96. 
Limaye, D.A., Nimbkar, A.Y., Jain, R. and Ahmed, M. (1995). Cardiovascular effects of 
Moringa pterygosperma. Phytotheraphy Research 9, 37–40. 
Lin, H.J., Hsieh, F.C., Song, H., and Lin, J. (2005). Elevated phosphorylation and activation 
of PDK-1/AKT pathway in human breast cancer. British Journal of Cancer. 93, 1372–1381. 
Link, J.J., Rohatgi, A. and de Lemos, J.A. (2007). HDL cholesterol: physiology, 
pathophysiology and management. Current Problems in Cardiology 32, 268–314. 
Liu, C.M., Hsu, C.T., Li, C.Y., Chen, C.C., Liu, M.L., and Liu, J.H.  (2012). A population-
based cohort study of symptomatic gallstone disease in diabetic patients. World Journal of 
Gastroenterology, 18, 1652–1659. 
Lodish, H., Berk, A., Zipursky, S.L., Matsudaira, P., Baltimore, D. and Darnell, J.  (2007). 
Molecular Cell Biology (6th ed.). W. H. Freeman and Company, New York. p. 658. 
Loppes-Virella M.F., Ellis, S. and Colwell, J.A.  (1977). Cholesterol determination in high 
density lipoproteins separated by three different methods. Clinical Chemistry 23, 882-884. 
Lowry, O.H., Rosebrough, N.J., Farr, A., Randall, A.J. (1951). Protein measurement with the 
Folin phenol reagent. Journal of Biological Chemistry 193, 265 – 275. 
Luo, X., Zhang, Y., Ruan, X., Jiang, X., Zhu, L., Wang, X., Ding, Q., Liu, W., Pan, Y., 
Wang, Z and Chen, Y. (2011). Fasting induced protein phosphatase 1 regulatory subunit 
contributes to postprandial blood glucose homeostasis via regulation of hepatic glycogenesis. 
Diabetes 60, 1435–1445. 
102 
 
Ma, J., Wang, Y., Zheng, D., Wei, M., Xu, H., and Peng, T. (2013). Rac1 signalling mediates 
doxorubicin-induced cardiotoxicity through both reactive oxygen species dependent and 
independent pathways. Cardiovascular Research 97, 77–87. 
Machado-Neto, J.A., Favaro, P., Lazarini, M., Costa, F.F., Olalla, Saad, S.T., and Traina, F., 
(2011). Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates 
Akt/mTOR and MAPK pathways in K562 cells. Biochimica et Biophysica Acta 1813, 1404-
1411 
Maeda, S., Matsui, T., and Yamagishi, S. (2012). Vildagliptin inhibits oxidative stress and 
vascular damage in streptozotocininduced diabetic rats. International Journal of Cardiology 
158, 171–173. 
Magre, J., Laurell, H., Fizames, C., Antoine, P.J., Dib, C., Vigouroux, C., Bourut, C., 
Capeau, J., Weissenbach, J., and Langin, D. (1998). Human hormone-sensitive lipase: genetic 
mapping, identification of a new dinucleotide repeat, and association with obesity and 
NIDDM. Diabetes 47, 284-286 
Mahomed, I.M., and Ojewole, J.A. (2003). Hypoglycemic effect of Hypoxis hemerocallidea 
corm (African potato) aqueous extract in rats. Methods and Findings in Experimental and 
Clinical Pharmacology 25, 617-623. 
Malaguarnera, R., and Belfiore, A. (2012). "Proinsulin Binds with High Affinity the Insulin 
Receptor Isoform A and Predominantly Activates the Mitogenic Pathway". Endocrinology 
153, 2152–2163. 
Mandarino, L.J., Wright, K.S., and Verity, L.S. (1987). Effects of insulin infusion on human 
skeletal muscle pyruvate dehydrogenase, phosphofructokinase and glycogen synthase. 
Journal of Clinical Investigation 80, 655-663. 
Manorenjitha, M.S., Norita, A.K., Norhisham, S., and Asmawi, M.Z. (2013). GC-MS 
Analysis of Bioactive Components of Ficus religiosa (Linn) stem. International Journal of 
Pharma and Bio Sciences 4, 99-103. 
Marchand, B., Tremblay, I., Cagnol, S., and Boucher, M.J. (2012). "Inhibition of glycogen 
synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through 
JNK-dependent mechanisms". Carcinogenesis 33, 529–537. 
103 
 
Martín, E.D., Sánchez-Perez, A., Trejo, J.L., Martin-Aldana, J.A., Cano Jaimez, M., Pons, S., 
Acosta, Umanzor, C., Menes, L., White, M.F., and Burks, D.J. (2012). IRS-2 Deficiency 
impairs NMDA receptor-dependent long-term potentiation. Cerebral Cortex 22, 1717-1727.  
Massague, J., and Czech M.P. (1982). Role of disulfides in the subunit structure of the insulin 
receptor. Reduction of class 1 disulfides does not impair transmembrane signalling. The 
Journal of Biological Chemistry 257, 6729-6738. 
Maurer, M., Su, T., Saal, L.H., Koujak, S., Hopkins, B.D., Barkley, C.R., Wu, J., Nandula, 
S., Dutta, B., and Xie Y, et al. (2009). 3-Phosphoinositide–dependent kinase 1 potentiates 
upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer 
Research 69, 6299–6306. 
McIntosh, C., Demuth, H., Pospisilik, J., and Pederson, R. (2005). "Dipeptidyl peptidase IV 
inhibitors: How do they work as new antidiabetic agents?". Regulatory Peptides 128, 159–
165. 
Mellem, J.J., Baijnath, H., and Odhav, B. (2013). Effect of the methanolic extract of 
Brachylaena discolor in a streptozotocin-induced diabetic rat model. African Journal of 
Pharmacy and Pharmacology 7, 636-642.  
Melmed, R.N., Benitez, C.J., and Holt, S.J. (1973). Intermediate cells of the pancreas, 
selective autophagy and destruction of β-granules in intermediate cells of the rat pancreas 
induced by alloxan and streptozotocin. Journal of Cell Science 13, 297-315. 
Metafro,B.E. (2009). Helichrysum Odoratissimum.” Prelude Medicinal Plants Database.   
Metzger, B. E., and Coustan, D. R. (1998). "Proceedings of the Fourth International 
Workshop-Conference on Gestational Diabetes Mellitus. The Organizing 
Committee". Diabetes Care 21, B1–B167. 
Min-Jung, B., Hee Soon, S., Dae-Woon, C., and Dong-Hwa, Shon. (2012). Antiallergic effect 
of Trigonella foenum-graecum L. extracts on allergic skin inflammation induced by 
trimellitic anhydride in BALB/c mice. Journal of Ethnopharmacology 144, 514–522 
Mitchell, R. S., Kumar, V., Abbas, A. K.and  Fausto, N. (2007). Robbins Basic Pathology: 
With STUDENT CONSULT Online Access (8th ed). Philadelphia: Saunders. p. 345. 
104 
 
Mithieux, G., Rajas, F., and Gautier-Stein, A. (2004). "A novel role for glucose 6-
phosphatase in the small intestine in the control of glucose homeostasis." The Journal of 
Biological Chemistry 279, 44231–44238. 
Mitra, S.K., Gopumadhavan, S., Muralidhar, T.S., Anturlikar, S.D., and Sujatha, M.B. 
(1995). Effect of D-400, a herbomineral preparation on lipid profile, glycated haemoglobin 
and glucose tolerance in streptozotocin induced diabetes in rats. Indian Journal of 
Experimental Biology 33, 798–800. 
Moller, D.E. (2001). "New drug targets for type 2 diabetes and the metabolic syndrome". 
Nature 414, 821–827. 
Moody, A.J., and Gliemann, J. (1968). The effect of insulin on the glycogen metabolism of 
isolated fat cells. Experientia 24, 628–630. 
Mora, A., Komander, D., van Aalten, D.M., and Alessi, D.R. (2004). "PDK1, the master 
regulator of AGC kinase signal transduction". Seminars in Cell and Developmental Biology 
15, 161–170. 
Morton, J.F. (1987). Fruits of Warm Climates. Julia F. Morton, Miami, FL, pp. 356-363. 
Mott, J.D., Khalifah, R.G., Nagase, H., Shield, C.F., 3rd, Hudson, J.K., and Hudson, B.G. 
(1997). Nonenzymatic glycation of type IV collagen and matrix metalloproteinase 
susceptibility. Kidney International 52, 1302-1312. 
Mukhtar, H.M., Ansari, S.H., Ali, M., Naved, T., Bhat, Z.A. (2004). Effect of water extract of 
Psidium guajava on alloxan-induced diabetic rats. Pharmazie 59, 734–735. 
Mukhtar, H.M., Ansari, S.H., Bhat, Z.A., Naved, T., and Singh, P. (2006). Antidiabetic 
activity of an ethanol extract obtained from the stem bark of Psidium guajava (Myrtaceae). 
Pharmazie 61, 725–727. 
Munro, S., Cuthbertson, D.J., Cunningham, J, Sales, M., and Cohen, P.T. (2002). Human 
skeletal muscle expresses a glycogen-targeting subunit of PP-1 that is identical to the insulin-
sensitive glycogen-targeting subunit G(L) of liver. Diabetes 51, 591-598. 
Murillo-Cuesta, S., Camarero, G., González-Rodríguez, A., De La Rosa, L.R., Burks, D.J., 
Avendaño, C., Valverde, A.M., and Varela-Nieto, I., (2012). Insulin receptor substrate 2 
105 
 
(IRS2)-deficient mice show sensorineural hearing loss that is delayed by concomitant protein 
tyrosine phosphatase 1B (PTP1B) loss of function. Molecular Medicine 18, 260-269. 
Mutel, E., Gautier-Stein, A., Abdul-Wahed, A., Amigó-Correig, M., Zitoun, C., Stefanutti, 
A., Houberdon, I., Tourette, J.A., Mithieux, G., and Rajas, F. (2011). "Control of blood 
glucose in the absence of hepatic glucose production during prolonged fasting in mice: 
induction of renal and intestinal gluconeogenesis by glucagon". Diabetes 60, 3121–3131. 
Nader, G.A., and Esser, K.A. (2001). Intracellular signaling specificity in skeletal muscle in 
response to different modes of exercise. Journal of Applied Physiology 90, 1936–1942. 
Nadkarni, K.M. (2009). Indian Materia Medica. Bombay Popular Prakashan, Vol.1, 21. 
Najjar, S. (2001). "Insulin Action: Molecular Basis of Diabetes". Encyclopedia of Life 
Sciences (John Wiley & Sons), United States of America. 
National Institutes of Health. National Heart, Lung and Blood Institute.  (2008). "Detection, 
Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
Final Report". http://www.nhlbi.nih.gov/guidelines/cholesterol. 
Ncube, B., Finnie, J., and Van Staden, J., (2012). Seasonal variation in the cyclooxygenase 
inhibitory activities of four South African medicinal bulbs. South African Journal of Botany 
78, 246–251. 
Neelesh, M., Sanjay, J., and Sapna, M. (2010). Antidiabetic potential of medicinal plants. 
Acta Poloniae Pharmaceutica -Drug Research 67, 113-118.  
Nelson, D. L., and Cox, M. M. (2000). Lehninger, Principles of Biochemistry 3rd Edition. 
Worth Publishing: New York, 2000. 
Nelson, D., and Cox, M. (2005). Lehninger Principles of Biochemistry (4th Ed.). W.H. 
Freeman and Company, New York, 1216. 
Nelson, R. G. Bennett, P.H., Beck, G.J., Tan, M., Knowler, W.C. and Mitch, W.E. (1996). 
Development and progression of renal disease in Pima Indians with non-insulin-dependent 
diabetes mellitus. Diabetic Renal Disease Study Group. The New England Journal of 
Medicine 335, 1636–1642. 
106 
 
Nelson, R.G., Knowler, W.C., Pettitt, D.J., Hanson, R.L., and Bennett, P.H. (1995). Incidence 
and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. 
Diabetes Care 18, 182–187. 
Neve, B., Fernandez-Zapico, M.E., Ashkenazi-Katalan, V.  Dina,C., Hamid,Y.H., Joly, 
E., Vaillant, E., Benmezroua, Y., Durand, E., Bakaher, N., Delannoy, V., Vaxillaire, 
M.,Cook, T., Dallinga-Thie, G.M., Jansen, H., Charles, M.A., Clément, K., Galan, 
P., Hercberg, S., Helbecque, N., Charpentier, G., Prentki, M., Hansen, T., Pedersen, 
O., Urrutia, R.,Melloul, D. and Froguel, P. (2005). Role of transcription factor KLF11 and its 
diabetes-associated gene variants in pancreatic beta cell function. Proceedings of the National 
Academy of Sciences 13, 4807-4812. 
Newgard, C.B., Brady, M.J., O’Doherty, R.M., and Saltiel, A.R. (2000). Organizing Glucose 
Disposal: Emerging Roles of the Glycogen Targeting Subunits of Protein Phosphatase-1. 
Diabetes 49, 1967-1977. 
Newgard, C.B., Hwang, P.K., and Fletterick, R.J. (1989). "The family of glycogen 
phosphorylases: structure and function". Critical Reviews Biochemistry and Molecular 
Biology 24, 69–99.  
Nikoulina, S.E., Ciaraldi, T.P., Mudaliar, S., Mohideen, P., Carter, L. and Henry, R.R.. 
(2000). Potential role of GSK-3 in skeletal muscle insulin resistance type 2 diabetes. Diabetes 
49, 263–271. 
Nilsson, N.O., Strålfors, P., Fredrikson, G., and Belfrage, P. (1980). Regulation of adipose 
tissue lipolysis: Effects of noradrenaline and insulin on phosphorylation of hormone-sensitive 
lipase and on lipolysis in intact rat adipocytes. FEBS Letters 111, 125-130. 
Nivoit, P. (2003). Effect of glycated LDL on microvascular tone in mice: a comparative study 
with LDL modified in vitro or isolated from diabetic patients. Diabetologia 46, 1550-1558.  
Njagi, J.M., Piero, N.M., Kibiti, C.M., Ngeranwa, J.J.N., Njue, W.M., Gathumbi, P., and 
Njagi, E.N.M. (2015). Hypoglycemic effect of Helichrysum odoratissimum in alloxan 
induced diabetic mice. The Journal of Phytopharmacology 4, 30-33 
107 
 
Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. and Olefsky, J. (1994). Improvement in 
glucose tolerance and insulin resistance in obese subjects treated with troglitazone. The New 
England Journal of Medicine 331, 1188-1193. 
Nowicki, M., Muller, K., Serke, H., Kosacka, J., Vilser, C., and Ricken A, Spanel-Borowski, 
K. (2010). Oxidized low-density lipoprotein (oxLDL)-induced cell death in dorsal root 
ganglion cell cultures depends not on the lectin-like oxLDL receptor-1 but on the toll-like 
receptor-4. Journal of Neuroscience Research 88, 403–412. 
Nuttal, F.Q. (1972). Endocrine pancreas: mechanisms of insulin action of glycogen synthesis. 
in: Handbook of Physiology series. The American Physiological Society. Williams and 
Wilkins, Baltimore 1, 395-413. 
Nwanjo, H.U. (2005). Efficacy of aqueous leaf extract of Vernonia amygdalina on plasma 
lipoprotein and oxidative status in diabetic rat models. Nigerian Journal of Physiological 
Sciences 20, 39-42. 
Oates, P.J. (2002). Polyol pathway and diabetic peripheral neuropathy.  International Review 
of Neurobiology 50, 325–392.  
Ogueri, C.C., Elekwa, I., Ude, C.V., and Ugbogu, A.E. (2014). Effect of Aqueous Extract of 
Guava (Psidium guajava) leaf on Blood Glucose and Liver Enzymes in Alloxan Induced 
Diabetic Rats. British Journal of Pharmaceutical Research 4, 1079-1087. 
Oh, W.K., Lee, C.H., Lee, M.S., Bae, E.Y., Sohn, C.B., and Oh, H. (2005). Antidiabetic 
effects of extracts from Psidium guajava. Journal of Ethnopharmacology 96, 411-415. 
Ohmori, R., Iwamoto, T., Tago, M., Takeo, T., Unno, T., Itakura, H., and Kondo, K. (2005). 
Antioxidant activity of various teas against free radicals and LDL oxidation Lipids, 40, 849–
853 
Oiknine, R.. and Mooradian, A.D. (2003). Drug therapy of diabetes in the elderly. 
Biomedicine and Pharmacotherapy 57, 231-239. 
Ojewole J.A. (2005): Hypoglycaemic and hypotensive effects of Psidium guajava Linn. 
(Myrtaceae) leaf aqueous extract. Methods and Findings in Experimental and Clinical 
Pharmacology 27, 689-695. 
108 
 
Okubo, M., Horinishi, A., Saito, M., Ebara, T., Endo, Y., Kaku, K., Murase, T., and Eto, M. 
(2007). "A novel complex deletion-insertion mutation mediated by Alu repetitive elements 
leads to lipoprotein lipase deficiency". Molecular Genetics and Metabolism 92, 229–233  
Okuda, T., Hatano, T., Yazaki, K. (1984). Guavin B, an ellagitannin of novel type. Chemical 
and Pharmaceutical Bulletin 32, 3787-3788 
Owolabi, M.A., Jaja, S.I., Oyekanmi, O.O., and Olatunji, O.J. (2008). Evaluation of the 
antioxidant activity and lipid peroxidation of the leaves of Vernonia amygdalina. Journal of 
Complementary and Integrative Medicine 5: doi:10.2202/1550- 3840.1152. 
Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.H., Iwakoshi, N.N., Ozdelen, E., Tuncman, G., 
Gorgun, C., Glimcher, L.H. and Hotamisligil, G.S. (2004). Endoplasmic reticulum stress 
links obesity, insulin action, and type 2 diabetes. Science 306, 457–461. 
Palm, D.C., Rohwer, J.M., and Hofmeyr, J.H. (2013). "Regulation of glycogen synthase from 
mammalian skeletal muscle--a unifying view of allosteric and covalent regulation." The 
FEBS journal 280, 2–27. 
Park, J., Leong, M. L., Buse, P., Maiyar, A. C., Firestone, G. L., and Hemmings, B. A. 
(1999). Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-
stimulated signaling pathway. The EMBO Journal 18, 3024–3033. 
Patel, S., Di Bartolo, B.A., Nakhla, S., Heather, A.K., Mitchell, T.W., Jessup, W., 
Celermajer, D.S., Barter, P.J. and Rye, K.A. (2010). Anti-inflammatory effects of 
apolipoprotein A-I in the rabbit. Atherosclerosis. 212, 392–397. 
Perkins, J.M., Dunn, J.P., and Jagasia, S.M. (2007). Perspectives in gestational diabetes 
mellitus: a review of screening, diagnosis, and treatment. Clinical Diabetes 2, 57-62. 
Postle, A. D., and Bloxham, D. P. (1980). The use of tritiated water to measure absolute rates 
of hepatic glycogen synthesis. The Biochemical Journal 192, 65-73. 
Prabhakar, P. K., and Doble, M. (2008). A target based therapeutic approach towards diabetes 
mellitus using medicinal plants. Current Diabetes Review 4, 291-308. 
109 
 
Pujol, J. (1990). Naturafrica—The Herbalist Handbook, Jean Pujol Natural Healers’ 
Foundation, Durban, South Africa. 
Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S.C., Hemmings, B.A., and 
Thomas, G. (1998). Phosphorylation and activation of p70s6k by PDK1. Science 279, 707-
710. 
Puri, D., Prabhu, K.M, and Murthy, P.S. (1995). Hypocholesterolemic effect of the 
hypoglycemic principle of fenugreek (Trigonella foenum graecum) seeds. Indian Journal of 
Clinical Biochemistry 9, 13-16. 
Puri, D., Prabhu, K.M., and Murthy, P.S. (2002). Mechanism of action of a hypoglycemic 
principle isolated from fenugreek seeds. Indian Journal of Physiology and Pharmacology 4, 
457-462. 
Ragheb, R., Shanab, G.M.L., Medhat, A., Seoudi, D.M., Adeli, K. and Fantus, I.G. . (2009). 
Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: Evidence 
for PKC activation and oxidative stress-activated signaling pathways. Biochemical and 
Biophysical Research Communications 389, 211-216. 
Rahbar, S., and Figarola, J.L. (2003). Novel inhibitors of advanced glycation endproducts. 
Archives of Biochemistry and Biophysics 419, 63-79. 
Rajesh, M., Mukhopadhyay, P., Batkai, S., Mukhopadhyay, B., Patel, V., Hasko, G.,  Szabo, 
C., Mabley, J.G., Liaudet, L., and  Pacher, P. (2009). Xanthine oxidase inhibitor allopurinol 
attenuates the development of diabetic cardiomyopathy, Journal of Cellular and Molecular 
Medicine 13, 2330–2341. 
Rameh, L. and Cantley, L. (1999). The role of phosphoinositide 3- kinase lipid products in 
cell function. Journal of Biological Chemistry 274, 8347-8350. 
Ramos, G.A., Hanley, A.A., Aguayo, J., Warshak, C.R., Kim, J.H., and  Moore, T.R. (2012). 
Neonatal chemical hypoglycemia in newborns from pregnancies complicated by type 2 and 
gestational diabetes mellitus — the importance of neonatal ponderal index. Journal of 
Maternal-Fetal and Neonatal Medicine 25, 267–271 
110 
 
Rang, H.P., Dale, M.M., Ritter, J.M., Moore, P.K. (2003). Pharmacology (5
th
 ed.) Pg 388. 
Edinburgh; New York: Churchhill Livingstone. 
Rao, K.S. and Misra, S.H. (1998). Anti-inflammatory and anti-hepatotoxic activities of the 
rats of Moringa pterygosperma Geaertn. Indian Journal of Pharmaceutical Sciences 60, 12–
16. 
Rao, P.V., Pugazhenthi, S., and Khandelwal, R.L. (1995). The Effects of Streptozotocin-
induced Diabetes and Insulin Supplementation on Expression of the Glycogen Phosphorylase 
Gene in Rat Liver. The Journal of Biological Chemistry 270, 24955–24960. 
Ravid, M., Brosh, D., Ravid-Safran, D., Levy, Z., and Rachmani, R. (1998). Main risk factors 
for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood 
pressure, and hyperglycemia. Archives of Internal Medicine 158, 998–1004. 
Rayasam, G.V., Tulasi, V.K., Sodhi, R., Davis, J.A., and Ray, A. (2009). "Glycogen synthase 
kinase-3: more than a namesake". British Journal of Pharmacology 156, 885–898.  
Reaven, P., and Witztim, J. (1996). Oxidized Low Density Lipoproteins in Atherogenesis: 
Role of Dietary Modification. Annual Reviews in Nutrition 16, 51-70. 
Reif, K., Burgering, B. M. T. and Cantrell, D. A. (1997). Phosphatidylinositol 3-kinase links 
the interleukin-2 receptor to protein kinase B and p70 S6 kinase. Journal of Biological 
Chemistry 272, 14426-14438. 
Reitman. S and Frankel, S. (1957). A colorimetric method for determination of serum 
glutamic oxaloacetic and glutamic pyruvic transaminases. American Journal of Clinical 
Pathology 28, 56-63. 
Ring, A. M., Manglik, A., Kruse, A.C., Enos, M.D., Weis, W.I., Garcia, C. and Kobilka, B.K. 
(2013). Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered 
nanobody. Nature 502, 575-579.  
Rios, C.D., Salazar, C.R., Cardona, C., Victoria, K. and Torres, M. (1977). Guayaba. En: 
Instituto Colombiano Agropecuario. Bogot´a (Colombia), second ed. Frutales. Manual de 
Asistencia T´ecnica 4, 221–248. 
111 
 
Robinson, L.J. Razzack, Z.F., Lawrence, J.C. Jr and James, D.E. (1993). Mitogen-activated 
protein kinase activation is not sufficient for stimulation of glucose transport or glycogen 
synthase in 3T3-L1 adipocytes. Journal of Biological Chemistry 268, 26422–26427. 
Roden, M., and Bernroider, E. (2003). Hepatic glucose metabolism in humans—its role in 
health and disease. Best Practice and Research Clinical Endocrinology Metabolism 17, 365–
383. 
Roloff, A., Weisgerber, H., Lang, U. and Stimm, B. (2009). Enzyklopadie der Holzgewachse, 
Handbuchund Atlas der Dendrologie, ISBN: 97-8-3-527-32141-4.  
Roschlau, P., Bernt, E. and Gruber, W.Z. (1974). Enzymatic determination of total 
cholesterol in serum. Zeitschrift fur Klinische Chemie und Klinische Biochemie 12, 403-407. 
Rosell-Perez, M., and Larner, J. (1964 a). “Studies of UDPG-Alpha-Glucan 
Transglucosylase. V. Two Forms of the Enzyme in Dog Skeletal Muscle and Their 
Interconversion.’’ Biochemistry 3, 81-88. 
Rosell-Perez, M., and Larner, J. (1964 b). Studies on UDPG-Alpha-Glucan Transglucosylase 
IV. Purification and Characterization of Two Forms from Rabbit Skeletal Muscle. 
Biochemistry, 3, 75-81. 
Rosell-Perez, M., Villar-Palasi, C. and Larner, J. (1962). Studies on UDPG-glycogen 
transglucosylase. I. Preparation and differentiation of two activities of UDPG-glycogen 
transglucosylase from rat skeletal muscle. Biochemistry 1, 763-768. 
Rosen, P., Du, X. and Tschope, D. (1998). Role of oxygen derived free radicals for vascular 
dysfunction in the diabetic heart: prevention by α-tocopherol? Molecular and Cellular 
Biochemistry 188, 103–111 
Ross, R., and Ross, Russell (1999). "Atherosclerosis — An Inflammatory Disease". New 
England Journal of Medicine 340, 115–126. 
Rothman, D.L., Shulman, R.G. and Shulman, G.I. (1992): 
31
P nuclear magnetic resonance 
measurements of muscle glucose-6-phosphate: evidence for reduced insulin-dependent 
muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes 
mellitus. Journal of Clinical Investigation 89, 1069-1075.  
112 
 
Russell, D.W. (2000). "Oxysterol biosynthetic enzymes". Biochimica et Biophysica Acta 
1529, 126–135. 
Russell-Jones, D., and Gough, S. (2012). Recent advances in incretin-based therapies. 
Clinical Endocrinology (Oxf), 77, 489–499 
Sachdewa, A., and Khemani, L.D. (2003). Effect of Hibiscus rosa sinensis Linn. ethanolic 
flower extract on blood glucose and lipid profile in streptozotocin induced diabetes in rats. 
Journal of Ethnopharmacology 89, 61–66. 
Said G. (2007). Diabetic neuropathy – a review. Nature Clinical Practice Neurology 3, 331–
340. 
Sakamoto, K., Aschenbach, W.G., Hirshman, M.F. and Goodyear, L.J. (2003). Akt signaling 
in skeletal muscle: regulation by exercise and passive stretch. American Journal of 
Physiology, Endocrinology and Metabolism 285, E1081–E1088. 
Saltiel, A. R. and Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and 
lipid metabolism. Nature 414, 799–806. 
Saltiel, A.R. (2001). "New perspectives into the molecular pathogenesis and treatment of type 
2 diabetes". Cell 104, 517–529. 
Sangeetha, R., Geetha, A. and Arulpandi, I. (2010). Concomitant production of protease and 
lipase by Bacillus licheniformis VSG1: Production, purification and characterization. 
Brazilian Journal of Microbiology 41, 179-185. 
Savage, D.B., Petersen, K.F. and Shulman, G.I. (2007). Disordered lipid metabolism and the 
pathogenesis of insulin resistance. Physiological Reviews 87, 507–520. 
Sawicki, P.T., Didjurgeit, U., Muhlhauser, I., Bender, R., Heinemann, L., and Berger, M. 
(1994). Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17, 
126 –131. 
Scheid, M.P, and Woodgett, J.R. (2003). Unravelling the activation mechanisms of protein 
kinase B/Akt. FEBS Letters 546, 108–112 
113 
 
Schlessinger, J., and Ullrich, A. (1992). Growth factor signaling by receptor tyrosine kinases. 
Neuron 9, 383-391. 
Schweiger, M., Schreiber, R., Haemmerle, G., Lass, A., Fledelius, C., Jacobsen, P., 
Tornqvist, H., Zechner, R., and Zimmermann, R. (2006). Adipose triglyceride lipase and 
hormone sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. 
Journal of Biological Chemistry 281, 40236-40241. 
Scollan-Kolippoulos, M., Guadagno, S., and Walker, E. (2006). Gestational diabetes 
management: guidelines to a healthy pregnancy. Nurse Practitioner 6, 14-19,  
Scortegagna, M., Ruller, C., Feng, Y., Lazova, R., Kluger, H., Li, J.L., De, S.K., Rickert, R., 
Pellecchia, M., Bosenberg, M., and Ronai, Z.A. (2014). "Genetic inactivation or 
pharmacological inhibition of Pdk1 delays development and inhibits metastasis of 
Braf(V600E)::Pten(-/-) melanoma". Oncogene33 34, 4330–4339. 
Seino, S., and Bell G.I. (1989). Alternative splicing of human insulin receptor messenger 
RNA. Biochemical and Biophysical Research Communications 159, 312-316. 
Sekiya, M., Osuga, J., Yahagi, N., Okazaki, H., Tamura, Y., Igarashi, M., Takase, S., Harada, 
K., Okazaki, S., Iizuka, Y., Ohashi, K., Yagyu, K., Okazaki, M., Gotoda, T., Nagai, R., 
Kadowaki, T., Shimano, H., Yamada, N., and Ishibashi, S. (2008). Hormone-sensitive lipase 
is involved in hepatic cholesteryl ester hydrolysis. Journal of Lipid Research 49, 1829-1838. 
Shield, J.P. (2000). Neonatal diabetes: new insights into aetiology and implications. Hormone 
Research 1, 7-11. 
Shinichiro, K., Toyoshi, I., Toshihide, Y., Mayumi, Y., Makoto I., Noriyuki S., Kenichi, Y., 
and Ryoichi, T. (2016). A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In 
vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 
deficient rats. Metabolism Clinical and Experimental 65, 138 – 145.  
Shulman, G. I. (2004). Unraveling the cellular mechanism of insulin resistance in humans: 
new insights from magnetic resonance spectroscopy. Physiology (Bethesda) 19, 183–190. 
Shulman, G.I. (2000). Cellular mechanisms of insulin resistance. Journal of Clinical 
Investigation 106, 171–176. 
114 
 
Shulman, G.I., Rothman, D.L., Jue, T., Stein, P., DeFronzo, R.A. and Shulman, R.G. (1990). 
Quantitation of muscle glycogen synthase in normal subjects and subjects with non-insulin-
dependent diabetes by 13C nuclear magnetic resonance spectroscopy. The New England 
Journal of Medicine 322, 223-228. 
Shulman, R.G., Bloch, G. and Rothman, D.L. (1995). In vivo regulation of muscle glycogen 
synthase and the control of glycogen synthesis. Proceedings of the National Academy of 
Sciences 92, 8535–8542. 
Simons, A.L., Orcutt, K.P., Madsen, J.M., Scarbrough, P.M., and Spitz, D.R. (2012). 
Oxidative Stress in Cancer Biology and Therapy. Humana Press. pp. 21–46. 
Singh, D.K.. and Winocour, P., K. (2011). Farrington Oxidative stress in early diabetic 
nephropathy: fueling the fire. Nature Review Endocrinology 7, 176–184 
Singh, R., Barden, A., Mori, T. and Beilin, L. (2001). Advanced glycation end products: a 
review. Diabetologia 44, 129–146 
Singh, R.B., Ghosh, S., Niaz, A.M., Gupta, S., Bishnoi, L., and Sharma, J.P. (1992). Effects 
of guava intake on serum total and high-density lipoprotein cholesterol levels and on 
systemic blood pressure. American Journal of Cardiology 70, 1287-1291. 
Singh, V.P., Bali, A., Singh, N. and Jaggi, A.S. (2014). Advanced Glycation End Products 
and Diabetic Complications. The Korean Journal of Physiology and Pharmacology. 18, 1-14. 
Siu, F.Y.  He, M., de Graaf, C., Han, G.W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, 
D., Joseph, J.S., Liu, W., Lau, J., Cherezov, V., Katritch, V., Wang, M.W. and Stevens, R.C. 
(2013). Structure of the human glucagon class B G-protein-coupled receptor, Nature 499, 
444-449.  
Skoglund, G., Lundquist, I., and Ahrén, B. (1987). "Alpha 1- and alpha 2-adrenoceptor 
activation increases plasma glucagon levels in the mouse". European Journal of 
Pharmacology 143, 83–88. 
Smythe, C., and Cohen, P. (1991). The discovery of glycogenin and the priming mechanism 
for glycogen biogenesis. European Journal of Biochemistry 200, 625-631.  
115 
 
Somsák, L., Nagya, V., Hadady, Z., Docsa, T., and Gergely, P. (2003). "Glucose analog 
inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments". 
Current Pharmacological Design 9, 1177–1189. 
Sonksen, P., and Sonksen, J. (2000). "Insulin: understanding its action in health and disease". 
British Journal of Anaesthesia 85, 69–79. 
Soriano, F. G., Pacher, P., Mabley, J., Liaudet, L. and Szabo, C. (2001). Rapid reversal of the 
diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) 
polymerase. Circulation Research 89, 684–691 
South African Medicines Formulary (SAMF). (2012). 10th ed. In: Rossiter D, editor. 
Rondebosch: Health and Medical Publishing Group, Cape Media House. 
South African National Biodiversity Institute (SANBI). (2009). Vernonia oligocephala (DC.) 
Sch.Bip. 
Sriplang, K., Adisakwattana, S., Rungsipipat, A., and Yibchok-Anun, S. (2007). Effects of 
Orthosiphon stamineus aqueous extract on plasma glucose concentration and lipid profile in 
normal and streptozotocin-induced diabetic rats. Journal of Ethnopharmacology 109, 510-
514. 
Steinberg, D. (2004). Thematic review series: The Pathogenesis of Atherosclerosis. An 
interpretive history of the cholesterol controversy: part I. The Journal of Lipid Research 45, 
1583-1593. 
Steinberg, D. (2008). The LDL modification hypothesis of atherogenesis: an update. The 
Journal of Lipid Research 50(Supplement), S376-S381. 
Steiner, D.F, and Oyer, P.E. (1967). "The biosynthesis of insulin and a probable precursor of 
insulin by a human islet cell adenoma". Proceedings of the National Academy of Sciences 57, 
473–480.  
Stocker, R., and Keaney, J.F. Jr (2004). "Role of oxidative modifications in atherosclerosis". 
Physiological Reviews 84, 1381–478. 
Stone, B. (1970). The flora of Guam. Micronesica 6, 454–455. 
116 
 
Sugimoto, K., Yasujima, M., and Yagihashi, S. (2008). Role of advanced glycation end 
products in diabetic neuropathy. Current Pharmaceutical Design 14, 953–961.  
Sumari, D. (2012). Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus. 
South African Pharmaceutical Journal 79, 22-26. 
Sun, X.J., Rothenberg, P., Kahn, C.R., Backer, J.M., Araki, E., Wilden, P.A., Cahill, D.A., 
Goldstein, B.J., and White, M.F. (1991). Structure of the insulin receptor substrate IRS-1 
defines a unique signal transduction protein. Nature 352, 73–77. 
Sun, X.J., Wang, L.M., Zhang, Y., Yenush, L., Myers, M.G Jr, Glasheen, E., Lane, W.S., 
Pierce, J.H., and White M.F. (1995). Role of IRS-2 in insulin and cytokine signalling. Nature 
377, 173–177. 
Suzuki-Sugihara, N., Kishimoto, Y., Saita, E., Taguchi, C., Kobayashi, M., Ichitani, M., 
Ukawa, Y., Sagesaka, Y., Suzuki, E., and Kondo, K. (2016). Green tea catechins prevent low-
density lipoprotein oxidation via their accumulation in low-density lipoprotein particles in 
humans. Nutrition Research 36, 16–2 3 
Szablewski, L. (2011). Glucose homeostasis and insulin resistance, Bentham E-Books, 
eISBN 978-1-6080 5-189-2. 
Szkudelski, T. (2001). The mechanism of alloxan and streptozotocin action in β cells of the 
rat pancreas. Physiological Research 50, 536-546. 
Sztalryd, C., and Kraemer, F.B. (1995). Regulation of hormone-sensitive lipase in 
streptozotocin - induced diabetic rats. Metabolism 44, 1391–1396. 
Tang, O., Chen, X.M., Shen, S., Hahn, M., and Pollock, C.A. (2013). Mirna-200b represses 
transforming growth factor-beta1-induced emt and fibronectin expression in kidney proximal 
tubular cells. Am. J. Physiol. Ren. Physiol., 304, F1266–F1273 
Taylor, A.J., Ye, J.M. and  Schmitz-Peiffer, C., (2006). Inhibition of glycogen synthesis by 
increased lipid availability is associated with subcellular redistribution of glycogen synthase. 
Journal of Endocrinology 188, 11-23. 
117 
 
Thaipong, K., Boonprakob, U., Cisneros-Zevallos, L., and Byrne, D.H., (2005). Hydrophilic 
and lipophilic antioxidant activities of guava fruits. Southeast Asian Journal of Tropical 
Medicine Public Health 36, 254–257. 
The Microalbuminuria Collaborative Study Group (MCSG). (1999). Predictors of the 
development of microalbuminuria in patients with type 1 diabetes mellitus: a seven year 
prospective study. Diabetic Medicine 16, 918–925. 
Thirone, A.C.P., Huang, C., and Klip, A. (2006). Tissue specific roles of IRS proteins in 
insulin signaling and glucose transport. Trends in Endocrinology and Metabolism 17, 70-76. 
Thorburn, A.W., Gumbiner, B., Bulacan, F., Wallace, P. and Henry, R.R. (1990). 
Intracellular glucose oxidation and glycogen synthase activity are reduced in noninsulin-
dependent (type H) diabetes independent of impaired glucose uptake. Journal of Clinical 
Investigation 85, 522-529.  
Tinahones, F.J., Rubio, M.A., Garrido-Sánchez, L., Ruiz, C., Gordillo, E., Cabrerizo, L., and 
Cardona F. (2008). "Green tea reduces LDL oxidability and improves vascular function". 
Journal of the American College of Nutrition 27, 209–213. 
Tiwari, A.K. (2001). Imbalance in antioxidant defence and human diseases: Multiple 
approach of natural antioxidants therapy. Current Science 81, No. 9, 1179-1187 
Toma, L. (2009). Irreversibly glycated LDL induce oxidative and inflammatory state in 
human endothelial cells; added effect of high glucose. Biochemical and Biophysical Research 
Communications 18, 877-882. 
Toth, C., Brussee, V., Martinez, J.A., McDonald, D., Cunningham, F.A., and Zochodne, 
D.W. (2006). Rescue and regeneration of injured peripheral nerve axons by intrathecal 
insulin. Neuroscience. 139, 429–449.  
Traut, R. R., and Lipmann, F. (1963). Activation of glycogen synthetase by glucose-6-
phosphate. Journal of Biological Chemistry 238, 1213-1221. 
Ullrich, A., and Schlessinger J. (1990). Signal transduction by receptors with tyrosine kinase 
activity. Cell 61, 203-212. 
118 
 
Vagionas, K., Graikou, K., Chinou, I.B., Runyoro, D. and Ngassapa, O. (2007). Chemical 
analysis and antimicrobial activity of essential oils from the aromatic plantsArtemisia afra 
Jacq. and Leonotis ocymifolia (Burm. f.) Iwarsson var. raineriana (Vis.) Iwarsson growing in 
Tanzania. Journal of Essential Oil Research 19, 396–400. 
Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T,, Mazur, M., and Telser, J. (2006). Free 
Radicals and Antioxidants in Normal Physiological Functions and Human Disease. 
International Journal of Biochemistry and Cell Biology 39, 44-84. 
Valla, V. (2010). Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin 
Pumps. Experimental Diabetes Research 2010, 1-14. 
Van de Werve, G., Sestoft, L, Folke, M., and Kristensen, L. O. (1984). The onset of liver 
glycogen synthesis in fasted-refed rats. Effects of streptozotocin diabetes and of peripheral 
insulin replacement. Diabetes 33, 944-949. 
van Dorland, H.A., Sadri, H., Morel, I., and Bruckmaier, R.M. (2011). Coordinated gene 
expression in adipose tissue and liver differs between cows with high or low NEFA 
concentrations in early lactation. Journal of Animal Physiology and Animal Nutrition 96, 
137–147 
van Wyk B. and van Wyk P. (2007). How to Identify Trees in Southern Africa. Struik 
Publishers, Cape Town. 
van Wyk, B.E., Van Oudtshoorn, B., and Gericke, N. (2002). Medicinal Plants of South 
Africa (2nd ed.), Briza Publications, Pretoria, pp. 156–157. 
van Wyk, B.-E., Van Oudtshoorn, B., and Gerike, N. (1997). Medicinal Plants of South 
Africa. Briza Publications, Pretoria. pp. 142.  
Vanhaesebroeck, B., and Alessi, D.R. (2000). The PI3K-PDK1 connection: more than just a 
road to PKB. Biochemical Journal 346, 561–576 
Varshosaz, J. (2007). Insulin delivery systems for controlling diabetes. Recent patents on 
endocrine, metabolic and immune drug discovery 1, 25-40. 




Villar-Palasi, C., and Larner. (1961). Insulin treatment and increased UDPG-glycogen 
transglucosylase activity in muscle. Archives of Biochemistry and Biophysics 94, 436-442 
Vincent, A.M., Hayes, J.M., McLean, L.L., Vivekanandan-Giri, A., Pennathur, S., and 
Feldman, E.L. (2009). Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. 
Diabetes 58, 2376–2385. 
Vincent, A.M., Perrone, L., Sullivan, K.A., Backus, C., Sastry, A.M., and Lastoskie C, et al. 
(2007). Receptor for advanced glycation end products activation injures primary sensory 
neurons via oxidative stress. Endocrinology 148, 548–558.  
Vora, J. P., Dolben, J., and Dean J.D., Thomas, D., Williams, J.D., and Owens, D.R. (1992). 
Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney 
International 41, 829–835. 
Walker, F., Abramowitz, L., Benabderrahmane, D., Duval, X., Descatoire, V., Hénin, D., 
Lehy, T., and Aparicio, T. (2009). "Growth factor receptor expression in anal squamous 
lesions: modifications associated with oncogenic human papillomavirus and human 
immunodeficiency virus". Human Pathology 40, 1517–1527. 
Wallis, M.G., Appleby, G.J., Youd, J.N., Clark, M.G., and Penschow, J.D. (1998). Reduced 
glycogen phosphorylase activity in denervated hindlimb muscles of rat is related to muscle 
atrophy and fibre type. Life Sciences 64, 221-228. 
Wang, X., Li, Y.-L., Wu, H., Liu, J.-Z., Xia Hu, J., Liao, N., Peng, J., Cao, P.-P., Liang, X., 
and Hai, C.-X. (2011). Antidiabetic Effect of Oleanolic Acid: A Promising Use of a 
Traditional Pharmacological Agent. Phytotherapy Research 25, 1031-1040. 
Waterfield, M.D., and Greenfield, C. (1991). Expression and properties of epidermal growth 
factor receptor expressed from baculovirus vectors. Methods in Enzymology 200, 627–645. 
Watt, J.M., and Breyer-Brandwijk, M.G. (1962). The Medicinal and Poisonous Plants of 
Southern and Eastern Africa, (2nd ed.), Livingstone, London, pp. 39. 
Widmaier, E. (2006). Vander's Human Physiology. McGraw Hill.Boston, p. 96. 
120 
 
Wiggin, T.D., Sullivan, K.A., Pop-Busui, R., Amato, A., Sima, A.A., and Feldman, E.L. 
(2009). Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58, 
1634–1640. 
Willcox, J.K., Ash, S.L. and Catignani, G.L. (2004). Antioxidants and prevention of chronic 
disease. Review. Critical Reviews in Food Science and Nutrition 44, 275-295. 
Williamson, J. R., Copper, R. H., and Hoek, J. B. (1981). The role of calcium in the hormonal 
regulation of liver metabolism. Biochimica et Biophysica Acta  639, 243-295. 
Withers, D.J., Gutierrez, J.S., Towery, H., Burks, D.J., Ren, J.M., Previs, S., Zhang, Y., 
Bernal, D., Pons, S., Shulman, G.I., Bonner-Weir, S. and White, M.F. (1998). Disruption of 
IRS-2 causes type 2 diabetes in mice. Nature. 391, 900–904. 
Wojtaszewski, J.F.P., MacDonald, C., Nielsen, J.N., Hellsten, Y., Hardie, D.G., Kemp, B.E., 
Kiens, B., and Richter, E.A. (2003). Regulation of 5’AMP-activated protein kinase activity 
and substrate utilization in exercising human skeletal muscle. American Journal of 
Physiology 284, E813–E822. 
Woodgett, J.R. (2001). Judging a protein more than its name: GSK-3. Science’s: Signal 
Transduction Knowledge Environment 100, RE12 
World Health Organisation. Diabetes fact sheet no. 312, 2014 (online). Available from URL: 
<http://www.who.int/mediacentre/factsheets/fs312/en>. 
Wright, J. R., Yang, H., Hyrtsenko, O., Xu, B., Yu, W., and Pohajdak, B. (2014). A review of 
piscine islet xenotransplantation using wild-type tilapia donors and the production of 
transgenic tilapia expressing a "humanized" tilapia insulin . Xenotransplantation 21, 485–
495. 
Wroblewski, F., and La Due, J.S. (1955). Lactic dehydrogenase activity in blood. 
Proceedings of the Society for Experimental Biology and Medicine 90, 210-213. 
Xu, E., Kumar, M., Zhang, Y., Ju, W., Obata, T., Zhang, N., Liu, S., Wendt, A., Deng, S., 
Ebina, Y., Wheeler, M.B., Braun, M., and Wang, Q. (2006). "Intra-islet insulin suppresses 
glucagon release via GABA-GABAA receptor system". Cell Metabolism 3, 47–58. 
121 
 
Yamagishi, S., and Imaizumi, T. (2005). Diabetic vascular complications: pathophysiology, 
biochemical basis and potential therapeutic strategy. Current Pharmaceutical Design 11, 
2279-2299. 
Yamagishi, S., Inagaki, Y., Okamoto, T., Amano, S., Koga, K.,  Takeuchi, M. and Makita, Z.  
(2002). Advanced glycation end product-induced apoptosis and overexpression of vascular 
endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured 
mesangial cells. Journal of Biological Chemistry 277, 20309-20315. 
Yang, Z., Zingarelli, B., and Szabo, C. (2000). Effect of genetic disruption of poly (ADP-
ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis 
during myocardial ischemia-reperfusion injury, Shock 13, 60–66. 
Ye, S.D., Zheng, M., Zhao, L.L., Qian, Y., Yao, X.M., Ren, A., Li, S.M. and Jing, C.Y. 
(2009). Intensive insulin therapy decreases urinary MCP-1 and ICAN-1 excretions in 
incipient diabetic nephropathy. European Journal of Clinical Investigation 39, 980-985. 
Yki-Järvinen H. (2004). Thiazolidinediones. The New England Journal of Medicine 351, 
1106-1118 
Yki-Järvinen, H. (2010). Liver fat in the pathogenesis of insulin resistance and type 2 
diabetes Digestive Disease, 28, 203–209 
Ylitalo, K., Large, V., Pajukanta, P., Reynisdottir, S., Porkka, K.M.K., Vakkilainen, J., 
Nuotio, I., Taskinen, M., and Arner, P. (2000). Reduced hormone-sensitive lipase activity is 
not a major metabolic defect in Finnish FCHL families. Atherosclerosis 153, 373–381. 
Yokozawa, T., Kim, H.Y. and Cho, E.J. (2002). Erythritol attenuates the diabetic oxidative 
stress through modulating glucose metabolism and lipid peroxidation in streptozotocin-
induced diabetic rats. Journal of Agricultural and Food Chemistry 50, 5485–5489. 
Zatz, R., Meyer, T. W., Rennke, H. G., and Brenner, B. M. (1985). Predominance of 
hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. 
Proceedings of National Academy of Sciences 82, 5963–5967. 
Zheng, L., and Kern, T.S. (2009). Role of nitric oxide, superoxide, peroxynitrite and PARP in 
diabetic retinopathy, Frontiers in Bioscience 14, 3974–3987. 
122 
 
Zhu, Q.Y., Huang, Y., Tsang, D., Chen, Z.Y. (1999). Regeneration of alpha-tocopherol in 
human low-density lipoprotein by green tea catechin Journal of Agricultural and Food 





























1. “Effects of Psidum guajava aqueous leaf extract on liver glycogen enzymes, 
hormone sensitive lipase and serum lipid profile in diabetic rats” Toluwani Tella, 
Bubuya Masola and Samson Mukaratirwa. Submitted to the Journal of 
Ethnopharmacology. Requested to revise paper. 
 
2. “Anti-diabetic potential of Psidium guajava leaf in streptozotocin induced 
diabetic rats” by Toluwani Tella, Samson Mukaratirwa and Bubuya Masola to 




















































Appendix 1: For materials and method see Figure 2.12 
 
 








Appendix 2: Folin-Lowry assay standard curve 
 
 








































Appendix 3: Biuret assay standard curve 


























Appendix 3: For materials and method see Figure 2.14.2 
 
 
 
 
 
 
 
 
 
 
 
 
